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“However hard we try and however clever we are, there is no question that organisms 
that have been around for 3 billion years and have adapted to survive under the most extreme 
conditions, will always overcome whatever we decide to throw at them.” 
Sir Richard Sykes 
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 Preface 
The work presented in this thesis was conducted between October 2013 and March 2018 
at the Research Group for Genomic Epidemiology of the National Food Institute, Technical 
University of Denmark. 
 
The thesis constitutes a part of a larger research project “Vetforlig II”, funded by the 
Danish Food and Veterinary Administration, aiming at developing a model capable of 
predicting the abundance of antimicrobial resistance genes in the gut microbiome of finishing 
pigs close to slaughter, as a response to their antimicrobial usage, for the majority of pigs 
slaughtered in Denmark. The predictive model will serve as a supportive tool for the Danish 
authorities to provide guidance for major political and targeted interventions in pig production 
in Denmark.  
 
The main goal of the thesis was to quantify the effect of antimicrobial usage in finishing 
pigs on the abundance of antimicrobial resistance genes in their gut microbiome close to 
slaughter, results that will compose input for the predictive model. Accordingly, the thesis 
focused first on the development and validation of an optimal method to quantify 
antimicrobial usage in finisher batches based on register-data and secondly on the quantitative 
effect of antimicrobial usage on resistance.  
 
 
Lyngby, March 2018 
Vibe Dalhoff Andersen 
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 Summary 
The increased emergence and spread of antimicrobial resistance caused by the widespread use 
and misuse of antimicrobials are considered among the most harmful threats to global health. It is 
generally accepted that antimicrobial usage in production animals contributes to the burden of 
antimicrobial resistant bacteria among humans. Consequently, attention towards antimicrobial usage 
in production animals has grown immensely during the past decade. In several countries, this has led 
to the establishing of surveillance systems that monitor trends and changes in antimicrobial usage and 
resistance in animals over time. In Denmark, the Danish Veterinary Medicines Statistic Program 
(VetStat) was established.  The monitoring systems have in turn been efficiently applied to facilitate 
interventions targeting antimicrobial usage in animal production. Several epidemiological studies 
have established that antimicrobial usage and antimicrobial resistance in production animals are 
closely related. By monitoring antimicrobial resistance over time, it has also been observed that when 
usage of specific antimicrobials ceased the counterpart antimicrobial resistance decreased. The 
quantitative relationship between antimicrobial usage and resistance is not as illuminated, as neither 
the quantification of usage nor the characteristics of the antimicrobials have been fully determined 
regarding key importance for the selection of antimicrobial resistance. In addition, most studies 
conducted so far have focused on few indicator bacteria, whereas the bulk of relevant antimicrobial 
resistance genes might be present in the entire gut microbiota. The recent developments in next 
generation sequencing allow complete quantification of the abundance of antimicrobial resistance 
genes in the entire gut microbiome. 
 
Currently, both scientists and authorities are struggling to determine the interventions that will 
most efficiently achieve the desired reduction in antimicrobial resistance at national level. For this 
reason, a model capable of predicting the potential effects of any intervention is much needed. 
Combining precise knowledge of the effect of antimicrobial usage on the abundance of antimicrobial 
resistance genes with knowledge of antimicrobial usage for larger parts of a population, allows for 
the prediction of an overall effect of interventions targeting antimicrobial usage in general or for one 
specific antimicrobial usage only in a population, a country for instance. 
 
The main aim of the thesis was to provide the effect estimates, based on regression analyses of 
the effect of antimicrobial usage on antimicrobial resistance, for a predictive model. The model was 
developed for the Danish authorities, as a supporting tool in assessments of the effects of interventions 
targeting antimicrobial usage on the antimicrobial resistance abundance in the gut microbiome of 
batches of finishing pigs (finisher batches) close to slaughter at national level.  
 
Objective I.  
To assess methods of measure antimicrobial usage in finisher batches close to slaughter independent 
of rearing site based on register-based data from national databases, by testing the different methods’ 
effects on antimicrobial resistance in the gut microbiome of the batches when antimicrobial resistance 
is obtained by cultivation and metagenomic (Manuscript I). 
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Objective II.  
To validate the developed method, called “lifetime antimicrobial usage”, by comparing VetStat-
records with farm-records. In addition, to assess the influence of an improved lifetime antimicrobial 
usage on analyses of the effect of antimicrobial usage on the resistance (Manuscript II). 
 
Objective III.  
To quantify the effect of lifetime antimicrobial usage in finisher batches on the abundance of 
antimicrobial resistance genes in their gut microbiome close to slaughter (Manuscript III, not included 
the predictive model). 
 
Objective I, three methods of calculating antimicrobial usage in finisher batches taking the rearing 
period and rearing site into account were evaluated by assessing their association with phenotypical 
resistance and abundance of resistance genes obtained from faeces samples from 10 finisher batches. 
The antimicrobial usage was calculated relative to the rearing period of the batches as (i) “Finisher 
Unit Exposure” at unit level, (ii) “Lifetime Exposure” at batch level and (iii) “Herd Exposure” at herd 
level. A significant effect on the occurrence of tetracycline resistance measured by cultivation was 
observed for Lifetime Exposure of tetracycline usage. Furthermore, for Lifetime Exposure for the 
antimicrobial-classes: macrolides, broad-spectrum penicillins, sulfonamides and tetracyclines as well 
as Herd Unit Exposure for the antimicrobial-classes: aminoglycosides, lincosamides and 
tetracyclines, a significant effect was observed on the occurrence of their respective genes. No effect 
was observed for Finisher Unit Exposure. Overall, the study showed that Lifetime Exposure (lifetime 
antimicrobial usage) is an efficient measurement of usage in finisher batches close to slaughter, i.e. 
the measurement has a significant effect on the occurrence of resistance, measured by either 
cultivation or metagenomics. 
 
Objective II, the foundation of lifetime antimicrobial usage; the daily usage, was validated by 
comparing the transformed data from VetStat with farm-records. Different transformation methods 
(smoothing) for VetStat-records were examined. Measurement comparisons included accuracy as; 
completeness and correctness, and precision as; relative difference of the error, correlation with Fisher 
z transformation and reliability coefficient. The most valid methods of those examined were then 
used in re-analyses of the abundance of antimicrobial resistance genes in 10 finisher batches from the 
previous study. Improved accuracy was found when detailed smoothing methods were applied. 
Although the precision also increased, the effect was not as pronounced, as the usage estimate of all 
smoothing methods deviated moderately compared with the farm-records. Overall, the smoothing 
methods underestimated the usage compared with the farm-records. Applying the most valid methods 
to the 10 finisher batches increased the statistical estimate of model fit for aminoglycosides, 
lincosamides, and tetracyclines, and decreased the statistical estimate of model fit for macrolides. The 
statistical estimate of model fit for sulfonamides and broad-spectrum penicillins remained the same. 
By means of data transformation, VetStat-records can be used to calculate a daily amount of 
antimicrobial usage per pig, reflecting the true usage accurately and moderately precisely, which is 
the foundation for calculating lifetime antimicrobial usage 
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Objective III, 83 farms were randomly selected based on a stratified design related to production-
type, annually number of suppliers and annually number slaughtered pigs. The quantitative effect of 
lifetime antimicrobial usage in the finisher batches on the abundance of antimicrobial resistance genes 
in their gut microbiome close to slaughter was assessed in regression models. The evaluation of the 
models’ diagnostic plots demonstrated that the assumptions for performing linear relationships were 
fulfilled, and additional robust regression indicated that the estimated effect was robust against 
outliers. When the production-type and updated design variables were included in the regression 
models, it could not be concluded that any of them were important confounders for the effect of 
lifetime antimicrobial usage. Using linear regression models, significant effects of lifetime 
antimicrobial usage of one or several antimicrobial classes at dispensing-type level were obtained for 
each of the seven antimicrobial-classes of resistance assessed. However, two significant effects did 
stand out, the difference between dispensing-type and the co-selecting effect of peroral macrolides, 
parenteral and peroral tetracyclines.  
 
This thesis shows that it is possible to describe the quantitative effect of lifetime antimicrobial 
usage on the occurrence of antimicrobial resistance in real-life conditions. The results are used to 
develop a predictive model for a large population, in our case most pigs delivered for slaughter in 
Denmark. A predictive model, where the effect on antibiotic resistance of potential interventions 
targeting antimicrobial usage, can be tested will be an important tool for the Danish authorities and 
other stakeholders. However, the predictive model also provides an example of what is feasible and 
what data will be needed to develop a model that can provide guidance for targeted interventions.  
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 Sammendrag 
Den øgede forekomst og spredning af antibiotika resistens er forårsaget af udbredt brug og 
misbrug af antibiotika. Antibiotika resistens betragtes i dag som en af de mest alvorlige trusler mod 
global sundhed. Det er almindeligt accepteret, at antibiotikaforbruget i husdyr produktionen bidrager 
til byrden af antibiotika resistente bakterier blandt mennesker. Opmærksomheden omkring 
antibiotikaforbruget i produktionsdyr er derfor vokset betydeligt det seneste årti. Det har i flere lande 
blandt andet ført til etablering af overvågningssystemer, der følger tendenser og ændringer i 
antibiotikaforbrug og resistens hos dyr. I Danmark blev databasen Veterinær Medicin Statistik 
Program (VetStat) etableret. Disse overvågningssystemer er efterfølgende blevet anvendt til 
implementering af målrettede interventioner mod antibiotikaforbruget i husdyrsproduktionen. Flere 
epidemiologiske undersøgelser har fastslået, at antibiotikaforbrug og resistens i produktionsdyr er tæt 
forbundet. Ved at overvåge antibiotika resistens over tid er det også blevet observeret, at når brugen 
af specifikke antibiotika ophører falder den specifikke resistens tilsvarende. Det kvantitative forhold 
mellem antibiotikaforbrug og antibiotikaresistens er mindre belyst, fordi hverken kvantificeringen 
eller karakteristika af antibiotika er klarlagt i forhold til betydning for selektion af antibiotika. Hertil 
kommer, at de fleste hidtil gennemførte undersøgelser har fokuseret på få indikator bakterier, mens 
størstedelen af relevante antibiotikaresistensgener kan være til stede i hele tarmmikrofloraen. Den 
nye udvikling inden for DNA sekventeringsmetoder muliggør fuldstændig kvantificering af 
forekomsten af antibiotikaresistensgener i tarm mikrobiomet. 
 
I øjeblikket arbejder både forskere og myndigheder ihærdigt på at bestemme hvilke interventioner 
rettet mod antibiotikaforbrug, der mest effektivt vil resultere i ønskede reduktioner af 
antibiotikaresistens på nationalt plan. Derfor er en model, som er i stand til at forudsige de potentielle 
resultater af enhver intervention særdeles tiltrængt. At have præcis viden om effekten af 
antibiotikaforbrug på forekomsten af antibiotikaresistensgener kombineret med viden om 
antibiotikaforbrug for større dele af en population muliggør prædiktion af den samlede effekt af en 
intervention rettet mod antibiotikaforbrug generelt eller for specifikke antibiotika i den population, 
eksempelvis et land. 
 
Den overordnede målsætning med afhandlingen var at beregne effektestimater baseret på 
regressionsanalyser af effekten af antibiotikaforbrug på antibiotikaresistens til en prædiktiv model. 
Modellen udvikles til de danske myndigheder, der skal anvende den, som et støtteværktøj i 
forbindelse med vurdering af effekter af interventioner rettet mod antibiotikaforbrug på forekomsten 
af antibiotikaresistens i slagtesvins tarmmikrobiom ved slagtetidspunktet. For at opnå målsætningen 
blev tre formål genereret: 
 
Formål I. 
At vurdere metoder til beregning af antibiotikaforbrug for slagtesvin ved slagtetidspunktet 
uafhængigt af opdrætssted på baggrund af registerbaserede data fra nationale databaser, ved at teste 
de forskellige metoders effekt på forekomsten antibiotikaresistensgener i slagtesvinenes tarm 
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mikrobiom, når resistensen er fundet dels ved dyrkning og dels ved sekventering af hele 
tarmmikrobiomet (Manuskript I). 
 
Formål II. 
At validere den udviklede metode til beregning af antibiotikaforbrug ved sammenligning af VetStat-
registreringer med besætnings-optegnelser. Derudover at vurdere indflydelsen af en forbedret metode 
på beregning antibiotikaforbrug i analyser af effekten af antibiotikaforbrug på resistens (Manuscript 
II) 
 
Formål III. 
At kvantificere effekten af livstids antibiotikaforbrug for batch af slagtesvin på forekomsten af 
antibiotikaresistensgener i deres tarmmikrobiom ved slagtetidspunktet (Manuskript III, the 
prædiktive model ekskluderet). 
 
Formål I, tre metoder til beregning af antibiotikaforbrug for batch af slagtesvin, der tager 
opdrætningsperioden og opdrætsstedet i betragtning, blev evalueret ved at vurdere deres 
sammenhæng til fænotype antibiotika resistens og forekomsten af antibiotika resistensgener i fæces 
prøver fra 10 batch af slagtesvin. Antibiotikaforbruget blev beregnet i forhold til opdrætningsperiode 
som (i) “Slagtesvins Eksponering” på enheds-niveau, (ii) “Levetids Eksponering” på batch-niveau og 
(iii) “Besætnings Eksponering” på besætnings-niveau. En signifikant virkning på forekomsten af 
tetracyklinresistens, målt ved dyrkning, blev identificeret for Levetids Eksponering for antibiotika-
klassen: tetracyklin. Endvidere blev der observeret en signifikant effekt for Levetids Eksponering af 
antibiotika-klasserne: makrolider, bredspektret penicilliner, sulfonamider og tetracykliner anvendelse 
samt for Besætnings Eksponering af antibiotika-klasserne: aminoglykosider, linkosamider og 
tetracykliner på forekomsten af deres respektive resistensgener målt ved DNA sekventering. Der blev 
ikke observeret effekt for Slagtesvins Eksponering. Samlet set viste studiet, at Levetids Eksponering 
(levetids antibiotikaforbrug) er en effektiv metode til beregning af antibiotikaforbruget for batch af 
slagtesvin ved slagtetidspunktet, med en signifikant effekt på forekomsten af resistens målt både ved 
dyrkning og ved sekventering. 
 
Formål II, livstids antibiotikaforbrug beregnes ud fra det daglige forbrug. Det daglige 
antibiotikaforbrug blev valideret ved at sammenligne transformerede data fra VetStat med 
besætnings-optegnelser. Forskellige transformationsmetoder (udjævning) for VetStat-registreringer 
blev undersøgt. Sammenligning mellem VetStat-data og besætnings-optegnelser udgjorde 
nøjagtighed som; fuldstændighed og korrekthed, og præcision som; relativ forskel på fejl, korrelation 
med Fisher z transformation og pålidelighedskoefficient. De mest valide metoder af de undersøgte 
blev efterfølgende anvendt i re-analyser af forekomsten af antibiotikaresistensgener for 10 batch af 
slagtesvin fra det tidligere studie. Forbedret nøjagtighed blev fundet, når detaljerede 
udjævningsmetoder blev anvendt. Selv om præcisionen også steg, var effekten ikke så udtalt, idet 
forbrugsestimatet for alle udjævningsmetoder afveg moderat i forhold til besætnings-registreringerne. 
Anvendelse af de mest valide metoder, gav anledning til øgede statistiske estimater for graden af 
model fit for aminoglykosider, linkosamider og tetracykliner og reducerede for makrolider. De 
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statistiske estimater for graden af model fit var uforandrede for sulfonamider og bredspektret 
penicilliner. Ved hjælp af data-transformation er det muligt at anvende VetStat-registreringer til 
beregning af et daglig antibiotikaforbrug pr. gris, der afspejler det rigtige forbrug nøjagtigt og moderat 
præcist, hvilket er grundlaget for beregning af levetids antibiotikaforbrug. 
 
Formål III, 83 gårde blev tilfældigt udvalgt på baggrund af et stratificeret design i forhold til 
produktionstype, antal leverandører og antal slagtede grise årligt. Den kvantitative effekt af levetids 
antibiotikaforbrug for batch af slagtesvin på forekomst af antibiotika resistensgener i deres tarm 
mikrobiom tæt på slagtning blev vurderet i regressionsmodeller. Evalueringen af modellernes 
diagnostiske plots demonstrerede at forudsætningerne for lineære regression var opfyldt, og 
yderligere robust regression viste, at den estimerede effekt var robust mod ekstreme observationer. 
Når produktionstypen og de opdaterede designvariabler blev inkluderet i regressionsmodellerne, 
kunne det ikke konkluderes, at nogen af dem var væsentlige konfundere for effekten af levetids 
antibiotikaforbrug. Ved anvendelse af lineære regressionsmodeller blev signifikante effekter af 
levetids antibiotikaforbrug af en eller flere antimikrobielle klasser på dispenseringstype niveau opnået 
for hver eneste undersøgte antibiotika-klasse resistens. Imidlertid var to signifikante effekter 
iøjnefaldende, forskellen mellem dispenseringstype og den co-selekterende effekt af perorale 
makrolider, parenterale og perorale tetracykliner. 
 
Denne afhandling viser, at det er muligt at beskrive den kvantitative effekt af antibiotikaforbrug 
på forekomst af antibiotikaresistens under virkelige forhold. Disse resultater vil blive anvendt til at 
udvikle en prædiktiv model for en større population, i vores tilfælde de fleste svin, der leveres til 
slagtning i Danmark. En prædiktiv model, hvor effekten på antibiotikaresistens af potentielle 
interventioner mod antibiotikaforbrug kan testes, vil være et vigtigt redskab for de danske 
myndigheder og andre interessenter. Den prædiktive model giver dog også et eksempel på, hvad der 
er muligt, og hvilke data der skal bruges med henblik på udvikling af en model, der kan yde vejledning 
til målrettede interventioner. 
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 Abbreviations 
AMR:   Antimicrobial resistance 
AM(s):  Antimicrobial(s) 
AMU:  Antimicrobial usage 
cfu:   Colony-forming units 
CHR:  Central Husbandry Register 
DADD: Defined Animal Daily Dose 
DDD:  Defined Daily Dose 
DVFA:  Danish Veterinary and Food Administration 
MIC:  Minimum Inhibitory Concentration 
PDD:  Prescribed Daily Dose 
PCR:  Polymerase Chain Reaction 
PMD:   Pig Movement Database 
qPCR:  Real-time Polymerase Chain Reaction 
TI:    Treatment Incidence 
TI200:  Lifespan Treatment Incidence 
VetStat: Danish Veterinary Medicines Statistic Program 
Vet:  Veterinarian 
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1. Objective and outline 
Antimicrobial resistance is one of the most worrying threats to global health, causing great socio-
economic costs, a trend that is expected to continue unabated. Therefore, extensive work is being 
carried out around the world on trying to curb the otherwise continued emergence and spread of 
antimicrobial resistance, including risk assessments and predictive models that encompass, the 
quantitative effect of antimicrobial usage on resistance. However, the quantitative relationship 
between antimicrobial usage and resistance has not been fully established. Three objectives were 
generated to fulfil the main aim of the thesis, which was to quantify the effect of antimicrobial usage 
in finishing pigs (finishers) on the occurrence of antimicrobial resistance in their gut microbiome 
close to slaughter. The objectives were: 
 
Objective I 
To assess methods for measuring antimicrobial usage in finisher batches close to slaughter 
independent of rearing site based on register-based data from national databases, by testing the 
different methods’ effects on antimicrobial resistance in the gut microbiome of the batches when 
antimicrobial resistance is obtained by cultivation and metagenomic (Manuscript I). 
 
Objective II  
To validate the developed method, called “lifetime antimicrobial usage”, by comparing VetStat-
records with farm-records. In addition, to assess the influence of improved lifetime antimicrobial 
usage on analyses of the effect of antimicrobial usage on the resistance (Manuscript II). 
 
Objective III  
To quantify the effect of lifetime antimicrobial usage in finisher batches on the abundance of 
antimicrobial resistance genes in their gut microbiome close to slaughter (Manuscript III, not included 
the predictive model). 
 
The thesis begins with an introduction yielding an overview of the subjects under study. The 
introduction presents the background that has led to the current antimicrobial resistance state. The 
subsequent overview of previous interventions targeting antimicrobial usage aimed at Danish 
production animals is followed by a description of the pig production, a description of their 
antimicrobial usage, and the monitoring of antimicrobial usage and resistance in Denmark. A 
description of methods to measure antimicrobial usage and resistance, the relationship between them 
and their mechanisms are also included. The introduction ends with an overview of potential risk 
factors to consider and an outline of the nature of register-based data. The introduction is followed 
by three sections comprising the three studies performed and their associated manuscript with 
supplementary material. A closing generic discussion follows each manuscript. The thesis ends with 
summative conclusions with a brief exposition of future perspectives. 
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2. Introduction 
 Background 
 
The discovering of antimicrobials (AMs) as treatment options for bacterial diseases has 
revolutionised modern medicine, by reducing the accompanying morbidity and mortality immensely. 
Since the first discovery of an inhibitory effect of penicillium mould on bacteria, numerous different 
AM substances have been developed and introduced successively for human and animal medicine 
(Silver, 2011; Aarestrup, 2015).  
 
In the 1930s and 1940s, sulfonamides and penicillin, respectively, were the first AMs introduced 
to treat humans with bacterial infections (Levy and Marshall, 2004). Shortly after their introduction 
in hospital settings, single-drug resistant strains appeared (Levy and Marshall, 2004; Laxminarayan 
et al., 2013). By the late 1950s, multi-drug resistant strains were detected, however, at that time 
perceived as a rarity with little health impact (Levy and Marshall, 2004). Similar patterns for 
evolution of antimicrobial resistance (AMR) have followed all AMs introduced in human and animal 
medicine, and more worrying. their effective lifespan has decreased over time. Presently, newly 
developed substances are expected to last only 10-20 years (Levy and Marshall, 2004; Marshall and 
Levy, 2011; Aarestrup, 2015). The emergence and spread of AMR combined with the lack of novel 
discoveries at a sufficient rate, increasingly compromise the number of AMs that can be used 
effectively to treat bacterial infections in humans and animals (Levy and Marshall, 2004; Silver, 2011; 
Aarestrup, 2015; Laxminarayan et al., 2016). 
 
At the beginning of the 2010s, the World Health Organization named AMR one of the most 
significant global threats to public health of the 21st century (WHO, 2012). The emergence and spread 
of AMR is currently devastatingly for society. In 2013, in the European Union, healthcare costs and 
loss of productivity associated with infections by multi-drug AMR bacteria were estimated to €1.5 
billion. Furthermore, these infections caused the deaths of at least 25,000 people (ECDC/EMEA, 
2009). During the same year in the United States, the costs related to AMR were estimated to $55 
billion and caused the deaths of at least 23,000 people (CDC, 2013). It has been estimated that by 
2050, 10 million lives a year will be at risk as a result of infections caused by AMR bacteria, with a 
cumulative economic cost of US$100 trillion (O’Neill, 2016). By comparison, of 56.4 million deaths 
worldwide in 2015, 8.8, 1.3 and 0.4 million deaths were caused by cancer, road injury and foodborne 
diseases, respectively. The threat from AMR is clear, and the world may be heading for a post-
antimicrobial era where common bacterial infections once more becomes lethal (WHO, 2014; 
O’Neill, 2016).  
 
The Swann report from 1969 began addressing a possible association between antimicrobial usage 
(AMU) in animals and findings of AMR bacteria in humans (Swann et al., 1969). Today, it is 
generally agreed that resistant strains of Salmonella, Campylobacter and some Enterococci in humans 
relate to the animal reservoir. In contrast, the actual contribution of AMR found in bacteria of animal 
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origin, as a burden to human health, is persistently debated (Fey et al., 2000; Marshall and Levy, 
2011; Aarestrup, 2015). At the present time, the majority of scientific experts agree that the AMR 
contribution from food-producing animals is disturbing, and efforts should be aimed at reducing 
AMU, thereby reducing the emergence and spread of resistance from this reservoir (Aarestrup and 
Wegener, 1999; Marshall and Levy, 2011; Laxminarayan et al., 2013; Zhang et al., 2013; Aarestrup, 
2015; Singer et al., 2016). 
 
 
 Interventions targeting antimicrobial usage in Danish food production 
 
The introduction of AMs in production animals in the 1950s, substantially improved the treatment 
of bacterial infections, with great effect on the overall health, welfare and productivity of the animals. 
Soon after, the growth-promoting effect of AMs were discovered, and usage for this purpose became 
widespread (Martel et al., 2001). 
 
Based on the Swann Committee recommendation (Swann et al., 1969), the European Council 
ruled in 1970 that AMU as feed additives was permitted provided the antibiotic did “not endanger 
animal or human health nor harm the consumer of livestock products” (European Council, 1970). 
However, as this precaution did not account for bacterial evolutional adaptability, the growth 
promoter avoparcin for pigs and chickens could be linked to increased findings of Enterococcus 
resistant to the antimicrobial; vancomycin, which at the time was a last resort drug in human medicine 
(Bager et al., 1997; Wielinga et al., 2014). After the avoparcin usage had ceased, the occurrence of 
vancomycin-resistant enterococci in production animals decreased (Aarestrup et al., 2001), though 
the occurrence of vancomycin-resistant enterococci in pigs did not decrease significantly until the use 
of growth-promotor; tylosin ceased (Jensen and Hayes, 2014). The persistence of VRE in pigs at low 
levels has been attributed to co-selection due to tylosin resistance genes and to copper resistance 
genes (Hammerum, Lester and Heuer, 2010). 
 
Battling AMR has high priority in Denmark, and several initiatives aimed at reducing resistance, 
through intervention targeting AMU, has successively achieved a decline in the usage in food-
producing animals, particularly in the pig sector (Wielinga et al., 2014), with an accompanying 
reduction in AMR (Aarestrup et al., 2001; Agersø¸ and Aarestrup, 2013). Moreover, the reduced 
AMU has apparently had no long-term negative effect on productivity in pig production (Aarestrup 
et al., 2010; Aarestrup, 2015) nor on prevalence of lesions at meat inspection as a proxy for an 
increased occurrence of diseases (Alban, Petersen and Busch, 2015). Several European Union 
countries, e.g. Belgium and the Netherlands, have implemented similar restrictive and comprehensive 
AMU interventions within the veterinary sector, and have also experienced reductions in AMR in 
production animals (Speksnijder et al., 2015; Dorado-García et al., 2016; Callens et al., 2017). 
 
As early as in 1995, using avoparcin as a growth promoter for production animals was banned in 
Denmark due the negative implications vancomycin-resistant enterococci could inflict on the health-
care system (Aarestrup et al., 2001) (Fig. 1). To curb AMU further, two limitations on veterinarians’ 
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(vets’) sales of prescribed medicines were introduced in 1995. 1) Practicing vets were not permitted 
to own a company that distributed prescription medications. 2) Vets could only resell legally bought 
medicines (from pharmacies) to farmers with a fixed profit. In exchange, vets were given new 
advisory responsibilities, based on monthly farm visits, to improve animal health and biosecurity, 
with the adoption of the Veterinary Health Advisory Contract between farmers and vets (Wielinga et 
al., 2014) (Fig. 1). The Veterinary Health Advisory Contract is mandatory for farms over a certain 
size (Wielinga et al., 2014). Out of consideration for the farmers, those with contracts are permitted 
to administer the prescribed AMs themselves between the regular vet visits. In the same year, actions 
were taken to increase awareness of the “Cascade rule”, which lowered the large magisterial 
production of prescribed chemicals occurring at the time (Fig. 1) (Wielinga et al., 2014). These  
initiatives resulted in a 40% decline in the AM amounts prescribed for therapeutic usage in production 
animals (Fig. 1). Of note, by 2000, the agricultural industry in Denmark had voluntarily banned usage 
of all antibiotic growth promotors in poultry and pig production (Emborg et al., 2001; Aarestrup et 
al., 2001), which accounted for the decline in AMU occurring between 1997-2000. The EU banned 
usage of antibiotic growth promotors for food-producing animals on January, 2006 (European 
Council, 1970) (Fig. 1). In the late 1990s, the Danish Veterinary and Food Administration (DVFA) 
introduced a detailed guideline, ranking drugs of choice for specified bacterial diseases in pigs, aimed 
at vets. The guideline is based on the available scientific evidence and changes continuously (DVFA, 
2005) (Fig. 1).  
 
The European Union launched the Microbial Threat conference in 1997, as resistance to 
antibiotics and other AM substances was increasing in human medicine. The conference was hosted 
by the Danish government in Copenhagen in September 1998 and resulted in five Copenhagen 
Recommendations (Frimodt-Møller, 2004). In Denmark, as a response to the recommendations, the 
authorities, research sectors, veterinary sector and the agricultural industry reached mutual consensus 
on the importance of monitoring AMU in production animals. This led to the establishment of the 
Danish Veterinary Medicines Statistic Program (VetStat) in 2000, which comprises records on all 
purchased medicines prescribed by veterinarians for animals (Stege et al., 2003).  
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Fig. 1. Prescribed antimicrobial agents in the human and veterinary sector compared with the number of pigs 
produced and pigs slaughtered in Denmark (SEGES, 2000, 2011, 2016). AMs in the veterinary sector are 
categorised as either therapeutics or growth promoters (DANMAP, 2017). At the top of the graph, 
interventions (grey) and voluntary provisions (green) targeted AMs at the year of implementation.  
 
Although the amount of AMU declined from 1994 to 1999, the use in production animals 
increased by 45% from 2001 to 2009, at which time app. 80% of the prescribed AMs were used in 
pig production (Fig. 1) (DANMAP 2009, 2010). Part of the increased usage could be explained by a 
concurrent increase in the production of pigs (Fig. 1). To curb this development, in 2010, the DVFA 
established the “Yellow Card” intervention, which was based on information from VetStat (Jensen et 
al., 2014; Wielinga et al., 2014). The Yellow Card intervention was designed to target pig and cattle 
farmers using high amounts of AMs, by setting national threshold limits for usage. If over a 9-month 
period a farm exceeds a threshold, the DVFA issues an enforcement notice requiring the farm owner 
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to bring down the AMU to below thresholds. If the farm does not comply within the granted period, 
additional enforcement notices are issued (Fig. 2) (DVFA, 2016). The 25% decline in AMU seen 
after 2010 is assessed to be mainly a result of the Yellow Card initiative (Jensen et al., 2014; Wielinga 
et al., 2014). The DVFA revises the thresholds every year, based on information from VetStat of 
changes in AMU (DVFA, 2016).  
 
 
 
Fig. 2. The Yellow Card (Executive order 179/2014). When a farm confirms exceeding thresholds, a 9-month 
enforcement notice (Yellow Card) is given to reduce usage in compliance with the thresholds. If the reduction 
is not achieved during the notice period, the farm is at its own expense, placed under increased supervision 
and given a 5-month enforcement notice (Increased Supervision) to reduce usage in compliance with the 
thresholds. If the reduction is not achieved during the notice period, the farm continues under increased 
supervision at its own expense and is given an additional enforcement notice regarding restrictions on AMU 
at the farm (Red Card), which is maintained until the AMU complies with the thresholds. When the appropriate 
reduction is achieved, independent of enforcement level, the farms are monitored for an additional 12 months. 
However, if the thresholds are surpassed during the 12-month monitoring period, the farm is placed under 
increased supervision in relation to a previous Yellow Card enforcement notice. Otherwise, the farm is placed 
at the Red Card level, with increased supervision and AMU restrictions. 
 
In 2010, the pig industry engaged in a voluntary ban of cephalosporin usage in pigs (Agersø and 
Aarestrup, 2013), and the subsequent year, launched good practice guidelines describing management 
methods to prevent diseases, and procedures for correct AM administration, aimed at pig farmers 
(Fig. 1) (SEGES, 2013). To further limit the usage, two interventions were adopted in 2013. Firstly, 
a differentiated tax favoured simple AMs and vaccines compared with extended substances such as 
3th and 4th generation cephalosporins and fluoroquinolones. Secondly, prescriptions issued for flock 
treatments by water or feed for intestinal and respiratory infections required laboratory verification 
of the diagnosis on an annual basis. To reduce the usage of critically important AMs for human 
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medicine (World Health Organization, 2016) in production animals, the most recent initiative 
involves the modification of the national maximum thresholds in the Yellow Card scheme. In this, 
the critically important AMs for human medicine have a lower maximum threshold of usage per 
animal than the AMs of lesser importance for human medicine. Therefore, farms using these classes 
are prone to meet the maximum thresholds faster (DVFA, 2016). Together, these interventions, 
particularly those implemented from 2010, appear to have ended the otherwise increasing trend in 
AMU observed since 1999 (Wielinga et al., 2014). That fact that the AMR levels in Denmark 
continue to be lower than some of the other EU countries (EFSA/ECDC, 2016) most likely results 
from the implemented interventions. 
 
Although the level of AMU per produced food animal is low in Denmark, the Danish authorities 
have committed themselves to ensuring responsible and optimal AMU in the agriculture as part of 
combatting AMR bacteria threatening public health. However, vets and farmers might not perceive 
it as equally important. In six European countries (Belgium, Denmark, France, Germany, Sweden 
and Switzerland), the intentions of vets and farmers to reduce AMU were assessed as their perception 
of levels of benefits and risks of AMU. Both vets and farmers perceived the benefits as surpassing 
the risks, however, particularly Danish vets and farmers perceived AMs as more beneficial and less 
risky than their colleagues from the other countries (Visschers et al., 2016). Visschers et al. (2016) 
argued that the finding might be due to the source of knowledge of benefits and costs, as well as a 
restrictive policy over a long period, therefore resulting in little scope for further reductions. 
Moreover, the perceived costs and benefits may be an erroneous perception. Rojo-Gimeno et al. 
(2016) demonstrated that AMU could be reduced by implementing management strategies; 
biosecurity and vaccines, with a net decrease in costs. The reduction in AMU at the farms related 
mainly to abandoning regular standard treatments (prophylactic). The discrepancy between vets’ and 
farmers’ perception and national AMU policy, combined with the available possibilities within 
strategic management and increased profit should be taken into account when further interventions 
targeting AMU are implemented, as vets and farmers are key in the battle against AMR in production 
animals.  
 
With the prospect of increased demand for animal products due to advances in countries economic 
status, a concurrent amplification of modern animal production and increase in AMU are expected 
(van Boeckel et al., 2015). Therefore, in order to enable reduced AMU successfully, targeted AMU 
interventions with an expected AMR result, combined with altered management strategies, should be 
employed in food production, through multidisciplinary efforts across sectors. 
 
 
 Antimicrobial usage in Danish pig production  
 
Since the late 1990s, Denmark has continuously produced an increasing number of live pigs for 
export and pork production (Fig. 1) (SEGES, 2017). The entire production of pigs reached 31.8 
million in 2016, of which 18.3 million finishers were slaughtered in Denmark, and 0.3 million 
finishers and sows plus 13.2 million 30kg weaners were exported (SEGES, 2017). In the same period, 
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a vast reduction in the number of farms from 19,823 to 3,294 took place, while the remaining farms 
increased in size and productivity, a tendency expected to continue in the years to come (Christiansen, 
2014; SEGES, 2017).  
 
In 2016, the overall pig production in Denmark took place at conventional farms, while less than 
1% of the yearly production of pigs occurs at free-range or organic farms (SEGES, 2017). Of note, 
some of the differences between these production systems include access to out-doors, available space 
per animal, feeding requirements, age of weaning and management of antimicrobials, some of which 
are risk factors demonstrated to potentially affect the amount of AMU and the occurrence of AMR 
(Mathew et al., 2003; van der Fels-Klerx et al., 2011).  
 
As a consequence of the specialised pig production in Denmark, several different farm systems 
exist, e.g. integrated production, sows only, sows including weaners, weaners and/or finishers only. 
The production of a finisher, i.e. rearing from the birth of the piglet to the finisher at time of slaughter, 
can take place at the same location, at several farms owned by one farmer or at several farms owned 
by different farmers. Therefore, the rearing pathway of a batch of finishers at time of slaughter could, 
through complex trade patterns, have passed through numerous farms (Andersen et al., 2017; 
Birkegård et al., 2017a). 
 
Despite the considerable number of pigs produced per year in Denmark, the biomass of pigs 
constitutes only 43% of the total biomass of production animals and pets (DANMAP, 2017). The 
biomass of the cattle population comprises 50% of the total biomass, however, the larger part of the 
this biomass relates to dairy production, adult animals, whereas the number of pigs produced mostly 
comprises young animals with a fast turnover rate of approximately 90 and 170 days for 30kg weaners 
and 100kg finishers, respectively (DANMAP, 2017; SEGES, 2017). The vast number of young pigs 
in the population may account for the high AMU within the pig production. In 2016, the AMU for 
pigs constituted 75% of the total usage for animals (Fig. 3). Therefore, the high AMU probably relates 
to younger pigs being more susceptible to infections combined with the intensive production, early 
weaning, movements between units in a farm or farms, different environments and mixing of pigs. 
These factors can cause a suppressing effect on the immune system and an increased spread of 
diseases (Ekkel et al., 1996; Merlot, Meunier-Salaün and Prunier, 2004; Damgaard, Studnitz and 
Jensen, 2009; Campbell, Crenshaw and Polo, 2013). 
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Fig. 3. Live biomass (mill. kg) and antimicrobial consumption (kg) in main animal species, Denmark 
(DANMAP, 2017)  
 
In line with this, the majority of AMU happens within the age-group; weaners, followed by the 
age-groups; finishers and sows-piglets-boars (Jensen et al., 2014; DANMAP, 2017). Of the total 
AMU from 2002 to 2012, 67% was administered perorally either by feed or more commonly by water 
(Jensen et al., 2014; Dupont et al., 2016). Furthermore, AMs for weaners and finishers were primarily 
for gastro-intestinal infections, weaners; 75% and finishers; 60%, respiratory infections, weaners; 
16% and finishers; 20%, and muscular-skeletal/CNS/skin infections, weaners; 8% and finishers 18%, 
(Jensen et al., 2014).  
 
The most used antimicrobials for pigs in the past decade, measured as the amount of defined 
animal daily dose (DADD), have been tetracyclines, macrolides, pleuromutilins and simple 
penicillins, whereas lesser amounts of lincosamides, extended penicillins, sulfonamides, and 
aminoglycosides have been used during this period (Jensen et al., 2014; DANMAP, 2017). From 
2002 to 2012, tetracyclines, macrolides and pleuromutilins accounted for 80% of the peroral usage 
and simple penicillins accounted for 39% of the parenteral usage (Jensen et al., 2014). 
 
Usage of the critically important 3th and 4th generation cephalosporin and fluoroquinolones has 
plummeted since the interventions implemented in 2002 and 2006, respectively. However, from 2009 
to 2016, the usage of the critical important colistin increased two-fold to 864kg, probably as an 
alternative to the concurrent reduction in tetracycline usage, which is used to treat gastro-intestinal 
infections caused by Enterobacteriaceae (DANMAP, 2017). Due to the increasing need for colistin 
in human medicine and the worrying horizontal spread of colistin resistance genes observed, the risk 
of colistin usage in veterinary medicine is currently being revised (Rhouma, Beaudry and Letellier, 
2016). 
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 Monitoring antimicrobial usage and resistance 
 
In 1995, the Danish Integrated Antimicrobial Resistance Monitoring and Research Programme 
(DANMAP) surveillance programme was established at the initiative of the Danish Ministry of 
Health and the Danish Ministry of Food, Agriculture and Fisheries as a coordinated monitoring and 
research programme. The strength of the programme results from multi-disciplinary collaboration 
between research sectors and official authorities on animal and human health and their mutual sharing 
of relevant data from animals, food and humans in order to monitor AMU and AMR across 
populations (Bager, 2000; Hammerum et al., 2007; DANMAP, 2017). The surveillance provides 
comparable data on AMU and AMR, and uses these data to follow trends and explore associations 
between AMU and AMR at regional and national levels. Results are published annually in DANMAP 
reports (DANMAP, 2017). 
 
VetStat provides the data on AMU in pigs, while the isolates used to monitor AMR are collected 
from randomly selected healthy pigs at slaughter. The indicator-bacteria E. coli is selected to monitor 
AMR in pigs due to its ubiquitous presence throughout the food chain from the primary producer to 
the consumer and its ease of gaining and spreading AMR as a response to AMU (Turnidge and 
Paterson, 2007; DANMAP, 2017). Resistance in Salmonella is also monitored for pigs to follow the 
AMR in zoonotic bacteria (DANMAP, 2017). 
 
The pig slaughterhouses included in DANMAP sampling comprise 95% of pigs slaughtered in 
Denmark. By means of stratification, the number of samples to collect per slaughterhouse is estimated 
proportionally based on the number of pigs slaughtered per location compared with the total number 
of slaughtered pigs from the previous year, in 2016. This secures a representative subset of the entire 
pig population of pigs at slaughter. When MIC analyses are included, one isolate of each bacterial 
species per farm per year is susceptibility tested. These procedures ensure that the samples are 
representative for the occurrence of AMR found in pigs at slaughter, and thus represent an estimate 
of the occurrence in the entire pig population in Denmark. 
 
 
 Measuring antimicrobial usage 
 
Different approaches for quantifying AMU at farm level have been presented, such as cost of 
therapy, total substance weight, defined daily dose (DDD), prescribed daily dose (PDD) and treatment 
incidence (TI) that uses the DDD in the calculation of AMU (Chauvin et al., 2001). The simplest 
measurement of AMU at farm level considers solely the weight of the substance used within a 
specified period for an entire farm. This method does not distinguish between substances with 
different potency, i.e., the same amount of two substances can be used to treat different number of 
animals. Therefore, variations in AM usage over time could be the result of product alterations alone. 
The DDD, PDD, and TI, all take the potency of the substance into account, thereby, providing an 
approach that measures the relative impact of different substances. Foremost, the choice of method 
for measuring AMU depends on the subject in study. Subsequently, monitoring of AMU trends over 
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time requires stability to enable comparison of usages, whereas association studies between AMU 
and AMR should reflect the level of exposure and the exposure duration  (Collineau et al., 2017). 
Whether the treatment intensity should be calculated as the number of DDD, TI or other comparable 
measure hereto, is ultimately a matter of tradition and preference. Unless the objective is to compare 
farms from different countries, then it is paramount to have standardised doses per kg animal and 
standardised weights per age-group of the species (Bondt et al., 2013; Postma et al., 2015; Taverne 
et al., 2015) 
 
In 2004 and 2012, the Animal Daily Dose (ADD) and defined animal daily doses (DADD), 
respectively, were introduced in Denmark as standardised technical measures of AMU (Jensen, 
Jacobsen and Bager, 2004; DANMAP, 2012). When the ADD is estimated per pig, standard weights 
for their age-groups are 200kg for sows/gilts/boars including piglets, 15kg for weaners and 50kg for 
finishers. AMU for piglets is registered in the sows/gilts/boars age-group (Dupont et al., 2016; 
DANMAP, 2017).  
 
In order to obtain data on AMU, two different approaches are available, obtaining data directly 
from farms or extracting data from databases. Applying the first will provide exact data, however, it 
is very time-consuming; due to the hours spent driving back and forth to farms, visiting the farms, 
and recording non-standardised data to form datasets (Sørensen, Sabroe and Olsen, 1996; 
Emanuelson and Egenvall, 2014). Consequently, the number of farms included in a study is often 
determined by these terms. The movements of pigs between farms at different geographical locations 
further complicates the process of obtaining farm data. For this reason, integrated production is often 
first choice, when studying associations between AMU during the entire rearing period and AMR in 
finishers close to slaughter (Postma et al. 2016; Rosengren et al. 2007; Timmerman et al. 2006). In 
Denmark, integrated production will not apply to a vast proportion of farms delivering finishers for 
slaughter (SEGES, 2017). When data are obtained by extraction from databases, it is possible to cover 
larger parts or entire populations. However, the data are not representative of farm usage, but merely 
a proxy (Sørensen, Sabroe and Olsen, 1996; Emanuelson and Egenvall, 2014). In Denmark, the 
extraction levels predominantly used in research consist of data at unit, farm and farm-owner level 
(Emborg et al., 2007; Vieira et al., 2009; Vigre et al., 2010). An AMU calculation restricted to a 
specified unit (age-group) may lack essential pieces of information when compared with the exposure 
during the entire rearing period from the birth of the piglet to the finisher at slaughter, because AMU 
in finisher units is low compared with weaners (DANMAP, 2017). Therefore, the estimation of usage 
at unit level does not reflect the full exposure during the rearing period. The farm-owner level 
measures of AMU may include usage of no relevance, i.e. farms and/or units that are not part of the 
rearing system (Andersen et al., 2017).  
 
The period set for data extraction is most often one year prior to sampling (Emborg et al., 2007; 
Vieira et al., 2009; Andersen et al., 2015). However, changes in amounts of AMR have been 
demonstrated to occur over much shorter timespans (Cavaco et al., 2008; Holman and Chénier, 2013), 
and yearly calculations of AMU might be too crude for association purposes at finisher batch level. 
Furthermore, in the finisher production, each group of animals (batch) is moved from farrowing to 
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weaning and then to the finisher unit, primarily on an all-in/all-out basis. Thus, the variation in AMU 
between batches due to the occurrence of diseases will not be observed, when the usage covers a 
whole year. 
 
Based on the three databases (CHR, PMD and VetStat), the lifetime AMU for a finisher batch 
was calculated in steps. First, using the sampling date, the batch was followed backwards through the 
rearing site(s) on the basis of the national rearing periods, as days in the farrowing, weaning and 
finisher units, respectively (Jessen, 2015). The number of days was only considered for conventional 
production, although organic production differs due to the longer period in the farrowing unit. Then, 
daily amounts of AMU were calculated for all AM-product records (l), during a period (k), in an age-
group (j) (piglet-sow/boar, weaner or finisher), for all farms (i) included in the rearing path of the 
finisher batch using the formula (Vigre et al., 2010): 
 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 (𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 𝑝𝑝𝑝𝑝𝐴𝐴.𝑑𝑑𝑑𝑑𝑑𝑑)⁄ =  𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖  (𝑚𝑚𝐴𝐴)𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑖𝑖 ∗ 𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖(𝑚𝑚𝐴𝐴 𝐴𝐴𝐴𝐴⁄ ) ∗ 𝑝𝑝𝑝𝑝𝐴𝐴𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖                         
 
where, product (mg) = the recorded amount of an AM product used in an age-group; piglet-sow/boar, 
weaner or finisher, corresponding to the units in a farm, days = the interval in days between the 
initial recorded date and the subsequent recorded date. The days were estimated first for both 
dispensing-types as; days between VetStat records at farm and age-group level (Manuscript I), and 
secondly for peroral as; days between VetStat records at farm, age-group and dispensing-type level, 
and for parenteral as; days between VetStat records at farm, age-group, dispensing-type and AM-
class level (Manuscript II and III). The ADD(mg/kg) = the standardised dose per kilogram pig, pigs 
= the number of pigs per age-group (j) in a farm unit on any given day obtained from the CHR 
(Manuscripts I and II), or can be estimated from PMD (Manuscripts II and III) data using the formula:  
𝑝𝑝𝑝𝑝𝐴𝐴𝑑𝑑𝑖𝑖 =  𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑡𝑡 𝑝𝑝𝑝𝑝𝐴𝐴𝑑𝑑𝑖𝑖 (𝑑𝑑𝑦𝑦𝑑𝑑𝑝𝑝) ∗ 𝑝𝑝𝑦𝑦𝑑𝑑𝑝𝑝𝑝𝑝𝑟𝑟𝐴𝐴𝑖𝑖365 (𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑)  
  
where, total pigs = the number of pigs produced in a year at a farm i.e. piglets, weaners and finishers, 
rearing =  number of days of rearing; 30 days as a piglet, 55 days as a weaner and 85 days as a 
finisher. The ADDkg/pig day, quantifies the daily number of kg-doses per pig in a farm unit (age-
group) of an AM product in the period between the initial recorded date and the subsequent recorded 
date. Hereafter, the daily usage in a finisher batch can be assembled in numerous ways e.g. product- 
or substance-specific, at age-group or rearing level, for a production period. Alternatively, the daily 
usage at a farm could be followed over a specified period. 
  
The absolute lifetime AMU was summarised at AM-class and dispensing-type levels by 
summarising the AMU in the three rearing periods, given by their rearing pathways and adjusted to 
the proportion of animals being moved from a farm.  The lifetime AMU quantifies the total number 
of ADD kilogram doses used per pig during the entire rearing period of 170 days at AM-class and 
dispensing-type levels (Andersen et al., 2017). Postma et al. (2016) used a similar method of 
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summarising age-group AMU has been described in a previous study, as a lifespan Treatment 
Incidence (TI200) calculated for a pig from birth until slaughter using standardised weights; piglets = 
2kg, weaners, 7kg and finisher = 35kg. 
 
 
 Measuring antimicrobial resistance 
 
There is a long tradition of using culture-based methods to determine the occurrence of AMR in 
research and monitoring systems. The culturing of indicator-bacteria and the determining of their 
phenotypical resistance include colony-forming units (cfu) counting and single-isolate Minimum 
Inhibitory Concentration (MIC) determination  (EFSA, 2008). The cfu method provides the level of 
resistance of the bacteria species in a sample by comparing enriched plates with and without a 
selective AM substance, while the MIC method determines the occurrence of multi-drug resistance 
at high accuracy in one single isolate. However, none of the methods offer any insight into the 
underlying mechanism of resistance or the epidemiology within a bacterial population (Munk et al., 
2017). The cultivation methods suffer from being time-consuming and labour intensive, but more 
important due to the limited isolates assessed, the methods provide limited knowledge of the 
occurrence of AMR across species (Munk et al., 2017)  
    
Several molecular methods focusing on DNA and RNA for characterising and quantifying 
antibiotic resistance are increasingly being utilised in research. The polymerase chain reaction (PCR) 
used to detecting AMR in samples is highly sensitive and generates direct information about the DNA 
sequence of interest within hours at low costs. The quantitative PCR (qPCR) is an expansion of the 
PCR, i.e. the method encompasses the efficiency of the PCR, providing, in addition, a quantitative 
estimate of the abundance of the AMR gene targeted. With the recent development in qPCR arrays, 
the number of genes assessed simultaneously has increased immensely and the method has been 
beneficially employed to manure and soil samples  (Luby et al., 2016; Birkegård et al., 2017). The 
most recent metagenomics methods are independent of resistance knowledge. Therefore, in a single 
sample, the collective genes can be sequenced, and using read mapping the AMR can be identified 
and quantified. The method has already been used for a broad number of sample types, ranging from 
water, waste-water, human stool and livestock faeces. Due to the usability of the metagenomics 
methods and the low-cost DNA sequencing technologies within range, these methods may surpass a 
PCR-based approach. Furthermore, metagenomics methods will provide additional knowledge of e.g. 
resistance mechanisms, gene location etc. (Luby et al., 2016; Munk et al., 2017). 
 
 
 Mechanisms of antimicrobial usage and resistance  
 
Long before AMs were discovered, AMR existed in nature, produced by funguses and bacteria as 
an advantage mechanism to ensure survival (Davies and Davies, 2010; Holmes et al., 2016). Some 
bacteria e.g. Actinobacteria, also contain the corresponding resistance gene, as a self-protection 
mechanism against the AM they produce themselves (Jiang et al., 2017). Nonetheless, the emergence 
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of bacteria with corresponding AMR genes as an adaptation defence mechanism against the AMs 
produced in the natural environment evolved concurrently (Kobayashi et al., 2007; Holmes et al., 
2016; Jiang et al., 2017). The group of AMs does not solely comprise the antibiotics; the antifungals, 
antivirals, and antiparasitics are also included in the AM category. In this thesis, AMs are 
synonymous with antibiotics only, whether they occur naturally or are produced synthetically.  
 
The different actions of AMs can roughly be categorised as four distinct mechanisms’, which 
include; i) interference with the synthesis of the cell wall or destruction of the cell wall; ii) interference 
with the DNA/RNA synthesis; iii) interference with the protein synthesis; and iv) inhibition of the 
metabolic pathway (Fig. 4). 
 
 
 
Fig. 4. Mechanisms of action of antimicrobial targets and antimicrobial resistance. 
 
 
Usage of AMs aims at reducing the occurrence of bacteria that negatively affect human and animal 
health. However, the widespread use and misuse in modern medicine has reinforced the evolutionary 
adaptive capacity of bacteria (Darwinism) in order for them to survive in their environment. It is 
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worth noting that other substances of importance potential causing the emergence and spread of 
resistance genes in bacteria include heavy metals and biocides, e.g. zinc, copper and quaterium 
ammonium compounds (Singer et al., 2016), however, the co-selecting effect of biocides is still 
debated (Wales and Davies, 2015).  
 
The mechanisms of action behind the resistance genes of AMs include; alteration by inactivation 
or modification of the substance that subsequently becomes inactive, alteration of target site or 
binding site of the substance that is imperative for the action, since alteration of the metabolic pathway 
bypasses the action of the substance, reducing membrane permeability (up-take) and causing efflux 
membrane pumps to actively force the substance out of the bacteria (Fig. 4) (Singer et al., 2016). 
 
AMR can be intrinsic, thus, a natural phenomenon found in the genome of some bacteria species 
and these resistance genes occur without selection pressure from animal and human AMU (Singer et 
al., 2016). Whereas acquired AMR is a response to animal and human AMU that develops by means 
of mutation in the genome, and is then vertically spread by bacteria replication, or happens by 
acquisition of resistance genes from other bacteria that have the genetic material located on mobile 
elements, which can then be transferred horizontally. Horizontal transfer includes; transfer through 
conjugation (contact transfer), transformation (via bacteriophages) or transduction (naked DNA). The 
mobile elements consist of plasmids, transposons, insertion sequences and integrons. In particular, 
conjugative plasmids facilitate the horizontal spread of resistance, since plasmids are capable of 
replication independent of the chromosomal DNA (Aarestrup et al., 2006; Barlow, 2009).  
 
In addition, the AMR level is also fostered by the increased prevalence of multi-drug resistant 
bacteria, where co-selection promotes the occurrence of resistance genes further. Co-selection is an 
overall term for co-resistance, where the selection of one resistance gene also promotes the prevalence 
of other resistance gene(s), through the genomic architecture e.g., combined resistance genes found 
within plasmids etc., and for cross-resistance, where one resistance gene safeguard from multiple 
substances e.g. efflux pumps (Cantón et al., 2011; Singer et al., 2016). 
 
Supported by experimental evidence, it is assumed that the carrying of AMR genes comes at a 
cost (fitness cost) i.e. the ability to survive in a competitive environment is reduced without the 
selective pressure from the AM. Thus, when an AM is withdrawn the resistant bacteria are out-
competed by organisms susceptible to the AM (Wright, 2007; Andersson and Hughes, 2010). 
However, it has been demonstrated that compensatory mutations can restore the fitness and that some 
AMR has insignificant or increased fitness (Wright, 2007; Andersson and Hughes, 2010). In an 
experimental study, it was demonstrated that 21 days after AMU ceased, resistant E. coli could still 
be found in faeces sample from weaners (Cavaco et al., 2008). Therefore, the withdrawals of AMs 
may not achieve a desired reduction in AMR (Holman and Chénier, 2013, 2015). 
 
Overall, the ability of bacteria to mobilise and transfer resistance genes between bacteria in 
numerous ways, combined with co-selection from AMs, makes the resistome of the environment, 
animals and humans, and their mutual connections relevant (Singer et al., 2016; Jiang et al., 2017).  
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 Factors affecting antimicrobial usage and resistance 
 
The use of AMs is the single most important risk factor in the emergence and spread of AMR in 
pig production. However, it has been demonstrated that factors related to the management of AMs 
have an interacting effect on the occurrence of AMR, e.g. usage of several AMs simultaneously and 
usage at sub-therapeutic doses (Dawson et al., 1984; Akwar et al., 2008; Varga et al., 2009; Looft et 
al., 2012) (Fig. 5).  
 
Previous studies have demonstrated that the dispensing-type (Varga et al., 2009; Zhang et al., 
2013; Burow et al., 2014) and the dose affected the occurrence of AMR (Varga et al., 2009; Zhang 
et al., 2013). However, these findings have not been supported by other studies involving dispensing-
type (Græsbøll et al., 2017) and dose (Burow et al., 2014; Græsbøll et al., 2017) (Fig. 5).   
 
 
 
Fig. 5. Causality diagram of antimicrobial usage and antimicrobial resistance in a batch of finishers and the 
factors with direct and interacting effect. 
 
The AMU history of a farm of origin can affect the AMR in pigs at the subsequent farm (Dawson 
et al., 1984; Dorado-García et al., 2016). Kietzmann et al. (1995) demonstrated that the 
concentrations of non-metabolised substances and active metabolites in blood of untreated pigs from 
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one pen depended on whether or not the previous pigs in the same pen had been treated perorally with 
antimicrobials (Fig. 5). 
 
High number of tetracycline-resistant bacteria in slaughter pigs from farms with no usage have 
been demonstrated (Dunlop et al., 1998; Vieira et al., 2009), which could be a baseline level as a 
result of previous usage and maintained by intrinsic or acquired co-selection. Zhang et al. (2013) 
demonstrated high levels of tetracycline resistance in organic farms with no tetracycline usage for 
years. Taylor et al. (2009) demonstrated fluoroquinolone resistance in 19% (E. coli) and 54% 
(Campylobacter) at 108 farms with no history of fluoroquinolone usage. Although at low levels, 
several resistances e.g. chloramphenicol and vancomycin can still be found in faeces samples from 
finishers even though the AM substances have not been used for several years (Aarestrup et al., 2001; 
Munk et al., 2017) (Fig. 5).   
 
A pathway for AM contamination from pigs into the surrounding environment is caused by AMU 
treatments, because 30-90% of the substances will be excreted either non-metabolised or as active 
metabolites with the manure and urine (Berendsen et al., 2015; Singer et al., 2016). As a result, AMs 
in waste from treated pigs are disseminated in the pen, and potentially to other pens or the stable. The 
level of non-metabolised substances and metabolites could be viewed as sub-therapeutic dosages that 
continuously affect the emergence and spread of AMR bacteria (Berendsen et al., 2015). The AM 
substances more frequently found in sludge were the less water soluble ones, e.g., trimethoprim, 
sulfamethoxazole, and doxycycline (Singer et al., 2016) (Fig. 5). 
 
A study comparing farms from Belgium, France, Germany and Sweden demonstrated that lifespan 
AMU was positively associated with the number of pathogens vaccinated against (Postma et al., 2016, 
2016a), and an experimental study demonstrated that the AMU could be reduced by the management 
strategies; biosecurity and vaccines (Rojo-Gimeno et al., 2016). However, an assessment of 
vaccination strategies and AMU could not find any relationships between increased usage of vaccines 
and reduced AMU (Kruse et al., 2017) (Fig. 5). 
 
Studies investigating farm factors related to AMU have demonstrated that integrated productions 
have lower AMU compared with finisher farms, and the higher the pig population density in a region 
the higher the farm AMU (Hybschmann et al., 2011; van der Fels-Klerx et al., 2011). Moreover, that  
higher AMU was associated with relatively smaller farms compared with larger and very large farms 
(Hybschmann et al., 2011; Vieira et al., 2011). Studies have indicated that vets have a larger influence 
on AMU at pig farms (Vigre et al., 2010; Hybschmann et al., 2011) (Fig. 5).   
 
The stage of production (piglets, weaner and finisher) has been demonstrated to be a predictor of 
AMR that could not be explained by AMU alone, with weaners being the age-group with the highest 
level of resistance (Gibbons et al., 2016). A decrease in AMR during the rearing period has been 
found in several studies (Dewulf et al., 2007; Hansen et al., 2013). Postma et al. (2016) demonstrated 
that the lifespan AMU (TI200) was reduced in farms with a farrowing rhythm above five weeks and 
weaning at older ages. As parallels to cross-contamination over time, the tetracycline resistance level 
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in off-springs has been found to be highly affected by the sow’s previous tetracycline usage (Mathew 
et al., 2005), and the AMR genes from sows have been demonstrated to persist in finishers at time of 
slaughter (Birkegård et al., 2018). Furthermore, an experimental study showed that transfer of 
resistance between pens by cross-contamination was possible (Dawson et al., 1984) (Fig. 5).   
 
Studies have demonstrated that mixing of pigs (Dawson et al., 1984; Andraud et al., 2011), 
crowding and cold stress (Mathew et al., 2003), inside pen hygiene (Dewulf et al., 2007), all-in-all-
out system (Schuppers et al., 2005), and lack of rodent control programmes all had an effect on the 
AMR level (Literak et al., 2009; Vico et al., 2011). Furthermore, AMR bacteria can be transferred 
between pigs and farmers (Moodley and Guardabassi, 2009; Hammerum et al., 2014). Some studies 
have demonstrated that heavy metals Zinc (Zn) and Copper (Cu) in soil (Singer et al., 2016; Song et 
al., 2017) and feed (Hasman and Aarestrup, 2005; Bergenholtz et al., 2009; Cavaco et al., 2010; 
Cavaco, Hasman and Aarestrup, 2011), by co-selection, affect the occurrence of resistance, and may 
even exert stronger selection pressure (Song et al., 2017) (Fig. 5). 
 
Increased farm biosecurity measured as transport of animals, removal of manure/dead animals 
and cleaning/disinfection, have been demonstrated to be associated with increased daily weight gain 
and reduced AMU, which was presumed to be related to the accompanying reduction of pathogens 
entering and spreading within a farm (Laanen et al., 2013; M. Postma et al., 2016, 2016a). Backhans 
et al. (2016) demonstrated that the level of biosecurity did not affect AMU, but the individual 
characteristics of farmer or employees such as age gender and years of experience influences the 
AMU level (Fig. 5).    
 
Notwithstanding AMs being the most important factor for the emergence and spread of AMR, 
the number of potential risk factors additionally influencing the occurrence of AMR either directly, 
through an interacting effect on the AMU and AMR relationship, or through factors affecting the 
AMU in a pig, is substantial (Fig. 6).  
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Figure 6. Factors with a potential effect on antimicrobial usage and occurrence of antimicrobial resistance in 
a pig. 
 
 
 Register-based data 
 
In epidemiological studies, primary data obtained at farm level are the best source of information, 
because they have been collected with a specific research question in mind, a hypothesis. In contrast, 
data extracted from databases, which initially were intended for a specific task, e.g. management, 
surveillance or control functions, are data collected for other purposes than the initially intended. 
Thus, the data will not have been collected with a specific research question in mind, and will 
therefore be considered secondary data. As secondary data has the advantage of often being available 
in large amounts, the time and cost of obtaining data are less in comparison to collecting the same 
amount of primary data. Because, secondary data can be obtained for a large part of the population, 
it is less likely to be affected by selection bias, which may occur when primary data are being 
collected. The disadvantage of secondary data is that the correctness may vary substantially between 
sources, and efforts to control or validate it may be beyond the reach of the researcher (Sørensen, 
Sabroe and Olsen, 1996; Emanuelson and Egenvall, 2014).  
 
With the increased use of register data in veterinary research, it is essential to validate data, in 
order to work out the extent of data coverage, e.g. the entire population of interest, the registration 
period time coverage, the accuracy of the data in completeness and correctness, moreover, how 
precise the data are themselves. These measures will, in turn, demonstrate the quality of the secondary 
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data, which will be supportive when evaluating the trustworthiness of studies of AMU and AMR 
relationships using these data (Sørensen, Sabroe and Olsen, 1996; Emanuelson and Egenvall, 2014). 
 
In Denmark, several databases have been established within the veterinary sector, such as the 
National Central Husbandry Register (CHR), Pig Movement Database, VetStat, National Veterinary 
practitioners register (VetReg), Laboratory tests register (national mandatory tests), Zoonosis register 
for Salmonella in swine (ZOOR), meat inspection database for cattle and swine, and Swine 
production data (Houe, Gardner and Nielsen, 2011). These databases are increasingly being used for 
research purposes due to their completeness at national level. 
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SUMMARY
The objectives were to present three approaches for calculating antimicrobial (AM) use in pigs
that take into account the rearing period and rearing site, and to study the association between
these measurements and phenotypical resistance and abundance of resistance genes in faeces
samples from 10 ﬁnisher batches. The AM use was calculated relative to the rearing period of the
batches as (i) ‘Finisher Unit Exposure’ at unit level, (ii) ‘Lifetime Exposure’ at batch level and
(iii) ‘Herd Exposure’ at herd level. A signiﬁcant effect on the occurrence of tetracycline resistance
measured by cultivation was identiﬁed for Lifetime Exposure for the AM class: tetracycline.
Furthermore, for Lifetime Exposure for the AM classes: macrolide, broad-spectrum penicillin,
sulfonamide and tetracycline use as well as Herd Unit Exposure for the AM classes:
aminoglycoside, lincosamide and tetracycline use, a signiﬁcant effect was observed on the
occurrence of genes coding for the AM resistance classes: aminoglycoside, lincosamide,
macrolide, β-lactam, sulfonamide and tetracycline. No effect was observed for Finisher Unit
Exposure. Overall, the study shows that Lifetime Exposure is an efﬁcient measurement of AM
use in ﬁnisher batches, and has a signiﬁcant effect on the occurrence of resistance, measured
either by cultivation or metagenomics.
Key words: Antimicrobial drugs, antimicrobial resistance in agricultural settings, cultivation,
metagenomic, pigs.
INTRODUCTION
The World Health Organization has declared that
antimicrobial resistance (AMR) is one of the most
worrying health threats to humans in the 21st century
[1], as it adversely affects treatment options in human
medicine [2]. Current AMR surveillance is based
mainly on passive reporting of clinical diagnoses
and phenotypical laboratory results for speciﬁc
pathogens [3]. However, an approach that provides an
insight into the phenotypical resistance may not be
representative for the overall occurrence of resistance
in the bacterial population it is derived from [3].
Swann et al. were the ﬁrst to raise awareness of a
potential link between veterinary use of antimicrobials
(AMs) and bacterial AMR in humans [4]. This relation-
ship has since been conﬁrmed by several studies [5–8].
Different methods have been used to measure AMR
in the livestock reservoir, including culture-based and
molecular methods [3, 9]. Metagenomics sequencing
and read mapping have recently been revealed as
powerful methods for quantifying AMR in the
* Author for correspondence: V. D. Andersen, Research Group
for Genomic Epidemiology, Technical University of Denmark,
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normal ﬂora of pigs [3]. Quantiﬁcation of the presence
of resistance genes is of relevance when attempting
to quantify the contribution from pigs to human
pathogens [7, 8, 10].
The association between veterinary use of AM and
AMR in bacterial isolates from pigs has been
demonstrated repeatedly [11–16] with variations in
its occurrence being related to variations in AM use
[12, 14–16]. Therefore, less frequent use of AMs in
pig farms is a vital factor in reducing the occurrence
of AMR in ﬁnishers [8, 17–19]. Thus, in order to
develop effective tools for interventions and targets
for AM reduction, a standardised method is required
that closely reﬂects the dynamics of AMR. As with
AMR, which may be measured in several different
ways, AM usage may be quantiﬁed using different
approaches [12, 14–16, 20].
AM use for ﬁnishers has traditionally been
calculated based on data obtained either from farm
records [16, 21–23] or from databases on prescribed
medicines: at unit [14, 16], farm [12, 14, 16] or farm-
owner level [20, 24]. An AM calculation restricted to
a speciﬁc unit may lack essential information when
compared with the exposure during the entire rearing
period from a piglet’s birth to the ﬁnal fattening stage.
This is often the case for the ﬁnisher unit, where AM
use is particularly low [25]. In Denmark, farm-level
(integrated) data will not be available for a vast pro-
portion of farms delivering ﬁnishers for slaughter
[26], as traditional integrated pig production has
largely been replaced by multisite pig production
where rearing (the farrowing unit→ the weaning
unit→ the ﬁnisher unit) takes place on farms at differ-
ent geographic sites that are owned either by the same
farmer or by different farmers [26]. Therefore, the esti-
mation of usage at farm level does not reﬂect the full
exposure during the rearing period. The farm-owner
level calculations may include AM use of no relevance
if one or more farms are not part of the rearing
system.
The periods set for the data extraction in the same stu-
dies were mostly 1 year prior to sampling [12, 14, 20].
However, changes in AMR amounts occur at much
shorter time spans [13, 16, 27], and yearly calculations
of AM use may therefore be insufﬁciently reﬁned for
the purpose of revealing associations at ﬁnisher batch
level. Furthermore, regarding ﬁnisher production, each
group of animals (batch) is moved from farrowing to
weaning and then to the ﬁnisher unit primarily on an
all-in/all-out basis. Thus, the variation in AM use
between batches due to the occurrence of diseases will
not be observed when the calculation of AM use covers
a whole year.
By means of the Central Husbandry Register
(CHR), the Danish Pig Movement Database (PMD)
and the Danish Veterinary Medicines Statistic
Program (VetStat), it is possible to calculate an
approximation of the AM use per batch based on
the rearing period and the rearing site/sites, thus cap-
turing variation in AM use between batches. AMR
results for ﬁnishers can therefore be obtained at time
of slaughter, without consideration for rearing site
(s). The objectives of the study were to: (i) develop
three different approaches for calculating AM use at
ﬁnisher batch level, taking into account the rearing
period and rearing site, and (ii) compare the associ-
ation with measured AMR in composite faeces sam-
ples from 10 batches of ﬁnishers.
METHODS
Data sources
Data on the farms and number of pigs were obtained
from the national CHR, where all farms with produc-
tion animals are recorded [28, 29]. The CHR stores
information linked to a farm code (ID), which refers
to a speciﬁc geographical location and includes, e.g.
animal species, the number of animals per age group
(sows, weaners, ﬁnishers), thus the number per unit
on any given day. The pigs owned by a producer
(the herd) can be kept at many geographical localities
(farms). For the sake of simplicity, all animals owned
by an individual producer are referred to as a herd
throughout the study even though some herds are
kept at many farms [24].
Data on movements of pigs between farms were
obtained from the PMD, an integral part of the
CHR. The PMD records the number of pigs, date,
ID of origin farm and ID of destination farm for
each movement [28, 29].
Data on AM use were obtained from VetStat,
which contains data on all medicine prescribed by
veterinarians for animals. Records are based on veter-
inarian prescriptions and contain information on
active substances, amounts, target species, age groups,
diagnosis groups and farm IDs [29]. The age groups in
VetStat correspond to the age groups in the CHR, and
the units, sows, weaners and ﬁnishers on a farm. In
order to produce comparable data across records,
active compounds were converted into a unit measur-
ing how many kilograms of pig could be treated per
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day – Animal Deﬁned Daily Doses per kilogram
(ADDkg) [30].
Study design
The study design used was ﬁrst described by Munk
et al. [3]. In brief, based on the average sizes for sow
and ﬁnisher farms in 2009 [31, 32], herds with more
than 500 sows and a production of at least 5000
ﬁnishers annually were selected using the CHR and
PMD. In total, 376 herds met these criteria. From
VetStat, the total amounts of AM and tetracycline
used in these herds from June to November 2013
were calculated as ADDkg and adjusted according
to the number of animals in the herds. To cover a
wide span of AM use, the 376 herds were ranked,
and the owners of the top and bottom 10% AM and
tetracycline use quantiles were invited to participate
consecutively until ﬁve herds within each quantile
had accepted. Each of these 10 herds was located
between one and seven farms. In total, 23 herds
from the top quantile and 15 herds from the bottom
quantile were invited.
In the ﬁnisher units of the 10 herds, composite
pen-ﬂoor samples were collected consisting of single
samples from 30 randomly chosen pens within the sec-
tion(s) with ﬁnishers weighing between 80 and 100 kg
(in Denmark, pigs are delivered for slaughter weighing
100–105 kg) [3,9]. For each herd, the group of pigs
from which samples were collected represents a
ﬁnisher batch. For each of the ﬁnisher batches, the
30 single faeces samples were pooled together, result-
ing in one pooled sample per batch. Sampling took
place from March to June 2014.
Measurements of AM use
For each batch of ﬁnisher, three quantitative usage
measurements of the AM classes: aminoglycoside, lin-
cosamide, macrolide, broad-spectrum penicillin, sul-
fonamide and tetracycline were calculated. They
were based on the day of sampling, as the start from
which backward assessment of time periods in the
rearing site(s) were established. The measurements
varied in terms of exposure, as explained below.
Danish national averages for pig production prod-
uctivity for 2014 were applied for the rearing periods
per unit (in days) [33–35], resulting in 25, 50 and 85
days in the farrowing (piglet), weaning (weaner) and
ﬁnisher units (ﬁnisher), respectively. Starting with
the ﬁnisher batches and the day of sampling, the
PMD was used to trace the movements of the batches
from sampling site back to birth site. Figure 1 shows
the pathways of the 10 ﬁnisher batches.
Each farmer in the study had a health advisory con-
tract with an individual veterinarian in accordance
with Danish legislation. These contracts permit veter-
inarians to prescribe AMs for treatment of plausible
diseases diagnosed at a farm visit for the subsequent
35 or 63 days (ﬁnishers only) at which point the next
visit must take place. Therefore, taking into account
the rearing period of 160 days, and the maximum per-
iod a prescription may cover (63 days), data from
VetStat on prescribed AMs 9 months prior to sam-
pling were extracted for the 22 farms comprising the
ﬁnisher batches’ pathways from birth to sampling
site (Fig. 1).
AM exposure was calculated for the classes: amino-
glycoside, lincosamide, macrolide, broad-spectrum
penicillin, tetracycline and sulfonamide, as these are
most commonly used in Danish pig production [25].
By adopting the method used by Vigre et al. [24],
the daily amounts of the six AM classes used were cal-
culated for sows, weaners and ﬁnishers in each of the
22 farms based on two assumptions. First, as veteri-
narians are permitted to prescribe for potential dis-
eases for 35 or 65 days, the interval between two
prescriptions was used to calculate the daily use for
each prescription of AM, assuming that an average
amount of the prescribed AM was used on each day
of the interval. The calculations were subsequently
added together per day per AM class. Second, if an
interval was shorter than 7 days, the following pre-
scription date was used to set the number of days
for the interval.
Thus, the daily use of an AM was calculated as an
average daily use per farm (F) per age group/unit (U)
and adjusted in accordance with the number of pigs at
risk per day per unit on each farm, as:
ADDkg day AM F U
= ADDkg AMprescribed F U
daysprescription interval H × pigsday F U ,
where ADDkg AMprescribed F U = the prescribed
amount per unit per farm measured as ADDkg,
daysprescription interval = the interval in days between
the day of the initial prescription and the day of the
subsequent prescription and pigsday_F_U= the number
of sows, weaners or ﬁnishers on any given day. The
number of sows substituted the number of piglets, as
the latter is not registered in the CHR.
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The number ofADDkg day AM F U was then sum-
marised per day for each AM class (AMc):
ADDkg day AMc F U =
∑n
AM=1
ADDkg day AM F U .
Based on the ﬁnisher batches’ rearing periods in
days: days 1–85 in the ﬁnisher unit, days 86–135 in
the weaning unit and days 136–160 in the sow unit,
where day 1 corresponds to the day of sampling
(Fig. 1), the number of ADDkg day AMc H U was
summarised for each rearing period (R) per unit,
and adjusted to suit the proportion (P) of animals
being moved from a farm (Fig. 1):
ADDkg AMc R U =
∑n
date=1
ADDkg day AMc F U × P.
For each AM class, three measurements of expo-
sure were calculated, given the rearing pathways, the
rearing periods (Fig. 1) and the unit(s) in each farm
(Fig. 2).
Finisher UnitExposure AMc
= ADDkg AMc Finisher Finisher
Lifetime Exposure AMc= ADDkg AMc Piglet Sow
+ADDkgAMc Weaner Weaner
+ADDkg AMc Finisher Finisher
Herd Exposure AMc = ADDkg AMc Piglet All
+ADDkg AMc Weaner All
+ADDkg AMc Finisher All.
For information on the units per farm included in the
exposure measurements in the rearing period of the 10
ﬁnisher batches, see Figure S1 in the Supplementary
data. For information on the obtained exposure vari-
ables, see Table S1 in the Supplementary data.
AMR measurements
In this study, the cultivation and metagenomic results
of the pooled samples from 10 pig herds described by
Munk et al. [3] were used as the AMR results.
Cultivation
In brief, for each pooled sample, faeces was suspended
in isotonic saline prior to serial dilution. Aliquots of
Fig. 1. The rearing pathway of each of the 10 ﬁnisher
batches from birth site to ﬁnisher site compared with the
day of sampling. The 10 horizontal bars depict the
movements of the batches. A colour shift in a bar denotes
that a farm has a different geographical location to the
farm where sampling took place and P denotes the
proportion of pigs being moved. Bars without P are equal
to one. Numbers 1–5 denote the initially high users and
6–10 depict the initially low users. The three vertical
coloured bars represent the assumed days of exposure to
AM in the: sow-piglet (farrowing) unit, weaner unit and
ﬁnisher unit.
Fig. 2. The exposure measurements of AM usage. The
orange square applies to Finisher Unit Exposure and
therefore comprises the AM usage in the ﬁnisher-rearing
period in the ﬁnisher unit. Lifetime Exposure applies to the
orange, green and blue squares, and therefore comprises
the AM usage in the piglet-rearing period in the sow unit,
the weaning-rearing period in the weaning unit and the
ﬁnisher-rearing period in the ﬁnisher unit. The red square
applies to Herd Exposure, and therefore comprises AM
usage throughout the entire rearing period in all units.
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dilutions were plated onto selective and non-selective
LB and MacConkey plates to quantify aerobic bac-
teria and Escherichia coli, respectively. Selective plates
contained 8 mg/l tetracycline (T3383 tetracycline
hydrochloride, former: Sigma-Aldrich, current:
Thermo Fisher Scientiﬁc, Roskilde, Denmark) in LB
and 16 mg/l ampicillin (A9393 Ampicillin, former:
Sigma-Aldrich, current: Thermo Fisher Scientiﬁc,
Roskilde, Denmark) or tetracycline in MacConkey.
All assays were performed in triplicate. For each trip-
licate set, a weighted average of resistance proportion
was calculated based on cfu counts per dilution [3].
For information on the obtained outcome variables,
see Table S1 in the Supplementary data.
Metagenomics
In brief, AMR genes for the classes: aminoglycoside,
lincosamide, macrolide, β-lactam, sulfonamide and
tetracycline were obtained using whole community
sequencing (WCS), and measured as reads per kilo-
base reference per million (RPKM). For information
on the genes within each AMR class, see Table S2
in the Supplementary data.
In order to compare the 10 faeces samples, the raw
read counts were normalised to the size of the dataset
for each AM class with the following formula:
Reads per kilobase reference per millionAMc
= n
N(l − (i − 2m))
( )
106R× 1000 bp,
where n= number of mapped reads, N= total number
of reads, l = gene length, i= insert size, m=minimum
mapping length, R= reads and bp = base pair.
The normalisation takes into account the fact
that the pooling and sequencing of several indexed
samples produces varying DNA library sizes, resulting
in comparable RPKM values and independence
of sequencing depth. For information on the obtained
outcome variables, see Table S1 in the Supplementary
data.
Data analyses
The quantitative effect of broad-spectrum penicillin
and tetracycline use, measured as Finisher Unit
Exposure, Lifetime Exposure and Herd Exposure, on
ampicillin and tetracycline resistance obtained by cul-
tivation was calculated using simple linear regression,
and as a measure of model ﬁt, the coefﬁcient of
determination (R2) was applied. The quantitative
effect of exposure for the AM classes: aminoglycoside,
lincosamide, macrolide, broad-spectrum penicillin,
sulfonamide and tetracycline, measured as Finisher
Unit Exposure, Lifetime Exposure and Herd
Exposure, on similar AMR gene abundance was cal-
culated using simple linear regression, and as a meas-
ure of model ﬁt, the coefﬁcient of determination (R2)
was applied. The assessment of homoscedasticity
was performed by visual inspection of the plots,
including measured values and regression lines.
WPS Workbench, Version: 3.1.1.0.0, and Microsoft
Excel 2010 were applied in data processing, and data
analyses were performed using R, version 3.
RESULTS
The three different quantitative measurements of total
AM use presented in Figure 3 show use within the
applied rearing periods. The Lifetime Exposure is
lower than Herd Exposure, as the former consists of
a part of the latter. The difference is caused by the
level at which data were obtained; the Lifetime
Exposure was obtained at rearing batch level, while
the Herd Exposure was obtained at rearing herd
level. A similar pattern applies to the Finisher Unit
Exposure compared with the Lifetime Exposure,
since the latter was obtained at batch level, whereas
the former was obtained at unit level. Figure 4
shows the distribution of the intervals in days between
prescriptions. Most of the intervals are between 24
and 45 days, with fewer between 7 and 21 days. The
short prescription intervals were observed mainly in
the initially high-user farms. Of these intervals, two-
thirds were due to a subsequent prescription of the
same AM, with the remaining third caused by a differ-
ent prescribed AM.
Association between AM use and phenotypical
measured resistance
Figure 5 shows the regression models with 95% conﬁ-
dence intervals of the quantitative effect of Lifetime
Exposure for broad-spectrum penicillin and tetracyc-
line use on the average proportion of ampicillin and
tetracycline-resistant E. coli (MacConkey), respect-
ively, and of Lifetime Exposure for tetracycline use
on the average proportion of tetracycline-resistant aer-
obic bacteria (LB). The β-values, P-values and R2
values for the regression analyses are shown in the
same ﬁgure. The regression analyses showed only a
signiﬁcant effect of Lifetime Exposure for tetracycline
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use on the average proportion of tetracycline-resistant
aerobic bacteria (Fig. 5).
No signiﬁcant effect was observed for Finisher Unit
Exposure or Herd Exposure (result not shown).
Association between AM use and metagenomic
measured resistance
No signiﬁcant effect was observed of Finisher Unit
Exposure for any of the AM classes on their respective
AMR gene classes (result not shown).
Figure 6 shows the regression models with 95%
conﬁdence intervals for the quantitative effect of
Lifetime Exposure for the AM classes: aminoglycoside,
lincosamide, macrolide, broad-spectrum penicillin, sul-
fonamide and tetracycline on the AMR gene classes:
aminoglycoside, lincosamide, macrolide, β-lactam,
sulfonamide and tetracycline. The β-values, P-values
and R2 values for the regression analyses are shown in
the same ﬁgure. The regression analyses revealed a
signiﬁcant effect of Lifetime Exposure for the AM
classes: macrolide, broad-spectrum penicillin, sulfona-
mide and tetracycline on AMR genes for macrolide,
β-lactam, sulfonamide and tetracycline, respectively
(Fig. 6).
Figure 7 shows the regression models with 95%
conﬁdence intervals of the quantitative effect for Herd
Exposure for the AM classes: aminoglycoside,
lincosamide, macrolide, broad-spectrum penicillin,
sulfonamide and tetracycline on the AMRgene classes:
aminoglycoside, lincosamide, macrolide, β-lactam,
sulfonamide and tetracycline. The β-values, P-values
and R2 values for the regression analyses are shown in
the same ﬁgure. The regression analyses revealed a
signiﬁcant effect of Herd Exposure for the AM classes:
aminoglycoside, lincosamide and tetracycline on the
AMR genes for aminoglycoside, lincosamide and
tetracycline, respectively (Fig. 7).
The regression models were re-analysed, excluding
the most extreme data point of each set, to assess
the robustness of the signiﬁcant results. The signiﬁcant
effect of Lifetime Exposure for the AM classes: macro-
lide, sulfonamide and tetracycline on the occurrence
of macrolide, sulfonamide and tetracycline resistance
genes, respectively, remained under the 5% signiﬁ-
cance level. This was not the case for the signiﬁcant
Fig. 3. Finisher Unit Exposure, Lifetime Exposure and Herd Exposure. The total AM use and the distribution between
sow piglets, weaners and ﬁnishers within the 10 ﬁnisher batches. Numbers 1–5 denote the initially high users and 6–10
depict the initially low users.
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effect of broad-spectrum penicillin usage on the occur-
rence of β-lactam resistance genes (result not shown).
Only the effect of Herd Exposure for tetracycline on
tetracycline-resistant genes remained under the 5%
signiﬁcance level (result not shown). The coefﬁcient
of determination (R2) analyses of the models with
signiﬁcant results revealed that the variation of
AMR that could be explained by the Lifetime
Exposure measurements varied from 0·42 (tetracyc-
line) to 0·72 (sulfonamide) for the variables (Figs 5
and 6), and from 0·47 (aminoglycoside) to 0·67 (linco-
samide) for the Herd Exposure measurements (Fig. 7).
DISCUSSION
Independent variables
The exposure measurements were derived from differ-
ent data sources, thereby integrating any errors of the
sources in the daily ADDkg.
The length of the rearing period inﬂuences the expos-
ure measurements; however, this study did not deter-
mine whether the rearing periods should be longer or
overlapped in order to assess the effect on the occur-
rence of AMR genes. Nevertheless, shorter rearing per-
iods reduce the AM amounts, resulting in less variation
in the exposure measurements between ﬁnisher batches.
Longer rearing periods have the opposite effect.
The intervals were calculated based on two assump-
tions. First, as the intervals were not drug-speciﬁc, a pre-
scription of tetracycline followed by a prescription of
macrolide counted as an interval because it was assumed
that any drug shifts were due to a different disease or a
change, as the veterinarian could not observe a sufﬁcient
effect caused by the ﬁrst drug. This is supported by veter-
inarians’ permission to prescribe AMs. Consequently, a
new situation is likely to have occurred on the farm if
AMs were prescribed with intervals shorter than 35
days. Short intervals result in high daily ADDkg, caus-
ing a substantial increase in themeasuredAMuse, as the
prescribed amount of AM is divided by fewer days.
Second, all prescription intervals of <7 days were
assumed to be due to technical issues at the pharmacies,
e.g. shortages of a drug or a shift in batches at the
pharmacy, or caused by the veterinarian issuing two
identical prescriptions (the sub-diagnosis differs) that
were handed in on different dates.
Fig. 4. The distribution of prescription interval days –
days between two prescriptions.
Fig. 5. Univariable linear regression plots (solid line) and
95% conﬁdence interval (dotted lines) of the average
resistance proportion of ampicillin and tetracycline
resistance from cultivation of Escherichia coli on
MacConkey agar with and without ampicillin and
tetracycline, as a function of Lifetime Exposure for the
AM classes; broad-spectrum penicillin and tetracycline,
respectively, and the average resistance proportion of
tetracycline resistance from cultivation of aerobic bacteria
on LB agar with and without tetracycline, as a function of
Lifetime Exposure for the AMc; tetracycline. The grey
points denote the initially high users and the black points
depict the initially low users. The effect (β), the P-value
(P) and the R2 value are shown in the top left corner of
each model.
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Dependent variables
Cultivation using aerobic bacteria and E. coli, respec-
tively, are traditional phenotypical methods for asses-
sing the occurrence of AMR in populations of animals
[9]. However, the approaches only provide insight into
a fraction of the intestinal microbiota, and thus poten-
tially underestimate the actual reservoir of AMR in a
population [3, 7, 9].
WCS measures the presence of known resistance
genes throughout the microbial community, and
therefore does not determine the genetic location of
the AMR genes and thereby whether they are likely to
transfer from the animal to the human reservoir [3].
A distinction between the two is important since
ubiquitous AMR genes may not pose a risk to humans
[19]. By contrast, any AMR genes in excessive
abundance in habitats with high AM use, such as pig
farms, are more likely to be relevant for AMR develop-
ment [7, 19]. Furthermore, as the ResFinder database
contains only AMR genes found in culturable bacteria,
a considerable number of ubiquitous functional AMR
genes may have been missed [3]. Therefore, although
not all AMR genes necessarily constitute a risk to
humans, different amounts in faeces frompigs represent
an available gene pool from which zoonotic bacteria
may obtain resistance genes [19].
Result discussion
The 10 ﬁnisher batches varied in rearing pathways
(Fig. 1) and the herds in which they were produced
differed concerning the number of farms per herd.
Thus, on that basis, no pattern or common feature
could be observed. Given that the study included
Fig. 6. Univariable linear regression plots (solid line) with 95% conﬁdence interval (dotted lines) of WCS – RPKM of the
AMR genes for: aminoglycoside, lincosamide, macrolide, β-lactam, sulfonamide and tetracycline as a function of Lifetime
Exposure for the AM classes: aminoglycoside, lincosamide, macrolide, broad-spectrum penicillin, sulfonamide and
tetracycline, respectively. The grey points denote the initially high users and the black points depict the initially low users.
The effect (β), the P-value (P) and the R2 value are shown in the top left corner of each model.
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only 10 ﬁnisher batches, no attempt was made to con-
duct an analytical adjustment of a potential confound-
ing effect from herd or farm management.
It is notable that the results of the regression models
for four out of six combinations of Lifetime Exposure
vs AMR obtained by WCS (Fig. 6) gave signiﬁcant
results, as did three out of six combinations of Herd
Exposure vs AMR obtained by WCS (Fig. 7). In
order to crudely evaluate the reliability of the results,
the individual observations in each of the signiﬁcant
plots that appeared to have the strongest inﬂuence
on the result were removed and the model was
re-analysed. The Lifetime Exposure measurement
still provided signiﬁcant results for all but broad-
spectrum penicillin, while only Herd Exposure
remained signiﬁcant for tetracycline, indicating that
the former method of measuring AM use is more sen-
sitive. Furthermore, the measurement of Herd
Exposure is highly inﬂuenced by differences in the
units present in each farm, rather than differences in
AM use. By comparing the pathways of the ﬁnisher
batches, large differences can be observed in the num-
ber of units per farm, which would greatly affect the
measurement (Fig. 1 and Supplementary Fig. S1).
The fact that overall the R2 models of Lifetime
Exposure explain more of the variation in AMR com-
pared with Herd Exposure indicates that Lifetime
Exposure has the strongest effect on AMR in ﬁnisher
batches. No effect of Finisher Unit Exposure on AMR
could be demonstrated; however, use of AM in this
unit is limited in terms of both AM classes and
amounts [25].
In this study, a signiﬁcant quantitative association
could be demonstrated for Lifetime Exposure of tetra-
cycline on AMR across methods of obtaining resist-
ance (Figs 5 and 6), which is in alignment with
Fig. 7. Univariable linear regression plots (solid plot) with 95% conﬁdence interval (dotted lines) of WCS – RPKM of the
AMR genes for: aminoglycoside, lincosamide, macrolide, β-lactam, sulfonamide and tetracycline as a function of Herd
Exposure for the AM classes: aminoglycoside, lincosamide, macrolide, broad-spectrum penicillin, sulfonamide and
tetracycline, respectively. The grey points denote the initially high users and the black points depict the initially low users.
The effect (β), the P-value (P) and the R2 value are shown in the top left corner of each model.
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Munk et al., who demonstrated a correlation in AMR
between cultivation and metagenomics [3].
The measurements were calculated as total amounts
throughout the rearing period for the six speciﬁed AM
classes, rather than ameasurement for each rearing per-
iod. Consequently, the measurements do not distin-
guish between different AM use patterns within the
three rearing periods. Batches with the same total AM
class usage might relate to use in different units; thus,
the rearing period, and the occurrence of AMR for
these ﬁnisher batches, may not be identical due to
rapid change in the occurrence of AMR [13, 36].
In this study, three different approaches for calcu-
lating use of AM at ﬁnisher batch level were devel-
oped. Using an optimal and standardised calculation
method is important for setting drug use targets and
for direct possible interventions with an expected
effect on AMR. Lifetime Exposure has the advantage
of being independent of production type/rearing site.
Furthermore, it follows ﬁnisher batches through rear-
ing site(s) in the actual rearing periods, hereby captur-
ing variations in AM use between batches. In contrast
to this, the analyses did not consider other factors e.g.
duration of treatment or dispensing type, which are
known to have an impact on the development and
spread of AMR [16]. Overall, this study showed that
the entire rearing period should be taken into account
when studying the association between AMR and AM
use, and revealed that the method developed for calcu-
lating Lifetime Exposure is an efﬁcient measurement
of the effect of AM use on AMR found in ﬁnisher
batches.
By using metagenomics, we measured the relative
abundance of speciﬁc genes in the faeces. Even if
more DNA fragments were sequenced per sample,
there is a likelihood that genes with a very low relatively
abundance would not be detected. In the estimation of
the association betweenAMandAMR, the abundance
of resistance genes was aggregated to phenotypical
level. The estimated associations should only be inter-
preted at this level and not to gene level. Due to the lim-
ited size of this study, an estimation of the quantitative
association between the AM usage and abundance of
the speciﬁc genes was not carried out.
Overall, the study has generated quantitative
knowledge of how the usage of AM through the entire
rearing period affects the occurrence of AMR in ani-
mals at the end of the production. This knowledge
will be valuable when assessing effects of alternative
AM usage on the occurrence of AMR in the pig pro-
duction. The validity of these assessments will
improve the robustness and precision of the decisions
about interventions targeted against reducing the
occurrence of AMR in pigs.
SUPPLEMENTARY MATERIAL
The supplementarymaterial for this article can be found
at https://doi.org/10.1017/S0950268817001285.
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Table 3.2.1. The independent and dependent variables - mean, median and range. 
Variables Mean Median Range 
Independent      
      
   Aminoglycosides      
        Finisher Unit Exposure 0.0 0.0 0.0 - 0.0 
        Lifetime Exposure 16.0 9.1 0.0 -  69,3 
        Herd Exposure 43.1 12.2 0.5 - 155.2 
   Lincosamides      
        Finisher Unit Exposure 11.3 3.8 0.0 - 79.4 
        Lifetime Exposure 12.9 7.6 0.0 - 41.3 
        Herd Exposure 35.5 14.4 0.0 - 177.2 
   Macrolides      
        Finisher Unit Exposure 27.2 0.0 0.0 - 98.9 
        Lifetime Exposure 57.0 51.6 4.7 - 117.0 
        Herd Exposure 160.7 86.5 10.9 - 493.4 
   Broad-spectrum penicillins      
        Finisher Unit Exposure 9.5 0.0 0.0 - 57.1 
        Lifetime Exposure 17.4 10.4 0.0 - 76.2 
        Herd Exposure 58.2 21.8 0.0 - 236.5 
   Sulfonamides      
        Finisher Unit Exposure 0.0 0.0 0.0 - 0.0 
        Lifetime Exposure 29.9 24.3 1.0 - 83.1 
        Herd Exposure 117.8 70.5 1.0 - 308.2 
   Tetracyclines      
        Finisher Unit Exposure 2.8 0.9 0.0 - 17.2 
        Lifetime Exposure 45.0 27.8 4.4 - 106.9 
        Herd Exposure 120.5 76.9 9.33 - 502.1 
      
Dependent      
      
   Cultivation      
        MacConkey: Ampicillin 0.2 0.1 0.0 - 0.7 
        MacConkey: Tetracycline 0.4 0.3 0.1 - 0.8 
         LB: Tetracycline 0.4 0.4 0.1 - 0.7 
   Whole community sequencing      
        Aminoglycoside 19.8 18.8 12.1 - 34.6 
        Lincosamide 62.1 60.7 40.4 - 107.8 
        Macrolide 162.0 140.9 74.7 - 313.7 
        Beta-lactam 64.9 59.3 31.7 - 120.3 
        Sulfonamide 0.6 0.4 0.1 - 1.9 
        Tetracycline 387.3 385.6 296.9 - 475.8 
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Fig. 3.2.2. The ten finisher batches rearing pathways. A colour shift in a bar denotes that a farm has a different 
geographical location to the farm where sampling took place. The top graph per ID shows the units within each 
farm included in the rearing path, and the graph below shows how the exposure measurements of AMU were 
obtained. The orange square applies to Finisher Unit Exposure and therefore comprises the AMU in the 
finisher-rearing period in the finisher unit. Lifetime Exposure applies to the orange, green and blue squares, 
respectively, and therefore comprises the AM usage in the piglet-rearing period in the sow unit, the weaning-
rearing period in the weaning unit and the finisher-rearing period in the finisher unit. The red square applies 
to Herd Exposure and therefore comprises AMU throughout the entire rearing period in all units. 
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 Discussion 
 
The first objective of the thesis was to develop a method to calculate the AMU in finishers close 
to slaughter based solely on register-data. Several Danish studies have used methods that either 
focused on AMU at farm level or farm unit level (Jensen et al., 2006; Emborg et al., 2007; Vieira et 
al., 2009; Vigre et al., 2010), which may over- and underestimate the amount of AMs a pig has been 
exposed to during the entire rearing period. In addition, studies have demonstrated that AMU during 
the earlier rearing stages influences the occurrence of resistance at later rearing stages (Dawson et al., 
1984; Dunlop et al., 1998; Rosengren et al., 2007). Subsequently, the developed method aimed at 
encompassing all rearing stages as primary sources for the selection of AMR. 
 
The pig industry’s production statistics provided the average rearing period in days per unit 
(piglets, weaners and finishers), however, these numbers should only be viewed as indicative 
(SEGES, 2017). In 2014, the average piglet-nursing period of the highest and lowest preforming 
farms differed by 2.7 days. While weaners’ and finishers’ daily weight gain of the highest and lowest 
performing farms differed by 57g and 120g, respectively (Jessen, 2016). Furthermore, several issues, 
e.g. aggregation of litters at weaning, uneven growth of pigs, limited space, are often solved by mixing 
pigs of similar size or by gathering the smaller (uneven) pigs in separate pens, though the procedures 
cause lack of consistency of individuals in a batch. Therefore, batches of finishers seldom consist of 
the same individuals throughout the rearing period due to different growth of pigs, mixing of pigs and 
movements between units during rearing. For finisher farms, farmers also have to take the slaughter 
house weight limits into account, in order to receive full settlement price for the delivered pigs 
(Danish Crown, 2017). Therefore, a small amount of pigs are often withhold until they have obtained 
the appropriate weight. The post-treatment retention period for AMs will also delay the delivering of 
finishers for slaughter. Consequently, the “finisher batch” represents only a mean rearing path. 
 
The CHR and PDM were used to trace finisher batches back to farm(s) of weaning and birth (Fig. 
3.2.2). Due to the ownership status throughout rearing pathways of the finisher batches in this study, 
the pathways were relatively simple. More complex movement patterns comprising several farms 
have been found in other studies (Birkegård et al., 2017a). The overall movements of pigs in Denmark 
is substantial. A study that included movements between farms in Denmark, showed that of the 3086 
finisher batches included, 80% were moved at least once (Birkegård et al., 2017a). The many 
movements are a result of the increased specialisation in production, i.e. breeding animals, 7kg 
piglets, 30kg weaners, finishers only etc. Nevertheless, difficulties in tracing pigs arise when they are 
moved between farms. It is mandatory to report data in PMD twice for each movement, first by the 
farm sending pigs and secondly by the farm receiving pigs (Executive order 598/2017). In this study, 
a few farmers owing several farms did not register any movements, or their registration only included 
one of the two required. A previous study found that finisher farms had no movements into the farm 
in 61% of cases. For the breeder and rearing farms, the numbers were 74% and 51%, respectively 
(Bigras-Poulin et al., 2007). Therefore, for finisher batches in this study, it was assumed that pigs 
were only moved between farms at ownership level, when movements between farms were 
untraceable.  
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VetStat was used to extract data on AMU. Using the Vigre method to calculate daily usage within 
farm units, provided the foundation for the approaches assessing relevant exposure with an effect on 
the occurrence of AMR in finisher batches close to slaughter (Vigre et al., 2010). Based on the rearing 
pathway, daily AMU amounts were summed at different levels; finisher unit exposure, lifetime 
exposure and herd exposure. The usage was estimated as the number of kilogram pigs that could be 
treated during a specified rearing period. The advantage of the measurement was that it could be 
summed irrespectively of the unit (piglets/sows, weaners and finishers). On the negative side, it was 
very hard to comprehend. The AMU measurements could beneficially have been converted into 
Treatment Incidence of the rearing period, by including kg animals at risk (sow - 200kg, weaner - 
15kg, finisher - 50kg), which would provide the number of treatment days in the batches’ rearing 
period (Jensen, Jacobsen and Bager, 2004; Callens et al., 2012; Postma et al., 2016, 2016a). Changing 
the unit of lifetime AMU to treatment days revealed that the R-squared (R2) of sulfonamides 
worsened, the R2 of aminoglycosides and extended-spectrum penicillins remained the same, and the 
R2 of lincosamides, macrolides and tetracycline improved. Therefore, using the sow weight had a 
negative effect on the sulfonamides primarily used in the sows-piglets unit, however, due to the 
weight of weaners and finishers, a beneficial effect on AMs primarily used in the weaner and finisher 
unit was found (Appendix A, Figure A1). Because the AMU in piglets cannot be established based 
on VetStat data, the biomass adjustment had not yet been considered in the lifetime AMU 
calculations. For the same reason, it was decided to proceed with the measuring unit; ADDkg/pig. 
 
The three approaches have the advantage of being independent of production-system/rearing site, 
as the method follows finisher batches through rearing site(s) in the actual rearing periods, hereby 
capturing variations in AMU between batches. However, none of the preliminary analyses included 
other risk factors, e.g. duration of treatment or dispensing-type, which are known to affect the 
emergence and spread of AMR (Zhang et al., 2013; Collineau et al., 2017). 
 
The AMR resistance was obtained by cultivation using aerobic bacteria and E. coli. These are 
traditional phenotypical methods when assessing the occurrence of AMR in populations of animals 
(Turnidge and Paterson, 2007; Schmidt et al., 2015), e.g. DANMAP.  In particular, E. coli are often 
used for epidemiological studies of AMR in the food chain due to their ubiquitous occurrence, their 
tendency to easily develop AMR, their ability to transfer resistance genes and their potential to work 
as an AMR source (Turnidge and Christiansen, 2005). However, the cultivation methods only provide 
insight into a fraction of the intestinal microbiota of which the majority are anaerobic, but they are 
all affected by AMU (Dawson et al., 1984; Holman and Chénier, 2015). Consequently, the methods 
potentially underestimate the actual reservoir of AMR in the microbiota of pigs (Marshall and Levy, 
2011; Schmidt et al., 2015; Munk et al., 2017).  
 
The shotgun metagenomic sequencing (called WCS in manuscript I and II) measures the relative 
presence of resistance genes throughout the microbial community. The method does not determine 
whether the genetic location of the AMR genes is intrinsic or acquired, thus, the method cannot 
establish if the genes are likely to be transferred from the pig to the human reservoir (Munk et al., 
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2017). A distinction between the two is important since intrinsic AMR genes may not pose a risk to 
humans (Martinez, Coque and Baquero, 2015). However, AMR genes in excessive abundance in 
habitats with high selection pressure from AMU, such as pig farms, are more inclined to be the result 
of acquired AMR, therefore, more relevant for the emergence and spread of AMR in and between 
reservoirs (Marshall and Levy, 2011; Martinez, Coque and Baquero, 2015). The ResFinder database 
contains only AMR genes found in culturable bacteria, which in the gut microbiota of pigs could be 
as little as 1% (Holman and Chénier, 2015; Munk et al., 2017). Therefore, a considerable number of 
ubiquitous intrinsic AMR genes may have been missed (Munk et al., 2017).  
 
For tetracycline, significant quantitative associations could be demonstrated for lifetime AMU on 
AMR obtained by cultivation (anaerobe bacteria) and shotgun metagenomics sequencing, which was 
in alignment with a previous study that demonstrated a correlation in AMR between cultivation and 
metagenomics (Munk et al., 2017). It is worth noticing that the E. coli cultivation did not provide any 
significant AMU and AMR associations across methods of measuring AMU, which was unexpected 
given its widespread usage as indicator-bacteria for resistance. Whether the cultivation method was 
biasing the resistance outcome, or the level of resistance found was a correct measure of phenotypic 
resistance could not be determined. However, resistance in E. coli might be affected by several other 
factors than the tetracycline lifetime usage alone. This is an important predicament to solve in order 
to being able to describe the link between phenotypic resistance and resistance gene abundance.  
 
Of the three approaches for measuring AMU assessed, the finisher exposure was the poorest, 
which indicates that the occurrence of AMR in finisher batches close to slaughter is not solely affected 
by the AMU in the finisher unit. This is in alignment with previous studies, which have found that 
off-spring are affected by the sow’s previous tetracycline usage (Mathew et al., 2005), and that the 
AMR genes persist from sows through rearing (Birkegård et al., 2018). Furthermore, thefarm of 
origin affects the spread of AMR in pigs at the subsequent farm (Dawson et al., 1984). A crude 
evaluation of the reliability of the significant results, by removing the observation in each of the 
significant plots that appeared to have the strongest influence on the result, demonstrated that the 
lifetime exposure provided most significant results. In contrast, the herd exposure remained only 
significant for one AM, indicating that the former method of measuring AMU is more sensitive. In 
addition, the measurement of herd exposure is highly influenced by differences in the units present 
in each farm, rather than the differences in AMU. By comparing the pathways of the finisher batches, 
large differences can be observed in the number of units per farm, which would greatly affect the 
measurement (Fig. 3.2.2.). Overall, the R2 explained more of the variation in AMR of the lifetime 
exposure models compared with herd exposure, indicating that the former has the strongest effect on 
AMR in finisher batches.  
 
The exposure measurements were calculated as total amounts throughout the rearing period for 
specified AM-classes, rather than a measurement for each rearing period. This evened out the 
distinction between different AMU patterns within the three rearing periods, e.g. differences in 
parenteral and peroral dispensing. Therefore, finisher batches with the same AM-class usage might 
relate to use in different units, and the occurrence of AMR may not be identical for these batches due 
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to changes in occurrence of AMR over time (Dunlop et al., 1998; Cavaco et al., 2008; Abatih et al., 
2009; Collineau et al., 2017). Subsequently, a limitation that might account for some of the non-
explained variation observed between batches.  
 
Although the lifetime AMU was found to be a good method for measuring the effect of AMU on 
AMR, the linear association could be the result of the study objects selected. Of the studies 10 finisher 
batches, 5 batches came from farms with very high usage and 5 batches came from farms with very 
low usage, provided two extremes between which to plot. Therefore, the association between AMU 
and AMR cannot for certain be presumed to be linear, and a random selection of finisher batches 
might have revealed a different association. The difference between the two high and low groups 
could be further strengthened by lack of typical risk factors affecting the AMR. First, for each finisher 
batch, one farmer owned all farms included in a rearing pathway. Therefore, as the vet connected to 
the farmer had Health Advisory Contracts with all farms owned by the farmer, thus, the farms within 
a rearing pathway would be expected to have similar treatment strategies, i.e. choice, dose and dosage 
of AMs, as usage in a farm (Vigre et al., 2010; Hybschmann et al., 2011). Since the occurrence of 
resistance genes has been demonstrated to be affected by the occurrence in farms of origin (Dawson 
et al., 1984; Birkegård et al., 2018), the effect of AMU per unit may therefore be reinforced over 
time. Secondly, the AMR level in the batches did not encounter AMR contaminants from outside-
pigs, which could have altered the AMR composition and level (Dawson et al., 1984).  
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Abstract
Assessing the relationship between antimicrobial usage (AMU) and antimicrobial resistance
(AMR) requires the accurate and precise utilisation of register data. Therefore, validation of
register-based data is essential for evaluating the quality and, subsequently, the internal valid-
ity of studies based on the data.
In this study, different smoothing methods for Veterinary Medicine Statistic Program data-
base (VetStat)-records were validated by comparing these with farm-records. Comparison
between measurements included accuracy as; completeness and correctness, and precision
as; a relative difference of the error, correlation with Fisher’s z transformation and reliability
coefficient. The most valid methods of those examined were then used in re-analyses of the
abundance of AMR genes in 10 finisher batches from a previous study.
Improved accuracy was found when detailed smoothing methods were applied. Although
the precision also increased, the effect was not as pronounced, as the usage estimate of all
smoothing methods deviated moderately compared with the farm-registrations. Applying
the most valid methods to the 10 finisher batches increased estimates of statistical model
fit for aminoglycosides, lincosamides, tetracyclines and decreased estimates of statistical
model fit for macrolides. The estimates of statistical model fit for sulfonamides and broad-
spectrum penicillins remained the same.
Through refined data transformation, VetStat-records can be used to calculate a daily
amount of AMU per pig reflecting the true usage accurately and moderately precisely,
which is the foundation for calculating lifetime AMU.
Introduction
As the emergence and spread of antimicrobial resistance (AMR) bacteria is increasing world-
wide, an understanding of the complex associations between antimicrobial usage (AMU) and
AMR is urgently needed [1]. The AMU is generally acknowledged as the main cause. However,
less is known of the quantitative relationship between AMU and AMR, as well as the interre-
lational effects between usage in humans, agriculture and veterinary sectors [2, 3]. Due to the
potential risk of conveying resistance from animal microflora to human pathogenic bacteria,
AMU for animals has gained increased attention [4].
Since antimicrobials (AMs) are vital for the treatment of bacterial diseases in veterinary
medicine, responsible AM interventions aimed at reducing usage must be sufficiently effective
to reduce AMR without compromising treatment options and animal welfare. Consequently,
knowledge of the quantitative ‘AMU-AMR’ relationship is fundamental in order to obtain pre-
dictable results from interventions targeting AMU in animal production [5].
Several surveillance databases on AMU for animals have been established [6]. Among the
first was the Danish Veterinary Medicine Statistic Program database (VetStat), which records
purchases of medicines prescribed for animals [7, 8] and is commonly used for epidemio-
logical studies of AMU–AMR relationships in Danish production animals [9–12]. As data
from VetStat lack information on actual usage in farms, studies using these data share a mutual
challenge in accuracy and precision compared with primary data and should, therefore, be
validated [13, 14].
Farmers are obliged to register AMU for production animals on a daily basis. These records
are often summed either by the farmer or by the veterinarian for the period between two con-
secutive visits by the veterinarian, which usually occurs at intervals of 30–65 days depending
on production type and Health Advisory Contract. In this study, the farm records were the
summed daily AMU between consecutive veterinarian visits. The farm records are not
mandatory, but they provide the farmer and veterinarian with a quick overview of AMU
and remnants from recent prescriptions. Validation measurements of VetStat-records com-
pared with farm-records should include (1) accuracy, as the completeness and correctness
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and (2) precision, as the correlation, as the relative difference and
as the coefficient of reliability of VetStat data. These measure-
ments will demonstrate the quality of the data, which will be sup-
portive when evaluating the trustworthiness of studies of AMU–
AMR relationships using such data [13–15].
Currently, the most influential exposure characteristics of
AMs, e.g. route of administration, level of dose, or duration of
treatment, have not been fully determined in relation to the selec-
tion of AMR [5]. In previous studies utilising VetStat as the data
source, data on AMU for pig herds have been extracted at the unit
(piglets-sows/weaners/finishers) or farm level for periods of 6–12
months prior to sampling [10, 12]. This constitutes minimal dif-
ferentiated estimates that do not take into account the variations
within the extracted period in question. A study used a method
that summed up a daily AMU as doses for finisher batches
from birth to slaughter, calculating the lifetime AMU through
the movements between units, thus, the method was independent
of rearing site and captured variations over time [9]. In the same
study, the daily usages were calculated by smoothing the amount
(a recorded entry) based on days between records. Subsequently
reflecting the number of days between one record and the next,
within each age-group unit per farm. In contrast, this way of
smoothing data does not take into account that different AMs
and dispensing-types may be used differently by the farmer.
The objective of this study was to validate five different
methods to smoothing VetStat data to estimate the number of
ADDkg per pig day, reflecting the ‘true’ usage at the farms by
comparing the results to farm-records in terms of accuracy and
precision. The results from a previous study focusing on the
effect of AM lifetime exposure on the abundance of AMR genes
were then re-analysed with the most valid methods of those exam-
ined, for calculating AMU at finisher batch level. Two different
farm size adjustments were then used to evaluate the same
methods.
Materials and methods
Data sources
Two data sources on AMU were applied in this study: farm-
records and VetStat-records.
The farm-records were manually registered by the owners or
employees and contained information on the amount of an AM
product used, including the dispensing-type, within the age-
groups; piglets-sows, weaners and finishers, during specified per-
iods. The farm-records were conveniently collected during farm
visits related to an ongoing AMU-AMR study consisting of 83
randomly identified farms. A total of 25 farmers were asked to
participate and 12 accepted. A total of 745 records on AMU
were obtained, comprising 12 farm owners, 16 farms and 23
units within the period from January 2014 to May 2016.
Data from VetStat contains records on purchased medicines
prescribed by veterinarians for animals. Each record has informa-
tion on the product name, active-substance, dispensing-type,
amount, target species, age-group, diagnosis group and farm
code (ID) [7]. Data from VetStat were extracted from 1 year before
the first farm recorded date to 3 months after the last of each farm
to establish sufficient buffer time before and after the study peri-
ods to account for negative entries [16]. The data were then
cleaned according to guidelines by correcting mismatches of ani-
mal species and/or age-group through cross-validating the data
with Central Husbandry Register (CHR) data [16].
In order to produce comparable data across records, active
compounds were converted into a unit measuring how many kilo-
grams of pig could be treated per day, known as – Animal Defined
Daily Doses per kilogram (ADDkg) [17].
Two sources of biomass estimates were applied as the adjust-
ment factor for farm size; (i) number of pigs on any given day
at the farms, obtained from the CHR, where all farms with pro-
duction animals are recorded and (ii) the yearly production
adjusted to the number of pigs on any given day, obtained from
the Pig Movement Database (PMD) [7]. The CHR stores informa-
tion on a farm code (ID), which refers to a specific geographical
location and includes information such as ownership, animal spe-
cies and the number of animals per age-group (sows/weaners/fin-
ishers), on any given day. Although sows and piglets are in the
sow unit, the number of sows is included in this age-group,
since piglets are not registered in the CHR. In the PMD, the num-
ber of pigs, date, ID of origin farm and ID of destination farm for
each movement is recorded [7].
Estimation of AMU
Validation
The usage of an AM product (l), during a period (k), in an
age-group ( j) (piglets-sows/weaners/finishers) in a farm (i) was
estimated as Dosesi,j,k,l with the unit; ADDkg/pig day, using for-
mula (1):
#Dosesi,j,k,l[ADDkg/pig day] =
#mgi,j,k,l
#daysk ∗ ADDkgl ∗ #pigsi,j,k
where: #mg = the amount of an AM product registered as usage or
recorded as a purchase in a specific farm/age-group/period, #days
= the number of days of the period when the recorded amount
was used, #pigs = the number of sows/weaners/finishers on any
given day registered in CHR, or the yearly production adjusted
to the number of pigs on any given day registered in PMD.
The #days was calculated using five different methods. The
first method (1) assumed that the AMU in a farm recorded period
was equivalent to the purchases of AMs in that recorded period.
The other four methods (2–5) were all calculated assuming that
the amounts of recorded AM products were used in a period
between one recorded date and the next. The subsequent date
was defined based on different assumptions related to usage pat-
tern over time at the farms. Consequently, the four smoothing
methods differed in the number of days (#days) between one
record entry date and the next, when the age-group, dispensing-
type and antimicrobial class (AMC) alternately and together were
taken into account (Fig. 1). In the less detailed method 2, the
#days between two record entries was set at the age-group level,
assuming that a new record of any AM product was due to the
previous recorded AM products were consumed by that
age-group. Method 3 assumes that when a new record of an
AM product of either parenteral or peroral dispensing occurs
within an age-group, all the former AM products of the same
dispensing-type were consumed. Method 4 assumes that when
new recorded AM product of an AMC occurs within an
age-group, all the former recorded AM products of the same
AMC, irrespectively of dispensing-type, were consumed.
Method 5 was a combination of methods 3 and 4 (Fig. 1).
The calculation of #days was based on three assumptions. First,
if the #days was less than 8 days, the following subsequent record
2 V. D. Andersen et al.
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date was used instead. Second, if no subsequent date was found,
the mean of the former was applied. If no subsequent date was
found and no mean of prior #days was available, 365 days was uti-
lised. Third, all #days exceeding 365 days were substituted by 365
days.
The calculated Dosesi,j,k,l obtained for methods 2–5 were date-
specific estimates. In order to compare these with the farm-
records, the date-specific estimates were summed equivalent to
the periods during which the farm-records were calculated and
a daily average Dosesi,j,k,l usage was calculated.
Re-analyses
For the ten finisher batches from the study [9], the date-specific
lifetime AMU (Doses) in the different age-groups was re-calcu-
lated by means of formula 1 for the AMCs; aminoglycosides,
broad-spectrum penicillins, lincosamides, macrolides, sulfona-
mides and tetracyclines, using the most valid methods.
Furthermore, two different biomass adjustments were applied as
the number of pigs on any given day; (A) the CHR and (B) the
PMD.
The number of Doses was summarised at AMC level for each
rearing period per unit, based on the finisher batches’ rearing per-
iods in days; days 1–85 in the finisher unit, days 86–135 in the
weaning unit and days 136–160 in the sow unit [18], where
day 1 corresponds to the day of sampling. The number was then
adjusted to suit the proportion of animals being moved from a
farm. Subsequently, for each AMC, the lifetime AMU were calcu-
lated for each finisher batch by summarising Doses through the
rearing pathways. Even though AMU for sows was included in
the usage for piglets, previous studies have shown that this affects
the abundance of AMR genes in the piglets’ microbiota, thus, it
was assumed equivalent to usage for piglets [19].
Data analyses
Validation
Throughout the validation, the VetStat estimates were compared
against the farm-record estimates, which were assumed to be
the ‘true’ state of AMU at the farms.
For the accuracy and precision assessments of the relationship
between farm-records and VetStat-records, the calculations per-
formed for the observations were mutually independent and
dependent, respectively. Consequently, to adjust for potential
within-level clustering, all of the validation results were
average-adjusted by farm, age-group, dispensing-type or AMC
levels to assess the impact of clustering compared with the
crude estimates.
Accuracy – completeness and correctness
The completeness constitutes the observed number of VetStat-
records compared with the number of farm-records (a/(a + c))
and the correctness constitutes the number of correctly identified
VetStat-records compared with the number of VetStat-records
that were found (a/(a + b)), set in a 2 × 2 table [13, 14].
Precision – relative difference
The relative difference of the error was calculated as the absolute
difference between farm and method, divided by the arithmetic
mean of the usage given by farm and method (rderror =
(Dosesfarm−Dosesmethod)/((Dosesfarm +Dosesmethod)/2)).
Precision – correlation coefficient
The correlation coefficient (rz) was calculated by applying Fisher’s
z transformation (rz = (e
2z–1)/(e2z + 1), where z = 0.5ln((1 + r)/(1
− r)) [20]. The adjusted rz should be interpreted as the general
correlations between farm and method at the level of adjustment.
The averaged correlations are less affected by sampling distribu-
tion skew, suggesting a less biased statistic [20].
Precision – reproducibility (reliability coefficient)
The reliability coefficient (ρxx = 1/(1 + (σError/σDosesfarm)
2), where
Error =Dosesfarm−Dosesmethod), between the Dosesfarm and
Error obtained, was calculated for each of the five methods [21].
The reliability coefficient describes the average magnitude of
the error, the reproducibility. For linear regression, this equals
the bias factor; βobserved = ρxx * βtrue and thus, can potentially be
used for adjustment of βobserved [21]. Subsequently, the effect esti-
mates obtained in the re-analysed linear regression models pre-
sented below were adjusted for the attenuation effect of data error.
Re-analyses
To investigate the influence of the validation results of this study,
the findings from the previous study [9] of the effect of six AMCs
on the abundance of the same classes of AMR genes were
re-analysed by applying the most valid methods in calculating
the lifetime AMU. In that study, AMR genes for the classes: ami-
noglycoside, lincosamide, macrolide, beta-lactam, sulfonamide
and tetracycline were obtained using whole community sequen-
cing (WCS) and were measured as reads per kilobase reference
per million [22].
Fig. 1. Illustration of the differences in Number of days (#days) for the five
methods of calculating antimicrobial usage at the farm level. For method
1, the #days was based on the farm record periods. From methods 2 to 5,
the #days increased as the intervals between one record entry date and
the next increased when similar records based on age-group, dispensing-
type and antimicrobial-class (AMC) were matched.
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The lifetime AMU measure, CHR adjusted (A), for the ten fin-
isher batches was used in linear regression re-analyses to assess
each effect on the abundance of AMR genes by evaluating the
changes in adjusted R-squared (Adj.R2), Akaike Information
Criterion (AIC) and the Bayesian Information Criterion (BIC).
In addition, the reliability coefficient of the most valid method
of the presented was applied to adjust the β-coefficients from
the linear regression re-analyses.
Finally, the difference of effect of the two lifetime AMU mea-
sures, (A) CHR adjusted and (B) PMD adjusted, was evaluated.
Tools
WPS Workbench, Version: 3.1.1.0.0, Microsoft Excel 2016 and R,
version 3.3.3 were used for data processing and data analyses.
Results
While cleaning the VetStat data, 19 records were encountered that
could not be corrected. Some AM products were prescribed and
purchased (recorded in VetStat) one time only, but the usage of
these could not be found in the farm-records. In addition, AM
products were recorded for one age-group but registered as
usage at the farm for another age-group, or for two age-groups.
Validation
Completeness and correctness
Table 1 shows the completeness and correctness results obtained
by comparing Dosesfarm to the five Dosesmethod, respectively. The
smoothing methods from 1 to 5 had a positive effect on the com-
pleteness, which increased from 0.60 to 0.86 and a minor negative
effect on the correctness, which decreased from 0.91 to 0.84
(Table 1). The results obtained when performing the average
adjustments at farm, age-group, dispensing-type and AMC levels
led to a decrease in the overall completeness and correctness
results, though the beneficial trend when smoothing remained
the same (Table 1).
Relative difference
The distributions of the rderror for the smoothing methods are
shown in Figure 2, illustrating that the number of farm-records
not found by the smoothing method (rderror = 2) decreased
from Dosesmethod 1 to 5. However, concurrently, the number of
spurious records (rderror =−2) was shown to increase, while the
distribution of rderror narrows around zero going from method
1 to 5.
The boxplots of the rderror of the five Dosesmethod, compared
with Dosesfarm show that the 0.75 quantile decreases substantially
and the rderror observations together with the median move
toward zero from method 1 to 5 (Fig. 3). Furthermore, it shows
that going from method 1 to 5, the mean and the range of the
standard deviation of the rderror decreases towards zero (Fig. 3).
Since the smoothing methods (#days) depended on similar
VetStat-records regarding the age-group, dispensing-type and
AMC levels, the rderror of the five Dosesmethod was average-
adjusted accordingly. Boxplots at an age-group level were in con-
cordance with general findings (Fig. 4). In contrast, boxplots at
dispensing-type level revealed that method upscaling from 1 to
5 was beneficial for parenteral dispensing, but not for peroral
(Fig. 5). For peroral dispensing, method 3 provided a better result
for the rderror.
The boxplots of the rderror of the five Dosesmethod at farm level
show considerable variation between farms, which is most likely
to be related to the difference seen between dispensing-types
(result not shown). Similar observations were made at AMC
level and at AMC combined with dispensing-type level, (result
not shown).
Correlation coefficient
In Table 2, the correlation coefficient (r) between the Dosesfarm
and the five Dosesmethod, show that by incorporating age-groups,
dispensing-type and AMC in the smoothing methods, the correl-
ation also increases. This mainly follows the beneficial trends of
smoothing from the completeness and relative difference of the
error results.
In relation to the z average-adjusted correlation coefficient (rz)
of the five Dosesmethod, the farm-level adjustment changed the
results most, followed by age-group, dispensing-type and AMC
level. However, the upscaling smoothing method trend remained
the same, independent of the average adjustment level (Table 2).
Furthermore, regardless of the level at which the average adjust-
ment is performed, the rz remains within a narrow range.
Reliability coefficient
For the five smoothing methods, the coefficient of reliability (ρxx)
ranged from 0.60 to 0.68 and the average adjustment at farm,
age-group, dispensing-type and AMC levels had a similar
decreasing effect on the values compared with previous findings.
However, the beneficial upscaling method trend remained the
same, independent of the average-adjustment level (Table 2).
The reliability coefficients of smoothing methods 1 to 5 were all
values below 1, meaning that the methods underestimate the
AMU compared with the ‘true’ state, obtained from the farm-
records (Table 2).
Table 1. The correctness and completeness of Dosesmethod 1 to 5, compared
with Dosesfarm at population level and average-adjusted at farm, age-group,
dispensing-type and antimicrobial-class levels
Method 1 2 3 4 5
Completeness
Study population 0.60 0.72 0.75 0.83 0.86
Adjusted by
Farm 0.56 0.69 0.74 0.80 0.83
Age-group 0.59 0.71 0.75 0.83 0.86
Dispensing-type 0.60 0.74 0.78 0.85 0.87
Antimicrobial-class 0.62 0.73 0.76 0.82 0.83
Correctness
Study population 0.91 0.89 0.87 0.85 0.85
Adjusted by
Farm 0.88 0.85 0.83 0.82 0.82
Age-group 0.91 0.88 0.87 0.85 0.85
Dispensing-type 0.89 0.86 0.85 0.82 0.82
Antimicrobial-class 0.91 0.88 0.86 0.84 0.84
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Re-analyses
For the ten finisher batches in the previous study, smoothing
methods 5 and 3 for parenteral and peroral AMs, respectively
and farm size adjusted using CHR, were applied to calculate the
lifetime AMU for the AMC; aminoglycosides, lincosamides,
broad-spectrum penicillins, macrolides, sulfonamides and tetracy-
clines. The lifetime AMU estimates sum up usage for the entire
rearing period per AMC. The lifetime AMU estimates were
used as explanatory variables in linear regression re-analyses on
the abundance of AMR genes attributed to those AM classes.
These results were subsequently compared with the regression
results obtained in the previous study (Table 3).
The application of smoothing methods 5 and 3 for parenteral
and peroral AMs, respectively, increased the estimated fit of the
models (Adj.R2, AIC and BIC) and therefore potentially explained
a larger part of the abundance of AMR genes against aminoglyco-
sides, lincosamides and tetracyclines. For sulfonamides and
broad-spectrum penicillins/betalactam, the estimated fit of the
models decreased slightly. In contrast, the estimated fit of the
model for macrolides decreased substantially (Table 3).
Fig. 2. The count distribution of the relative difference of the error (rderror) for the Dosesmethod 1 to 5 compared with Dosesfarm.
Fig. 3. Boxplots of the relative difference of the error (rderror) for the Dosesmethod 1 to 5 compared with Dosesfarm. The black dots show the individual observations.
The orange dots and error bars represent the mean and standard deviation of the rderror.
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When the β-coefficient estimate of the model comprising
methods 3 and 5 was adjusted in relation to the population ρxx,
the β-coefficient increased by 49%.
The model comprising methods 3 and 5 combined was further
evaluated based on alterations of the biomass, model A and B
(Table S1 in the supplementary material). The adjustment change
of the number of pigs from CHR to PMD had an overall improved
effect on tetracyclines, broad-spectrum penicillins, macrolides and
lincosamides and the opposite result was found for aminoglyco-
side and sulfonamides (Table S1 in the supplementary material).
The impact of adjusting with PMD rather than CHR related
mainly to usage in the age-group; piglets. For the CHR, the
Fig. 4. Boxplots at the age-group level of the relative difference of the error (rderror) for the Dosesmethod 1 to 5 compared with Dosesfarm. The black dots show the
individual observations. The orange dots and error bars represent the mean and standard deviation of the rderror.
Fig. 5. Boxplots at the dispensing-type level of the relative difference of the error (rderror) for the Dosesmethod 1 to 5 compared with Dosesfarm. The black dots show
the individual observations. The orange dots and error bars represent the mean and standard deviation of the rderror.
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number of sows is used as the adjustment factor, resulting in a
high number of doses for the piglet age-group, compared with
the PMD adjusted estimates (result not shown).
The most notable results were the B models, which had AMU
split by dispensing-type into two variables. For these, the esti-
mates of statistical model fit were improved for aminoglycosides,
lincosamides and tetracyclines, (Table S1 in the supplementary
material).
Discussion
Validation
The completeness of VetStat-records increased from the less
detailed method 1 to the more detailed method 5. This was due
mainly to the pattern for parenteral usage of AMs, small amounts
were used each month and rarely recorded in VetStat. Therefore,
the detailed method 5 reflected the true usage of parenteral AMs
more closely. Simultaneously, the pattern for peroral usage of
AMs caused a reduction in the correctness. According to the
farm-records, large amounts of AMs were used for group-
treatment within a limited time. As a result, more detailed
smoothing caused spurious AMU. Major variations in correctness
and completeness could be observed between farms, which could
mainly be attributed to dispensing-type and incorrect
VetStat-records.
The same pattern for parenteral and peroral AMU affected the
relative difference and the correlation coefficient. These became
more precise for parenteral usage only when more detailed
smoothing methods were applied. Consequently, our results indi-
cate that, due to the differences in usage patterns seen between
dispensing-types, the overall most valid method, method 5, for
smoothing out the VetStat-records is not applicable for both par-
enteral and peroral dispensing. For the latter, method 3 is the
most valid of the examined methods.
In order for the secondary data, to reflect the true state in a
population, high completeness and correctness are required [13,
14]. For the overall most valid method, method 5, the complete-
ness can be categorised as fair [23] and applying different
smoothing methods to dispensing-type increased the complete-
ness. In addition, obtaining values of the precision and the impact
of the estimate on the statistical association are important for
result assessments [15, 21]. A good correlation between farm-
records and smoothing method was demonstrated, though it
has been pointed out that correlation estimates may not be the
optimum method for assessing agreement between methods
[15]. In contrast, the standard deviation of the relative difference
of the error and the reliability coefficient demonstrated a less pre-
cise estimate. Regardless, the reliability coefficient can be used to
adjust the β-coefficient in a linear regression, thus the estimate
influences the statistical association between AMU and AMR
[15, 21].
VetStat gives unique opportunities to study AMU at farm level
and its effect on AMR. AM stewardship at farm level and correct
recording in VetStat are essential to improve data transformation
further. VetStat can provide accurate and precise measurements of
AMU through data transformation, which was observed for a
number of farms in the validation part. Moreover, VetStat is easily
accessible for large parts of a population at farm level [24]. Access
to accurate and precise data can then form the basis for establish-
ing knowledgeable guidance and/or adjustments of AMU prac-
tices at herd level, with considerably lowering effect on AMU as
a result [25]. In addition, the knowledge may also be supportive
for detailed risk assessments and trend analyses.
Re-analyses
The results of the re-analyses study indicate that using the alter-
native smoothing methods produces a better fit regarding the
models estimating the effect of AMU on AMR gene abundance.
Moreover, when the estimated effects were adjusted by applying
the population reliability coefficient, an even higher effect of the
lifetime AMU on the abundance of AMR genes was observed,
which indicates that the effects estimated in the regression ana-
lyses are all underestimated. These results highlight the general
importance of valid data in epidemiological studies in order to
obtain unbiased quantitative estimates of effects [13–15, 21, 26].
As indicated by the results from the re-analyses, by optimising
the utilisation of register data as a proxy for the AMU in pigs
and adjusting the regression results obtained based on the results
of this validation study, the usage, measured as lifetime AMU, can
explain up to 70–80% of the variation in abundance of AMR
genes observed between finisher batches.
The deviating result of the effect of macrolide may arise from
the time of usage, as the estimated lifetime AMU takes no time-
component into account, e.g. usage at different ages has a differ-
ent impact on the abundance of AMR genes [27–29].
The results of the biomass adjustments according to the CHR
and PMD number of pigs revealed that the latter could be a
potential substitute for the former. The PMD adjustment was
the number of pigs on any given day, estimated from the produc-
tion of pigs 1 year prior to sampling. This estimate is neutral, as it
solely reflects the number of animals being moved, in contrast to
the CHR number of pigs, which is a farmer’s evaluation of man-
agement performance and averages on any given day, thus, more
subjective to bias.
Table 2. The correlation coefficient (r), the Fisher z transformed correlation
coefficient (rz) and the reliability coefficient (ρxx) between the Dosesfarm
and the five Dosesmethod are shown, respectively along with the average-
adjustment by farm, age-group, dispensing-type and antimicrobial-class
levels, of each coefficient
Method 1 2 3 4 5
r (crude)
Study population 0.70 0.75 0.76 0.77 0.77
rz (adjusted by)
Farm 0.59 0.67 0.70 0.71 0.72
Age-group 0.65 0.70 0.71 0.71 0.71
Dispensing-type 0.70 0.73 0.75 0.76 0.76
Antimicrobial-class 0.73 0.76 0.77 0.81 0.81
ρxx (crude)
Study population 0.60 0.65 0.67 0.68 0.68
ρxx (adjusted by)
Farm 0.50 0.56 0.60 0.60 0.61
Age-group 0.58 0.62 0.64 0.64 0.64
Dispensing-type 0.60 0.64 0.66 0.67 0.67
Antimicrobial-class 0.57 0.62 0.64 0.68 0.68
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Table 3. The results of the linear regression of the previous model and the smoothing methods 3 combined with 5, adjusted by CHR model for usage and
abundance of AMR genes to aminoglycosides, lincosamides, broad-spectrum penicillins/betalactam, macrolides, sulfonamides and tetracyclines
Estimate SE P-value Adj.R2 AIC BIC
Aminoglycosides
Model (previous) 0.04 68.64 69.55
(intercept) 18.08 (12.40–23.76) 2.47 0.000
Aminoglycosides 0.11 (−0.11–0.33) 0.09 0.272
Model A (methods 3/5) 0.28 65.75 66.66
(intercept) 16.82 (11.73–21.92) 2.21 0.000
Aminoglycosides 0.19 (−0.02–0.39) 0.09 0.070
Lincosamides
Model (previous) 0.20 89.22 90.12
(intercept) 53.51 (36.73–70.29) 7.28 0.000
Lincosamides 0.68 (−0.19–1.54) 0.38 0.109
Model A (methods 3/5) 0.51 84.31 85.22
(intercept) 52.54 (40.50–64.59) 5.22 0.000
Lincosamides 0.64 (0.18–4.28) 0.20 0.012
Penicillins (broad) – Betalactam resistance
Model (previous) 0.45 90.26 91.17
(intercept) 52.55 (36.01–69.09) 7.17 0.000
Penicillins (broad) 0.71 (0.15–1.27) 0.24 0.020
Model A (methods 3/5) 0.31 92.54 93.45
(intercept) 53.41 (34.40–72.42) 8.24 0.000
Penicillins (broad) 0.56 (−0.01–1.12) 0.25 0.054
Macrolides
Model (previous) 0.66 108.03 108.93
(intercept) 58.34 (−5.52–122.20) 27.69 0.068
Macrolides 1.82 (0.85–2.78) 0.42 0.002
Model A (methods 3/5) 0.15 117.38 118.29
(intercept) 105.03 (18.77–191.29) 45.53 0.023
Macrolides 0.86 (−0.35–1.92) 0.49 0.100
Sulfonamides
Model (previous) 0.74 7.14 8.04
(intercept) −0.16 (−0.50–0.19) 0.15 0.327
Sulfonamides 0.02 (0.01–0.03) 0.00 0.001
Model A (method 5) 0.65 9.99 10.90
(intercept) −0.11 (−0.50–0.29) 0.17 0.552
Sulfonamides 0.02 (0.01–0.03) 0.00 0.003
Tetracyclines
Model (previous) 0.35 108.83 109.74
(intercept) 346.13 (294.36–397.89) 22.45 0.000
Tetracyclines 0.92 (0.04–1.79) 0.38 0.042
Model A (methods 3/5) 0.66 102.48 103.38
(intercept) 334.75 (297.17–372.33) 16.30 0.000
Tetracyclines 0.88 (0.41–1.36) 0.21 0.003
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Conclusions
Based on the validation results, it can be concluded that the
VetStat database can be used for refined data transformation to
improve accuracy and precision to reflect ‘true’ AMU at the
farm level. Furthermore, the reliability coefficients show that the
calculations of the daily amount of AMs used per pig underesti-
mate the usage independent of method.
The knowledge obtained was used to re-calculate lifetime
AMU, which in linear regression models provided an overall
more beneficial effect on the estimates of statistical model fit
than the previous calculation of lifetime AMU. The linear models
can be compared only in terms of estimates of statistical model fit,
whereas the coefficient estimates should be interpreted with cau-
tion due to the limited number of finisher batches in the study.
The PMD could represent an alternative to the CHR for bio-
mass adjustment or should be used to cross-validate the CHR.
Supplementary material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0950268818000134.
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Table 4.2.1. The estimates, standard error (SE) and p-value of the coefficients of the previous method (yellow 
marking), smoothing methods 3, 5, 3 combined with 5 as one and as two variables, farm size adjusted as 
number of pigs per day given CHR (model A, green marking)), and PMD (model B, blue marking), of linear 
regression models of aminoglycosides, lincosamides, broad-spectrum penicillins/beta-lactams, macrolides, 
sulfonamides, and tetracyclines usage and resistance. In addition, the information measures, adjusted R-
squared (Adj.R²), Akaike information criterion (AIC) and Bayesian information criterion (BIC) for each model. 
  Estimates SE p-value  Adj.R² AIC BIC 
Aminoglycosides (Ami.)        
Model (previous)        0.04 68.64 69.55 
  (intercept) 18.08 (12.40 - 23.76) 2.47 0.000  
   
  Ami. 0.11 (-0.11 - 0.33) 0.09 0.272  
   
           
Model A (method 3)        0.21 66.67 67.58 
  (intercept) 17.19 (11.93 - 22.45) 2.28 0.000  
   
  Ami. 0.17 (-0.04 - 0.38) 0.09 0.101  
   
Model A (method 5)        0.25 66.13 67.04 
  (intercept) 17.02 (11.89 - 22.15) 2.23 0.000     
  Ami. 0.17 (-0.03 - 0.37) 0.09 0.079     
Model A (methods 3 and 5)        0.28 65.75 66.66 
  (intercept) 16.82 (11.73 - 21.92) 2.21 0.000  
   
  Ami. 0.19 (-0.02 - 0.39) 0.09 0.070  
   
Model A (methods 3 and 5)        0.57 61.29 62.51 
  (intercept) 12.82 (7.29 - 18.34) 2.34 0.003  
   
  Ami. parenteral 0.90 (0.21 - 1.59) 0.29 0.018 * 
   
 Ami. peroral -0.10 (-0.41 - 0.21) 0.13 0.483     
           
Model B (method 3)        0.10 67.98 68.88 
  (intercept) 17.90 (12.51 - 23.28) 2.33 0.000     
  Ami. 0.16 (-0.10 - 0.43) 0.12 0.192     
Model B (method 5)        0.12 67.76 68.67 
  (intercept) 17.77 (12.40 - 23.14) 2.32 0.000  
   
  Ami. 0.17 (-0.09 - 0.43) 0.11 0.172  
   
Model B (methods 3 and 5)        0.14 67.61 68.72 
  (intercept) 17.66 (12.28 - 23.04) 2.33 0.000     
  Ami. 0.18 (-0.09 - 0.44) 0.11 0.159     
Model B (methods 3 and 5)        0.62 59.99 61.20 
  (intercept) 11.16 (5.31 - 17.01) 2.47 0.003     
  Ami. parenteral 1.83 (0.66 - 3.01) 0.50 0.009 *    
 Ami. peroral -0.16 (-0.46 - 0.14) 0.13 0.239     
           
           
           
           
 
 
 
 
          
 
 
73 
 
 
 
           
  Estimates SE p-value  Adj R² AIC BIC 
Lincosamides (Lin.)           
Model (previous)        0.20 89.22 90.12 
  (intercept) 53.51 (36.73 - 70.29) 7.28 0.000  
   
  Lin. 0.68 (-0.19 - 1.54) 0.38 0.109  
   
           
Model A (method 3)        0.49 84.72 85.63 
  (intercept) 52.11 (39.57 - 64.66) 5.44 0.000     
  Lin. 0.62 (0.16 - 1.07) 0.20 0.015 *    
Model A (method 5)        0.51 84.40 85.31 
  (intercept) 52.59 (40.49 - 64.68) 5.24 0.000     
  Lin. 0.64 (0.18 - 1.10) 0.20 0.013 *    
Model A (methods 3 and 5)        0.51 84.31 85.22 
  (intercept) 52.54 (40.50 - 64.59) 5.22 0.000     
  Lin. 0.64 (0.18 - 1.10) 0.20 0.012 *    
Model A (methods 3 and 5)        0.63 82.24 83.45 
  (intercept) 58.24 (45.29 - 71.18) 5.48 0.000     
  Lin. parenteral -0.20 (-1.33 - 0.94) 0.48 0.689     
  Lin. peroral 2.23 (0.18 - 4.28) 0.86 0.037 *    
           
Model B (method 3)        0.58 82.66 83.57 
  (intercept) 52.19 (41.18 - 63.21) 4.78 0.000     
  Lin. 0.81 (0.30 - 1.31) 0.22 0.006 *    
Model B (method 5)        0.56 83.26 84.17 
  (intercept) 52.98 (41.85 - 64.12) 4.82 0.000     
  Lin. 0.78 (0.27 - 1.30) 0.22 0.008 *    
Model B (methods 3 and 5)        0.57 83.09 84.00 
  (intercept) 52.85 (41.79 - 63.92) 4.53 0.000     
  Lin. 0.79 (0.28 - 1.30) 0.11 0.007 *    
Model B (methods 3 and 5)        0.63 82.24 83.45 
  (intercept) 57.49 (44.73 - 70.25) 5.40 0.000     
  Lin. parenteral -0.17 (-1.74 - 1.40) 0.66 0.807     
  Lin. peroral 2.79 (-0.36 - 5.94) 1.33 0.075 *    
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  Estimates SE p-value  Adj R² AIC BIC 
 Penicillins (Pen.) (broad) – Beta-lactam resistance 
Model (previous)        0.45 90.26 91.17 
  (intercept) 52.55 (36.01 - 69.09) 7.17 0.000     
  Pen. (broad) 0.71 (0.15 - 1.27) 0.24 0.020 * 
   
           
Model A (method 3)        0.36 91.87 92.78 
  (intercept) 53.74 (35.87 - 71.60) 7.75 0.000  
   
  Pen. (broad) 0.54 (0.03 - 1.04) 0.22 0.040 * 
   
Model A (method 5)        0.49 89.65 90.56 
  (intercept) 49.48 (32.15 - 66.82) 7.52 0.000  
   
  Pen. (broad) 0.76 (0.19 - 1.33) 0.25 0.015 * 
   
Model A (methods 3 and 5)        0.31 92.54 93.45 
  (intercept) 53.41 (34.40 - 72.42) 8.24 0.000  
   
  Pen. (broad) 0.56 (-0.01 - 1.12) 0.25 0.054  
   
Model A (methods 3 and 5)        0.35 92.74 93.95 
  (intercept) 58.31 (36.88 - 79.81) 9.08 0.000  
   
  Pen.(broad) parenteral -0.31 (-2.14 - 1.52) 0.77 0.700  
   
  Pen.(broad) peroral 0.86 (0.02 - 1.70) 0.35 0.045 * 
   
           
Model B (method 3)        0.50 89.38 90.28 
  (intercept) 53.89 (38.81 - 68.97) 6.54 0.000  
   
  Pen. (broad) 0.70 (0.19 - 1.21) 0.22 0.013 * 
   
Model B (method 5)        0.62 86.64 87.55 
  (intercept) 50.52 (36.59 - 64.46) 6.04 0.000  
   
  Pen. (broad) 0.89 (0.37 - 1.42) 0.23 0.004 * 
   
Model B (methods 3 and 5)        0.49 89.66 90.57 
  (intercept) 53.41 (37.86 - 68.96) 6.74 0.000  
   
  Pen. (broad) 0.73 (0.18 - 1.27) 0.24 0.015 * 
   
Model B (methods 3 and 5)        0.54 89.16 90.37 
  (intercept) 58.12 (41.14 - 75.10) 7.18 0.000  
   
  Pen.(broad) parenteral -0.53 (-2.72 - 1.65) 0.92 0.581  
   
  Pen.(broad) peroral 0.94 (0.30 - 1.58) 0.27 0.010 *    
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  Estimates SE p-value  Adj R² AIC BIC 
 Macrolides (Mac.) 
Model (previous)        0.66 108.03 108.93 
  (intercept) 58.34 (-5.52 - 122.20) 27.69 0.068  
   
  Mac. 1.82 (0.85 - 2.78) 0.42 0.002 * 
   
           
Model A (method 3)        0.23 116.30 117.20 
  (intercept) 101.54 (14.46 - 188.63) 37.76 0.028     
  Mac. 0.94 (-0.18 - 2.06) 0.49 0.090     
Model A (method 5)        0.19 116.89 117.79 
  (intercept) 110.40 (25.87 - 194.93) 36.67 0.017     
  Mac. 0.76 (-0.21 - 1.76) 0.43 0.118     
Model A (methods 3 and 5)        0.15 117.38 118.29 
  (intercept) 105.03 (18.77 - 191.29) 45.53 0.023     
  Mac. 0.86 (-0.35 - 1.92) 0.49 0.100     
Model A (methods 3 and 5)        0.28 116.30 117.51 
  (intercept) 121.76 (32.19 - 211.57) 37.93 0.015     
  Mac. parenteral -0.08 (-2.06 - 1.89) 0.83 0.923     
  Mac. peroral 1.04 (-0.05 - 2.13) 0.46 0.059     
           
Model B (method 3)        0.33 114.97 115.87 
  (intercept) 99.51 (22.51 - 176.51) 33.39 0.018     
  Mac. 1.24 (0,01 - 2.47) 0.53 0.048 *    
Model B (method 5)        0.31 115.25 116.16 
  (intercept) 101.96 (24.79 - 179.14) 33.47 0.016     
  Mac. 1.17 (-0.03 - 2.38) 0.52 0.055     
Model B (methods 3 and 5)        0.34 114.86 115.77 
  (intercept) 98.74 (21.90 - 175.60) 33.33 0.018     
  Mac. 1.23 (0.03 - 2.44) 0.52 0.046 *    
Model B (methods 3 and 5)        0.27 116.40 117.62 
  (intercept) 112.76 (12.03 - 213.48) 42.60 0.033     
  Mac. parenteral 0.28 (-3.85 - 4.41) 1.75 0.875     
  Mac. peroral 1.22 (-0.07 - 2.51) 0.55 0.060     
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  Estimates SE p-value  Adj R² AIC BIC 
 Sulfonamides (Sul.) 
Model (previous)        0.74 7.14 8.04 
  (intercept) -0.16 (-0.50 - 0.19) 0.15 0.327  
   
  Sul. 0.02 (0.01 - 0.03) 0.00 0.001 * 
   
           
Model A (method 3)        0.70 8.23 9.14 
  (intercept) -0.08 (-0.42 - 0.26) 0.15 0.593  
   
  Sul. 0.02 (0.01 - 0.03) 0.00 0.001 * 
   
Model A (method 5)        0.65 9.99 10.90 
  (intercept) -0.11 (-0.50 - 0.29) 0.17 0.552  
   
  Sul. 0.02 (0.00 - 0.03) 0.00 0.003 * 
   
           
Model B (method 3)        0.49 13.84 14.75 
  (intercept) 0.00 (-0.45 - 0.45) 0.19 0.997  
   
  Sul. 0.04 (0.01 - 0.03) 0.01 0.015 * 
   
Model B (method 5)        0.50 13.63 14.54 
  (intercept) -0.04 (-0.51 - 0.42) 0.20 0.833  
   
  Sul. 0.04 (0.00 - 0.06) 0.01 0.014 * 
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  Estimates SE p-value  Adj R² AIC BIC 
 Tetracyclines (Tet.) 
Model (previous)        0.35 108.83 109.74 
  (intercept) 346.13 (294.36 - 397.89) 22.45 0.000  
   
  Tet. 0.92 (0.04 - 1.79) 0.38 0.042 * 
   
           
Model A (method 3)        0.69 101.39 102.30 
  (intercept) 332.60 (296.63 - 368.56) 15.60 0.000  
   
  Tet. 0.91 (0.45 - 1.36) 0.20 0.001 * 
   
Model A (method 5)        0.72 100.36 101.27 
  (intercept) 331.55 (297.38 - 365.73) 14.82 0.000  
   
  Tet. 1.03 (0.55 - 1.52) 0.21 0.001 * 
   
Model A (methods 3 and 5)        0.66 102.48 103.38 
  (intercept) 334.75 (297.17 - 372.33) 16.30 0.000  
   
  Tet. 0.88 (0.41 - 1.36) 0.21 0.003 * 
   
Model A (methods 3 and 5)        0.66 103.05 104.27 
  (intercept) 329.04 (288.51 - 369.57) 17.14 0.000  
   
  Tet. parenteral 1.41 (0.12 - 2.70) 0.55 0.037 * 
   
  Tet. peroral 0.77 (0.21 - 1.33) 0.24 0.014 * 
   
           
Model B (method 3)        0.71 100.64 101.55 
  (intercept) 339.01 (306.89 - 371.13) 13.93 0.000  
   
  Tet. 0.87 (0.45 - 1.28) 0.18 0.001 * 
   
Model B (method 5)        0.74 99.38 100.29 
  (intercept) 337.36 (306.98 - 367.73) 13.17 0.000  
   
  Tet. 1.00 (0.56 - 1.44) 0.19 0.000 * 
   
Model B (methods 3 and 5)        0.65 102.75 103.65 
  (intercept) 340.65 (307.23 - 274.06) 14.49 0.000  
   
  Tet. 0.93 (0.42 - 1.28) 0.19 0.002 * 
   
Model B (methods 3 and 5)        0.82 96.69 97.90 
  (intercept) 326.85 (298.12 - 355.57) 12.15 0.000  
   
  Tet. parenteral 2.12 (0.94 - 3.31) 0.50 0.004 * 
   
  Tet. peroral 0.71 (0.35 - 1.07) 0.15 0.002 * 
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 Discussion  
 
Several studies have assessed CHR, PMD and VetStat in terms of data quality and usability for 
surveillance (Houe, Gardner and Nielsen, 2011; Dupont et al., 2016, 2017). The objective of this 
study was not to assess the databases themselves. The objective was to assess how well transformation 
of VetStat data could mimic the AMU in pigs through rearing, together with an assessment of the 
impact on the AMU and AMR association of using two different biomass adjustments obtained from 
the CHR and the PMD databases. 
 
The underlying principles of the lifetime AMU were several unproven assumptions. However, it 
was key that when a VetStat-record was followed by a new VetStat-record, the amount prescribed 
was assumed to have been used during the period between records (smoothing). Therefore, taking the 
periods between VetStat-records into account, five different approaches to transforming data from 
VetStat were compared with farm-records. The limitation of the validation was the incomplete 
availability of farm-records equivalent to finisher batches’ entire rearing pathways. Instead, records 
were obtained from farm units with no coherent production enrolled in another study. Consequently, 
the validation related just to the estimated daily AMU per pig (ADDkg/pig.day), which is the 
foundation for lifetime AMU.  
 
High accuracy (completeness and correctness) and precision (correlation, relative difference of 
the error and the reliability coefficient) are required in order for register data, to reflect the true state 
in a population (Sørensen, Sabroe and Olsen, 1996; Armstrong, 1998; Bland and Altman, 2010; 
Emanuelson and Egenvall, 2014). The accuracy and precision estimates describes the measurement 
error of the daily AMU estimate. In addition, the reliability coefficient can be used to adjust the point 
estimate of linear regression models using these data, thus providing an estimate of the influence of 
the measurement error on the statistical association between AMU and AMR. 
 
The validation estimates for accuracy and precision all demonstrated that the intervals in days 
between VetStat-records should be calculated taking two additional levels (dispensing-type and AM-
class) into account, when data were smoothed over a period, and that different smoothing approaches 
should be employed for parenteral and peroral dispensing, respectively, to obtain the best measure of 
the daily AMU per pig. The difference observed between the parenteral and peroral smoothing 
method could be explained by the difference in the prescription pattern and the subsequent farm 
usage. For the parenteral AMs, they were infrequently prescribed in large amounts and AM-class 
alterations within a diagnosis seldom occurred. However, in the farms, small amounts were used on 
a regular monthly basis. For the peroral AMs, they were infrequent prescribed in large amounts, but 
used irregularly, furthermore, in several cases the amount prescribed (AM product) in connection 
with a mandatory vet visit had not been used at the time of the next mandatory vet visit, and yet at 
this visit, the same AM product was prescribed once again. In addition, for the peroral AMs, AM-
class alterations within a diagnosis occurred regularly. Any injudicious prescriptions of AMs, e.g. 
prescriptions without usage of the previous prescribed, has a harmful effect on the precision of the 
daily usage estimate. In contrast to this, in some study farms the farm-records and VetStat-records 
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were in almost perfect alignment in terms of accuracy and precision, which shows that when farmers 
and vets practice prudent AM stewardship (Appendix B - Table B1) the measure of daily AMU 
improves. In general, independent of smoothing method, the calculated daily AMU underestimated 
the usage compared with the “true” state, obtained from farm record.  
 
Another issue encountered related to VetStat involved records for one age-group, whereas farm-
records revealed usage in two age-groups or usage in a different age-group. It is mandatory to register 
the correct age-group in VetStat (Executive order 1353/2017), but the DVFA also accepts that 
prescriptions assigned to one age-group can be used for several age-group in a farm (DVFA, 2017). 
This counterproductive practice will reduce both the accuracy and precision of the daily AMU, by 
wrongly assigning usage in one age-group at the expenses of reduced usage in another. Since it is 
legal, the practice could be common, however, besides the encountered praxis in this study, the 
authors have no knowledge of the extent of the praxis in Danish pig production (Appendix B – Table 
B2). Furthermore, the table provides a little insight into the differences between AMU in piglets and 
sows, e.g. aminoglycosides, aminoglycosides combined with narrow-spectrum penicillins, colistin, 
lincosamides combined with spectinomycin and long-lasting macrolides were only used for piglets, 
whereas narrow-spectrum penicillins and tetracyclines were only used for sows, knowledge which 
may assist in attempts to separating AMU between the two.   
 
With the purpose of gathering knowledge of the differences between the vets’ instructions on 
AMU and those recorded in VetStat, the instructed dose was compared with the standard ADD and 
the duration was compared with the recommended duration in the product catalogue of the Danish 
Veterinary Medical Industry. A vet instruction guides the farmer on AMU, i.e. disease symptom to 
be detected before initiating treatment, treatment dose per kg pig per day and duration of the treatment 
in days. The dose and duration evaluation revealed that the vets over-dosed the parenteral AMs, in 
particular, the long-lasting parenteral AMs, while the peroral AMs were slightly under-dosed 
(Appendix B - Fig. B3 – B4). A finding that other studies have also demonstrated (Timmerman et al., 
2006; Callens et al., 2012; Trauffler et al., 2014). An overview of the diseases that the AMs were 
prescribed for showed similarities between farms, e.g. long-acting extended penicillin (amoxicillin) 
was the only product used to treat omphalitis, single drug peroral aminoglycosides and colistin were 
only used to treat diarrhea, while parenteral aminoglycosides in combination with narrow-spectrum 
penicillins were only used to treat arthritis (Appendix B – Fig. B5). Part of the treatment instructions 
for specific diagnosis did not change over time, which could indicate that some treatments are 
standard management procedures. Callens et al. (2012) found that 93% of group-treatments were 
preventive and often lacked a precise diagnosis. They argued that highly specialised farms often have 
standardised management procedures to prevent production losses, and that these standard treatments 
are easier and less labour intensive to implement than treating clinically diseased animals with 
concomitant losses in production. The higher usage was attributed to treatments during critical 
management procedures, such as castration, tail docking and weaning, because the farmer foresees 
pigs becoming diseased during these circumstances. This practice is not unfamiliar in Danish pig 
farms, which face the same consideration of optimising production by reducing foreseen diseases 
(Jørgensen et al., 2007; Nielsen, 2015). 
 
 
80 
 
 
 
When the alternative smoothing methods were employed in the re-analyses of 10 finisher batches 
from a previous study, the results produced an overall better statistical estimate of model fit of the 
regression analyses estimating the effect of AMU on AMR gene abundance compared with the 
previous models. Moreover, when the reliability coefficients were employed to the point estimate of 
the regression analyses, they increased by 49%. Subsequently demonstrating that the measurement 
error were biasing the effect estimates towards zero. The deviating result of the effect of macrolide 
may arise from the time of usage. This predicament might be solved by including the weight of the 
pigs, which in the first study beneficially altered the effect of macrolide usage on the occurrence of 
macrolide resistance, thus the variation in macrolide resistance that macrolide usage was able to 
explain changed from 66% to 72% (Appendix A - Fig. A1).  
 
Also, in this study, two different biomass adjustments based on data from the CHR and the PMD 
databases were assessed. The former database is commonly used in Danish research (Emborg et al., 
2007; Vieira et al., 2009; Vigre et al., 2010). However, in recent years an increased deviation between 
the number of pigs in farms and the number of pigs delivered for slaughter has been noticed, which 
was also demonstrated in this study by comparing the number of animals obtained from the two 
databases (Appendix B - Fig. B6). The comparison between the numbers of pigs revealed that when 
the number of piglets was calculated based on the production data from the PMD, per se exceeded 
the number of sows registered in the CHR, which may provide a better biomass adjustment in the 
calculation of lifetime AMU. The number of weaners was higher and the number of finishers was 
lower in the CHR than the number of weaners and finishers in the PMD. The PMD biomass 
adjustment may be less biased, as it solely reflects the number of animals being moved, in contrast 
with the CHR number of pigs, which is a farmer’s evaluation of management performance and 
averages on any given day, and is therefore more subject to bias. 
 
Then, based on how much variation of AMR the AMU could explain, comparison between the 
number of pigs at any given day obtained from the CHR and the PMD revealed that using the PMD 
in regression analyses gave improved statistical models fit estimates. The impact of adjusting with 
the PMD rather than the CHR related mainly to usage in piglets. When the number of sows (CHR) 
was used as the biomass adjustment, the estimated number of daily AMU in piglets rose, compared 
with the PMD adjusted estimates. A high number of daily doses in the piglet rearing period can distort 
the AMU-AMR relationship by putting too much emphasis on this period. Generally, the results of 
the biomass adjustments revealed that the PMD performed better than the CHR, suggesting that the 
PMD provides a more accurate and reliable estimate of the number of pigs at a farm. 
 
The improved results of the regression analyses led to the analyses of the effect of parenteral and 
peroral AMU on the AMR abundance of the ten finisher batches. Besides the difference between 
dispensing-types per se, the two variables also comprise a somewhat semi-representation of time of 
usage, because parenteral AMs primarily were used for sows and piglets, whereas peroral AMs were 
primarily used for weaners and finishers (Jensen et al., 2014; Dupont et al., 2016). The results of 
these analyses revealed that the effect estimates were indeed affected differently by dispensing-type, 
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and to some degree the strongest effects were in alignment with the time of usage observed for the 
batches, i.e. parenteral aminoglycosides were used primarily for piglets – sows and tetracyclines were 
used in all age-groups independent of dispensing-type (Table 3.2.1. and Table 4.2.1).  
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Abstract 
It is generally accepted that production animals contributes to the 
burden of antimicrobial resistance (AMR) in humans. To curb the 
increased occurrence of AMR in food animals requires in-depth 
knowledge of the quantitative relationship between antimicrobial 
usage (AMU) and AMR to achieve desired resistance reductions 
from interventions targeted AMU. The relationships between 
lifetime AMU in finisher batches close to slaughter and the 
abundance of AMR genes (AMR abundance) in their gut 
microbiome were quantified using linear regression. These results 
and the national AMU in pigs were included in a predictive model 
that allowed testing of different lifetime AMU scenarios for 
finishers slaughtered in Denmark. Three different scenarios of 
lifetime AMU were simulated in the model. When all tetracycline 
usage were ceased, the aminoglycoside, lincosamide and 
tetracycline resistance were reduced by 4-42%, 0-8% and 9-18%, 
respectively. When the peroral tetracycline usage of the 10% 
highest users were replaced with peroral macrolide usage, the 
tetracycline resistance was reduced by 1-2% and the macrolide 
and MLSb resistance increased by 5-8%. When all extended-
spectrum penicillin usage were replaced with parenteral 
lincosamide usage, the beta-lactam resistance reduced by 2-7%, 
but the lincosamide usage and resistance increased by 200% and 
13-42%, respectively. Nonetheless, interventions targeting AMU 
will reduce the overall AMR abundance, though differently 
depending on the targeted AM-class and provided the reduction 
in usage of one AM-class is not replaced with usage of another. 
This study provides a framework for further development, which 
may assist in reducing AMR thus safeguarding AMs for the 
future. 
 
Significance 
Being able to predict the quantitative effects of interventions 
targeting AMU on AMR, comprises a valuable guidance tool for 
authorities and stakeholders. Quantified relationships between 
finisher batches lifetime AMU and AMR abundance in their gut 
microbiome combined with national AMU at farm level were 
included in a predictive model, which allowed for testing of 
different AMU scenarios of finishers slaughtered in Denmark. 
The model shows that large reductions of commonly used AMs 
led to minor reductions in AMR, and might increase the overall 
abundance, if reduction of one AM-class is replaced with usage 
of another AM-class. However, targeted interventions will 
potentially provide an overall beneficial effect. This study 
provides a framework for further developments in animal and 
human settings globally. 
 
\body 
Introduction 
Antimicrobial resistance (AMR) is considered one of the most 
harmful threats to global health, and it is widely accepted that the 
antimicrobial usage (AMU) is the main cause (1, 2). In an attempt 
to reduce the occurrence of AMR, several AMU stewardship 
programs have been implemented, but these programs have 
proven difficulties in introducing major declining effects on the 
occurrence of AMR, and none of them were able to predict any 
changes (3, 4). 
Even though it is generally accepted that production animals 
contribute to the burden of AMR among humans (5, 6), less is 
known about the causes of the emergence and spread of AMR in 
the food chain and the risk posed to humans (6). In particular, 
there is a large debate on the contribution of foodborne AMR to 
human infections (5–7). Consequently, attention towards AMU 
in production animals has grown immensely during the past 
decade (5). In several countries, this has led to the establishing of 
surveillance systems that monitor trends and changes in AMU in 
animals (8). These monitoring systems has in turn been efficiently 
applied to facilitate interventions and guidelines for improved 
antimicrobial (AM) stewardship (3, 4, 9).  
Epidemiological studies have established that AMU and AMR in 
production animals are closely related (6), and it has also been 
proven that halted usage of a compound, e.g. vancomycin and 
third-generation cephalosporin will lead to declined occurrence 
of AMR (10, 11). However, the quantitative relationship between 
AMU and AMR is not as illuminated, because neither the 
quantification of AMU nor the characteristics of the AMs, e.g. 
route of administration, dose, duration of treatment, and 
concurrent interrelation between AM-compounds have been fully 
determined in terms of importance for the selection of AMR (12). 
In addition, most studies conducted so far have focused on only 
one or a few indicator bacteria, whereas the bulk of relevant AMR 
genes might be present in the entire gut microbiome. The recent 
developments in next generation sequencing allow complete 
quantification of the abundance of AMR genes (AMR 
abundance) in the entire gut microbiome (13). 
Denmark is one of the largest exporters of pork products globally 
(14), and the total AMU within the Danish pig production is 
considerable; in 2016, it represented 75% of the total amount of 
kilogram active substance for animals and it was 57% higher 
compared to human usage (15). In a public health perspective, the 
AMU in the pig production in Denmark is worrying therefore, 
even though the Danish authorities since have launched several 
initiatives to reduce the usage in pigs. 
To provide the means of estimating an association between 
specific AMU and AMR at national level, two previously 
conducted studies developed and validated a method based on 
register-data, which quantified the associations between lifetime 
AMU of six AM-classes used in the pig production and AMR 
abundance of these classes for ten finisher batches close to 
slaughter. Subsequently, a method that measured AMU in 
finisher batches throughout their lifetime by combining usage in 
the piglet (sow), weaner and finisher rearing period, independent 
of rearing site. In the study, the AMR abundance was measured 
using shotgun metagenomic sequencing, which gave a 
proportional content of AMR abundance independent of bacteria 
species (13, 16, 17).   
Studies have been published focusing on predicting the effect of 
AMU changes on the occurrence of AMR  (18–21). Most of these 
studies were based on theoretical data and to the best of the 
authors’ knowledge, none concerning AMR abundance in the gut 
microbiome of animals. Having precise knowledge of the effect 
of lifetime AMU of individual AM-classes on all AMR 
abundances, combined with knowledge of either AMU or AMR 
for larger parts of a population, allows for the prediction of the 
overall effect of an intervention targeting AMU in general or for 
specific AM-classes only in that population, for instance a 
country (22, 23). Additionally, a modelling framework of the 
epidemiology of AMR abundance used to describe differences in 
the gut microbiome of finishers under the influence of AM 
pressure can also be used to support knowledgeable guidance of 
AMU practices at farm level.  
In this study, first a characterisation of the gut resistome of 83 
finisher batches representing the majority of pigs slaughtered in 
Denmark in 2013 was performed, and through data 
transformation of register data, the lifetime AMU for these 
batches were calculated. Based on the data, the quantitative effect 
of lifetime AMU on the AMR abundance in the gut microbiome 
of finisher batches close to slaughter were estimated. Then, the 
AMU for all pig farms at unit level in Denmark was calculated. 
From the effect estimates and the national data on AMU, a 
 
 
predictive model was developed, wherein the effect of different 
scenarios of nationwide reduction in AMU on the AMR 
abundance in the gut microbiome of finishers close to slaughter 
in Denmark can be assessed. 
 
Results 
Study population 
The finisher batches varied in rearing pathways, however, the 
pathway of the majority of batches were simple, i.e. pigs in a unit 
originated from the same farm or from one farm only (Fig. S1). 
Two finisher batches did stand out, due to the complexity of their 
rearing pathway that included five and seven farms, respectively 
(Fig. S1).  
The parenteral and peroral lifetime AMU of nine AM-classes; 
aminoglycosides including spectinomycin, extended-spectrum 
penicillins, lincosamides, macrolides, narrow-spectrum 
penicillins, pleuromutilins, polymyxins, sulfonamides including 
trimethoprim and tetracyclines of the 83 finisher batches is 
presented in Fig. S2. The extended-spectrum penicillins, 
macrolides, narrow-spectrum penicillins and tetracyclines were 
the most commonly used AM-classes of parenteral dispensing, 
whereas the most commonly used AM-classes of peroral 
dispensing were macrolides, pleuromutilins and tetracyclines. 
The distribution of parenteral and peroral lifetime AMU per 
rearing unit revealed that parenteral dispensing was mainly used 
for piglets, including sows, while the main usage for weaners and 
finishers were peroral dispensing (Fig. S2). In the scatterplots 
(Fig. 1), the AMR abundance per AM-class of the 83 finisher 
batches is shown. Overall, tetracycline resistance was most 
abundant, followed by macrolide resistance. In contrast, 
resistance of sulfonamide was scarcely found. 
 
Regression analyses 
The model assumptions of constant variance and normality of 
residuals were evaluated by visually inspection of the diagnostic 
plots of the models. From this, it was concluded that the 
assumptions to perform linear regression explaining AMR by the 
AMU were fulfilled without any kind of data transformation.  
Though, for lincosamides, one observation with a Cook’s 
distance higher than one was identified, and when the impact of 
excluding this observation on the model was assessed, the 
lifetime usage of lincosamides were still significant, but the β-
coefficient of lincosamides increased app. 49% and the R2 
decreased app. 43%. Nonetheless, it was decided to keep the 
observation in the subsequent analyses. Overall, the results from 
the bi-square robust regression models indicated that the data did 
not have any notable influential observations (Fig. 1 and Table 
S3). 
 
Uni-variable model - Model 1  
For all AM-classes, except narrow-spectrum penicillins and 
sulfonamides, the lifetime usage demonstrated a significant effect 
on the resistance abundance (Fig. 1). For the significant results, 
the proportion of observed variation (R2) in AMR abundance that 
could be explained by the lifetime usage ranged from 6% 
(extended-spectrum penicillin on beta-lactam) to 49% 
(macrolides on MLSb resistance) (Fig. 1). When the estimated 
models of bi-square robust regressions were added to the 
scatterplots, the obtained estimates of the fitted models showed to 
be similar to the estimates obtained in the linear regression 
models, which indicated that the data did not have any notable 
influential observations (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Plotted observations of lifetime AMU (ADDkg/pig) against resistance abundance (FPKM)  for conventional (blue) and organic 
farms (brown) of; a) aminoglycoside usage and resistance, b) extended-spectrum penicillin usage and beta-lactam resistance, c) 
lincosamide usage and resistance, d) macrolide usage and resistance, e) macrolide usage and MLSb resistance, f) narrow-spectrum 
penicillin usage and beta-lactam resistance, g) sulfonamide usage and resistance, and h) tetracycline usage and resistance. In addition, 
the three regressions of FPKM as a function of ADDkg/pig; i) LOESS local (dotted grey line), ii) linear with 95% confidence interval 
(CI) (black line and grey area), and bi-square robust (orange dotted line) together with the function, p-value and R2 value are shown 
in each plot. 
Model 1 included updated design variables – Model 2 
When the design variable, production-type was included in the 
initial uni-variable models (Model 1), the estimated β-coefficients 
of the lifetime AMU differed from the β-coefficients of Model 1 
by 0% to 19%, thus, it could not be concluded that production-
type was an important confounder for the effect of lifetime AMU 
(Table 1). In the organic farms, the abundance of beta-lactam and 
sulfonamide resistance was significantly higher, while the 
abundance of aminoglycoside, lincosamide, macrolide, and 
tetracycline resistance was significant lower. When the updated 
design variables; the annual number of suppliers of pigs and the 
annual number of slaughtered finishers were included in the 
initial uni-variable models (Model 1), the estimated β-coefficients 
of the lifetime AMU differed from the β-coefficients of the Model 
1 by 0% to 16%. Therefore, it could not be concluded that these 
variables were important confounders for the effect of lifetime 
AMU (Table 1).  
 
Multi-variable model at dispensing-type level – Model 3 
The multi-variable regression models of the effect of parenteral 
and peroral lifetime usage of aminoglycosides, extended-
spectrum penicillins, lincosamides, macrolides, sulfonamides and 
tetracyclines on aminoglycoside, beta-lactam, lincosamide, 
macrolide/MLSb, sulfonamides and tetracycline resistance 
abundance, respectively, displayed a substantial difference 
between the parenteral and peroral β-coefficients for all AM-class 
resistances. Therefore also a substantial difference compared to 
the β-coefficients of the uni-variable models (Table 1). The β-
coefficients of peroral aminoglycosides, parenteral extended-
spectrum penicillins and parenteral macrolides were without 
effect, therefore, significant results were only obtained for 
parenteral usage of aminoglycosides, for peroral usage of 
extended-spectrum penicillins and macrolides, and for both 
parenteral and peroral usage for lincosamides and tetracycline 
(Table 1). Neither parenteral nor peroral usage of sulfonamides 
provided any significant results (Tables 1).  
 
Table 1. β-coefficients of the lifetime AMU estimated  as total 
usage (Models 1 - 2) and as parenteral and peroral usage (Models 
3 – 4) of aminoglycosides, extended-spectrum penicillins, 
lincosamides, macrolides, sulfonamides and tetracyclines. Grey 
numbers of β-coefficients of Models 2 indicate the updated 
variable(s) were not significant in the regression analyses. *  Production-type 
† Annual number of slaughtered finishers  
‡  Annual number of suppliers of pigs 
§  Variable was not significant in the regression analyses 
 
Multi-variable model included all AM-classes at dispensing-type 
level and updated design variables - Model 4 
When the β-coefficients of the reduced multi-variable regression 
models were compared to the Model 3 significant β-coefficient of 
the same AM-class resistance, the β-coefficients of peroral 
extended-spectrum penicillins, parenteral lincosamides, peroral 
macrolides (MLSb), parenteral and peroral tetracyclines changed 
by 7%, 9%, 8%, 6% and 10%, respectively. In contrast, parenteral 
aminoglycosides, peroral lincosamides and peroral macrolides, 
did not change (Tables 1). The updates design variables; annual 
  Model  β-coefficient   
    1 2 3  4 
   Prod. * 
Slaught. † 
Suppl. ‡ 
Slaught.-Suppl. 
   
          
Aminoglycosides        
 Total 0.28 0.24 0.24 0.23 0.19     -   - 
 Parenteral - - - - - 0.34   0.34 
 Peroral - - - - - 0.04 §   - 
         
Extended-spectrum penicillins      
 Total 0.11 0.13 0.13 0.13 0.13     -    - 
 Parenteral - - - - - 0.00 §   - 
 Peroral - - - - -  0.14  0.15 
       
Lincosamides       
 Total 0.37 0.36 0.35 0.36 0.36     -    - 
 Parenteral - - - - -  0.65  0.59 
 Peroral - - - - -  0.32  0.32 
         
Macrolides       
 Total 0.29 0.28 0.27 0.28 0.37     -    - 
 Parenteral - - - - - -0.01 §   - 
 Peroral - - - - -  0.28  0.28 
         
Macrolides (MLSb)       
 Total 0.12 0.11 0.11 0.12 0.12     -    - 
 Parenteral - - - - -  -0.04 §   - 
 Peroral - - - - -  0.12  0.11 
         
Sulfonamides       
 Total -0.00§ 0.00 0.00 0.00 0.00     -    - 
 Parenteral - - - - -  0.00 §   - 
 Peroral - - - - -  -0.00 §   - 
          
Tetracyclines        
 Total 0.53 0.43 0.46 0.44 0.45     -    - 
 Parenteral - - - - -  0.64   0.68 
 Peroral - - - - -  0.41   0.45 
          
 
 
number of slaughtered finishers and annual number of suppliers 
of pigs were excluded during model reduction of all AM-class 
resistances (Table S3). 
The significant results of the resistance abundance of the seven 
AM-classes demonstrated two noticeable outcomes, the overall 
difference between parenteral and peroral dispensing and the 
effect of peroral macrolides and both parenteral and peroral 
tetracyclines on several AMR-classes. In addition, even though 
the β-coefficient values were minute, the sulfonamide resistance 
abundance seemed to be affected by peroral polymyxins (Fig. 2 
and Table S3). 
The obtained estimates of the fitted bi-square robuast regression 
models changed the significant β-coefficient of parenteral 
aminoglycosides, parenteral lincosamides and peroral macrolides 
(MLSb) by 7%, 7% and 6%, respectively, within their respective 
AM-classes, whereas the β-coefficient of peroral extended-
spectrum penicillins, peroral lincosamides, peroral macrolides, 
parenteral and peroral tetracyclines within their respective AM-
classes changed 2% or less (Table S3). Results, which indicate 
that the estimated effect are robust against outliers.
 
Fig. 2. Results of Model 5 of the effect of parenteral and peroral lifetime AMU of aminoglycosides, extended-spectrum (Ext) 
penicillins, lincosamides macrolides, pleuromutilins, polymyxins, sulfonamides and tetracyclines on the aminoglycoside, beta-lactam, 
lincosamide, macrolide, MLSb, sulfonamide and tetracycline resistance abundance. Black lines indicate the main significant result, 
and thickness is proportional to the relative size of the β-coefficient. Grey lines indicate significant result with β-coefficient less than 
0.05. 
Uni-variable model at resistance gene level – Model 5. 
The multi-variable regression models of the effect of parenteral 
and peroral lifetime usage of aminoglycosides, extended-
spectrum penicillins, lincosamides, macrolides, narrow-spectrum 
penicillins, pleuromutilins, polymyxins, spectinomycin, 
sulfonamides, tetracyclines and trimethoprim on each resistance 
gene of the AM-classes; aminoglycosides, beta-lactams, 
lincosamides, macrolide/MLSb, sulfonamides and tetracycline, 
demonstrated that the specific AM-class resistance genes was 
foremost affected by the same AM-class usage (Fig. S4). 
Conversely, the abundance of aminoglycoside resistance genes 
was affected by several AM-classes, which is consistent with the 
results of Model 4 of aminoglycoside resistance, where it was 
demonstrated that several AM-classes had an impact on the 
occurrence (Table S3). In addition, the abundance of MLSb 
resistance genes, erm(B), erm(F) and erm(G), seemed to be 
affected by the parenteral aminoglycoside usage, which was in 
alignment with the MLSb result of Model 4 (Fig. 2 and Table S3). 
The sulfonamide sul3 resistance gene was the only AM-class 
specific gene affected by sulfonamide usage, a finding that 
differed from the Model 4, where sulfonamide usage had no effect 
on sulfonamide resistance. Although most of the tetracycline 
resistance genes were affected by peroral tetracycline usage, 
several tetracycline resistance genes were affected by other AM-
classes. In contrast, tet(X) was not affected by tetracycline usage, 
instead it was affected by the usage of parenteral 
aminoglycosides, parenteral lincosamides, peroral macrolides 
and peroral polymyxins (Fig. S4). 
 
Correlation matrix at resistance gene level – Matrix 6 
The correlation matrix of the resistance genes of the 
aminoglycoside, beta-lactam, lincosamide, macrolide, MLSb, 
sulfonamides and tetracycline classes is presented in Fig. S5. 
Within the AM-classes; aminoglycosides, beta-lactams and 
lincosamides, none of the resistance genes were highly correlated. 
In the macrolide-class, the mef(A) gene correlated with the 
msr(D). Within the MLSb-class, the erm(B), erm(F), erm(G), 
erm(Q) and erm(T) genes correlated with each other, thus, formed 
a cluster. For the sulfonamide-class, the sul1 gene correlated with 
the sul2 gene. In the tetracycline-class, the tetA(P) and tetB(P) 
genes correlated, for that reason, both of them correlated with the 
tet(44) gene. The tet(32) gene correlated foremost with the 
tet(40), tet(L) and tet(W) genes, and the tet(40) gene correlated 
with the tet(Q) and tet(W) genes (Fig. S5). 
Several correlations between genes of different AM-classes were 
notable. The aminoglycoside aadE gene correlated with the 
lincosamide lnu(B) gene, the aminoglycoside strA and strB genes 
correlated with the sulfonamide sul1 and sul2 genes, the 
aminoglycoside ant(6)-I gene correlated with the tetracycline 
tet(44), tetA(P) and tetB(P) genes, and the aminoglycoside 
aph(3’)-III gene correlated with the tetracycline tet(32), tet(40), 
and tet(Q) genes. The beta-lactam resistance genes did not 
correlate with resistance genes of other AM-classes, while the 
 
 
macrolide mef(A) and msr(D) gene correlated with most of the 
MLSb genes and tetracycline-tet(X) gene (Fig. S5)  
 
Predictive model 
First, the AMU in the farms contributing with finisher batches to 
the observational study was evenly distributed among the farms 
contributing with batches used for prediction. For every AM-
class at dispensing-type level, within every decile of the 3080 
finisher batches used for the prediction model, it was found that 
5-15 % of the batches originated from farms, which also 
contributed with batches in the observational study.  
The predicted effect of different lifetime AMU scenarios in the 
Danish pig production on the overall resistance abundance of 
different AM-classes is presented in Table 2. 
 
Table 2. Result from the simulation studies predicting the effect in percentages of three different scenarios of lifetime AMU in Danish 
finisher batches on AMR abundance of different AM-classes in the bathes microbiome close to slaughter at national level.   
 Change in AMR abundance (%) Change in  lifetime AMU (%) 
   Scenario 
 A
m
inoglycosides 
 B
eta-lactam
s 
 Lincosam
ides 
 M
acrolides 
 M
LSb 
 Tetracyclines 
 Penicillins (ext.)  
 Lincosam
ides 
 M
acrolides  
 Tetracyclines 
           
Ceased parenteral and peroral 
tetracycline usage  -42; -4 - -8; +0 - - -18; -9 - - - -100 
           
Reduction by the top 10% users of 
peroral tetracycline usage and 
replacement with peroral macrolide 
usage  
-1; +1 +1; +3 -0; +0 +5; +7 +5; +8 -2; -1 -  24 -16 
           
Ceased peroral and parenteral extended-
spectrum penicillins usage and 
replacement with parenteral lincosamide 
usage 
 
- -2; -7 +13; +42 - - - -100 194 - - 
 
In the scenario where the entire tetracycline usage were ceased, it 
can be expected that the tetracycline resistance abundance will be 
reduced by 9-18%. In addition, it can be expected that the 
lincosamides and aminoglycosides resistance abundance also will 
be reduced, even though the size of these reductions is surrounded 
by more uncertainty (Table 2).  
In the scenario where the top 10% highest users of peroral 
tetracycline reduced usage by replacing it with peroral usage of 
macrolides, at national level, the usage of tetracyclines can be 
expected to be reduced by 16%, and the usage of macrolides can 
be expected to be increased by 24%. If the total tetracycline usage 
in the Danish pig production were to be reduced by app. 16%, the 
tetracycline resistance abundance can only be expected to be 
reduced by 1-2%. At the same time, the resistance abundance of 
beta-lactams, macrolides and MLSb can be inspected to increase 
relatively more compared to the reduction of tetracycline 
resistance abundance, due to the increased macrolide usage 
(Table 2). 
In the scenario where parenteral and peroral usage of extended-
spectrum penicillin usage were replaced with parenteral 
lincosamide usage, the beta-lactam resistance can be expected to 
be reduced by 2-7%, but the lincosamide usage and resistance 
abundance can be expected to be increased by 200% and 13-42%, 
respectively (Table 2). 
 
Discussion 
Study population 
The restrictive farm selection and stratification yielded a source 
population representative of the vast majority of farms delivering 
pigs for slaughter in Denmark, which makes it possible to draw 
inference from the study sample to the source population. The 
study had an over-representation of larger farms, which was 
established to study the AMU-AMR associations in farms with a 
size and production system in alignment with the structural 
development in pig farms expected by the pig industry in the near 
future (24).  
In the regression models, nothing indicated that the annual 
number of slaughtered pigs or the annual number of suppliers of 
pigs of the sampled farm interacted with the effect of lifetime 
AMU on the AMR abundance. Furthermore, the comparison 
between lifetime AMU in the finisher batches included in the 
observational study and all batches used for prediction, did not 
indicate any extrapolation of the observed results to batches with 
very different usage. Therefore, the batches included in the 
observational study can be considered representative for the 
investigation of the general association between lifetime AMU 
and AMR abundance in finishers in the Danish pig production, 
and the observed associations can thereby be used to predict the 
effect of different lifetime AMU scenarios across the pig 
production.  
 
 
 
Regression analyses 
Lifetime AMU was calculated as total amounts throughout the 
rearing period at dispensing-type and AM-class level. By doing 
so, it was not possible to distinguish between differences in AMU 
within the three rearing periods. For that reason, finisher batches 
with similar AMU might relate to usage in different units, thus, 
the AMR abundance in the gut microbiome of these pigs, may be 
different as changes in AMR can happen over short periods (13, 
25, 26). Subsequently, the lifetime AMU does not take into 
account the influence of usage in the rearing period of piglets 
compared to usage closer to slaughter.  
In the study, shotgun metagenomic sequencing was used to 
measure the relative AMR abundance in the microbial 
community of feces from finishers, therefore, the method does 
not distinguish between intrinsic and acquired (transferable) 
resistance genes in a bacterial population (27). A distinction 
between the two might be important for public health since 
intrinsic AMR poses a minor risk to humans compared to 
transferable AMR (27). Notwithstanding the difference between 
intrinsic and acquired AMR, any AMR gene in excessive 
abundance in habitats with high AMU, can contribute to the 
spread of AMR along the food chain (13). Furthermore, as the 
ResFinder database contains mainly AMR genes detected in 
clinically relevant bacteria, a considerable number of intrinsic 
AMR genes may have been missed (5, 13). Therefore, although 
not all detected AMR genes necessarily pose a risk to human 
health, their presence in feces from pigs represents an available 
gene pool from which zoonotic bacteria and human pathogenic 
bacteria may obtain resistance genes (12, 28, 29).  
None of the significant β-coefficients in Models 1-4 of any AM-
class resistances altered notably when the updated design 
variables or the additional AM-classes were added, indicating 
that the effect of AMU on AMR at AM-class level is not strongly 
influenced by factors as farm size, supplier number or other AMs. 
However, the design variables take only the finisher unit into 
account not the entire rearing pathway (Fig. S1). Subsequently, 
the updated design variables may not apply as traditional 
confounders for a finisher batch. Instead, characteristics such as 
rearing pathway or ownership through the rearing pathway could 
be more explanatory for finisher batches.   
The significantly lower AMU and AMR abundance of most AM-
classes in the organic production compared to conventional 
production was expected (30). The high level of beta-lactam 
resistance in the organic farms coincided with parenteral narrow-
spectrum penicillin usage as their main drug choice. In contrast, 
the higher level of sulfonamide resistance in organic farms 
compared to conventional farm could not be explained.  
The initial scatterplots of the uni-variable regression models 
indicated simple linear relationships between lifetime AMU and 
AMR abundance for all AM-classes. Hence, in the multi-variable 
regression models, the effects of lifetime AMU were estimated as 
linear. The visual inspection of the diagnostic plots of the multi-
variable regression models supported the selected relationship 
between lifetime AMU and AMR abundance. The AMU is low 
in Denmark, therefore, extrapolation of the observed linear 
relationship between lifetime AMU and AMR abundance to 
higher levels of AMU should be done with caution.  
Generally seen, the peroral AMs affected the AMR abundance far 
broader than the parenteral AMs, which in turn had a higher effect 
on resistance abundancy. The broader effect of peroral AMs may 
be due to its widespread but intermittent usage during the weaner 
and finisher rearing periods, which is supported by findings in 
other studies (31, 32). The lacking effect of parenteral extended-
spectrum penicillins, macrolides and sulfonamides should be 
interpreted with caution, as they were foremost used at the piglet 
rearing period. The lifetime AMU does not distinguish between 
usages at different rearing periods, consequently, a usage of these 
AMs in the finisher unit might have had an effect on resistance 
abundance. Therefore, in this study it cannot be demonstrated that 
usage of parenteral extended-spectrum penicillins, macrolides 
and sulfonamides in the piglet rearing period have an effect on 
the resistance abundance of their corresponding AM-classes in 
finishers gut microbiome close to slaughter. Nonetheless, the 
observed difference between parenteral and peroral AMs on 
AMR abundance may arise from absorption, distribution and 
elimination of the AM substances (31, 33).  
The higher effect of parenteral usage of lincosamide and 
tetracycline on their respective resistance abundance compared to 
peroral is less clear. Peroral and parenteral lincosamides were 
mainly used for weaners and finishers, respectively, which may 
explain why parenteral usage was having a higher effect on 
lincosamide resistance abundance.  It is less clear why the effect 
of parenteral tetracyclines was higher than peroral tetracycline. 
Findings from Model 6 show that peroral tetracyclines have an 
effect on several genes, while the parenteral tetracyclines seemed 
to affect only a single gene.  
The excessive effect of parenteral aminoglycosides on MLSb 
resistance is connected associations to three MLSb genes;  
erm(B), erm(F) and erm(G) may be due to co-selection. 
The wide-ranging co-selection of macrolides in the multi-variable 
regression models (Model 4) was a finding with parallels to 
Rosengren et al. (34) which found that the occurrence of 
sulfamethoxazole and chloramphenicol resistance was six times 
higher in farms with high usage compared to farms with no usage 
of macrolides. In addition, co-selection of macrolide resistance 
by both glycopeptides and copper has previously been shown in 
Danish pig farms (35–37). Looft et al. also demonstrated the 
potential for co-selection from a single AM-class usage (38). 
Also, the uni-variable models of the effect of lifetime AMU on 
the abundance of AMR genes (Model 5) showed that peroral 
macrolide usage affected other AM-classes, however, primarily 
related to a few number of resistance genes. Similar findings were 
shown for the parenteral aminoglycoside usage, which affected a 
few number of resistance genes of several other AM-classes. The 
correlation matrix between abundance of AMR genes, revealed 
the background for the deviating behavior of tet(X), and the lack 
of effect of the sulfonamide usage on the corresponding genes 
This study includes a vast amount of analyses for the uni-variable 
analyses at gene level and for the correlation matrix. As a 
consequence, it is highly probable that the false discovery rate  is 
very high. Therefore, the significance level was reduced from 
0.05 to 0.01. Despite taking this precaution, the results from these 
analyses should be viewed at as indicative only and as a 
supporting tool for the assessment and understanding of Model 4. 
In general, the estimated effects of lifetime AMU on AMR 
abundance can be interpreted as the effect on the overall pool of 
AMR abundance in the gut microbiome of finishers close to 
slaughter in Denmark. The biological mechanism behind the 
observed effects is most likely that any given AM will reduce the 
growth of some bacteria, and thereby making room for an 
increase of the relative abundance of bacteria with intrinsic and 
acquired AMR against the given AM. This may also explain some 
of the unexpected effects observed, i.e. the effect that some AMs 
have on some of AMR abundances, even if there is no know co-
resistance or cross-resistance, e.g. the effect of parenteral 
aminoglycoside usage on several resistance genes from different 
AM-classes. Although significant associations were found 
between AMU and AMR of every AM-class resistance, the AMU 
were only able to explain between 9% - 52% of the variation in 
AMR. While some of the un-explained variation are due to 
 
 
measurement error, a substantial part still need to be explained 
(39). 
Overall, the study has generated knowledge of the quantitative 
relationship between parenteral and peroral lifetime AMU and 
AMR abundance, at AM-class level, in the gut microbiome of 
finisher batches close to slaughter, which in turn can be used in 
predictive modelling. 
 
Predictive model 
The majority of predictive studies of occurrence of AMR has 
different structures in terms of complexity and inherent 
assumptions. Conversely, common for these models were the 
assumption that the treatment effect was constant (19, 40). By 
applying the actual information of the AMU at unit level in each 
farm, the movement of pigs between farms and the number of 
pigs delivered for slaughter from each farm, the predicted results 
can be anchored in the actual conditions in the Danish pig 
production (22).  
The initial predicted AMR abundance for every batch does not 
include the unexplained variation in abundance between farms. 
Therefore, these predictions should be interpreted as a mean 
AMR abundance in batches with the given lifetime AMU. If the 
intention were to predict the AMR abundance for a specific batch, 
the prediction interval would be larger, because the observed 
unexplained variation between batches from different farms 
should be taken into account.  
A previous validation study of VetStat data (17), demonstrated 
that the variation in AMR abundance that could not be explained 
by the lifetime AMU in finisher batches could partly be due to 
measurement error in the VetStat data. In addition, the validation 
study demonstrated that these measurement errors were also 
biasing the effect estimates towards zero, and the predicted 
effects of different lifetime AMU are therefore biased towards 
zero. The predictions have not been adjusted for this bias, hence, 
the predicted relative effects of different AMU in the pig 
production were conservative predictions.  
The model predicted the AMR abundance given a change in the 
lifetime AMU within the whole or a subset of the pig production. 
The model has a static nature, and assumes that changes in AMR 
abundance are reached immediately. However, because of the 
living nature of the microbiome at a farm, it is expected that in 
reality the change will occur successively over a longer period 
until a new level of AMR abundance is reached.  
It has proven difficult to introduce major changes in AMU that 
significantly reduce the occurrence of AMR in humans. A reason 
is that it can be very difficult to predict both exactly which 
interventions that will prove more efficient, i.e. how large a 
reduction in AMU will be needed to achieve a desired change in 
AMR. Previous predictive models have been based on theoretical 
assumptions sometimes supported by laboratory data (19, 40). 
This study shows that it is possible to describe the association 
between AMU and AMR under real-life conditions and suggest 
that it is feasible to develop a predictive model for a huge 
population, in our case the majority of pigs delivered for slaughter 
in Denmark, where potential scenarios can be tested. In itself, this 
provides a significant tool for the Danish authorities and other 
stakeholders, but it also provides an example for what is feasible 
and which data will be needed in order to provide guidance for 
major political and targeted interventions in production animals 
and humans globally. Thus, this study provides a framework for 
further development, which might eventually assist in reducing 
AMR and safeguard AMs for the future.  
 
 
Methods 
Study design 
The study was designed as an observational cross-sectional study of 
Danish pig farms that delivers more than 800 pigs annually and 
received pigs from a maximum of four supplier annually. The 
selected farms were stratified, based on the farm characteristics; 
production-type (conventional or organic), annual number of pigs 
delivered for slaughter and annual number of suppliers of pigs. The 
aim of the stratification was to obtain a representative study sample 
compared to farms producing the majority of pigs slaughtered 
annually in Denmark, with the predominant supplier paths. 
Based on explorative analyses of data from 2013 from the Central 
Husbandry Register (CHR), conventional farms with >200 pen-
places for finishers accounted for the delivery of more than 98% of 
the finishers slaughtered in Denmark. The corresponding percentage 
of organic farms was 95% (Table 3). On average, 200 pen-places for 
finishers are the equivalent to delivering app. 800 pigs for slaughter 
annually. Based on data from 2013 from the Pig Movement Database 
(PMD), farms delivering more than 800 pigs for slaughter annually 
were found. Among these, farms were selected using a maximum of 
four as cut off value for annual number of suppliers (Table 3). 
Subsequently, of the 19.3 million pigs slaughtered that year, the 
selected source population comprised 90% of the total number of 
slaughtered pigs (41), and 57% of the total number of pig farms 
(Table S3). 
Then the source population was separated into two sub-populations; 
i) the current most common farm size delivering pigs to the pork 
industry in Denmark and ii) larger scale farms delivering more than 
5000 slaughtered pigs annually, which is expected to be the 
predominant farm size to deliver slaughter pigs in the near future 
(42). Afterwards, the two sub-populations were separated based on 
the annual number of suppliers, purposely to signify ownership 
complexity compared to the rearing pathway of finisher batches. 
Thus, a rearing pathway with 0-1 supplier annually was assumed 
farms, owned by one farmer, and a rearing pathway with 2-4 
suppliers was assumed farms owned by different farmers. The source 
population included 3,859 conventional and 24 organic pig farms, 
which were stratified into four groups based on the annual number of 
suppliers (0-1 supplier / 2-4 suppliers of pigs per year) and the annual 
number of pigs sent for slaughter (800-4999/ ≥5000 slaughtered pigs 
per year). For purpose of comparison, the organic farms were chosen 
in Group 1 only (Table 3).   
Identification of study sample 
The collection and laboratory analysis of samples from about 80 
farms aligned with the overall resources in the project, thereby 
aiming for app. 20 farms in each group – 80 conventional and 5 
organic. 
The list of potential farms was randomized within each stratum, and 
initially, letters of invitation were sent to 20 farms in each group. 
Farms were then contacted by telephone in the following weeks to 
determine if they were interested in participating and if so, to plan the 
visits. Hereafter, 20 additional farms across the groups were invited. 
Farms were invited and contacted in groups of 10-20 farms at a time 
until 83 farms had agreed to participate; 78 conventional and 5 
organic. In total, eight rounds of invitation-letters were sent. Two 
thirds of the invited farmers agreed to participate, thus, for the strata 
1 to 4; 23, 13, 22 and 25, respectively, participated in the study. Five 
of the 23 farms in stratum 1 where farms with organic production. 
Subsequently, 83 farms stratified into four groups were included in 
the study sample (Table 3).  
 
Table 3. The stratified distribution of number of farms and 
slaughtered pigs in the source population in 2013 in Denmark and 
number of farms in the study sample of conventional and organic 
production. 
Strata   Source population Study sample 
 
 
    Farms Slaught.
† Farms 
Suppl.* Slaught.† Conv.‡ Org.§ Conv.‡ Org.§ Conv.‡ Org.§ 
0 -1 800-4999 1,816 24 4,773,000 54,921 18 5 
2 - 4 800-4999 685 - 1,835,966 - 13 - 
0 -1 ≥5000 938 - 7,398,554 - 25 - 
2 - 4 ≥5000 420 - 3,325,021 - 22 - 
Total  3,859 24 17,332,541 54,921 78 5 
*  Annual number of suppliers of pigs 
† Annual number of slaughtered finishers  
‡  Conventional production 
§  Organic production 
 
From each farm, samples were collected from the oldest finishers. 
With the help of the farmer, all sections containing finishers >80kgs 
were identified. The number of pens was counted and randomized 
using random.org/lists. Hereafter the 30 first pens on the list were 
sampled. In case the farm had less than 30 pens containing finishers 
>80kg, each pen was sampled 2-3 times in order for the total number 
of samples to reach 24-30 pens. One person along with an assistant 
carried out the sampling in all farms. The sampling material was fecal 
material collected directly from the pigs as they defecated or 
immediately after from the pen floor. If collected from the floor, only 
the top of an undisturbed pile was collected. In the laboratory, each 
sample was mixed thoroughly and an equal amount from each sample 
was weighed out and pooled into one. This composite sample was 
then used for further analyses. Sampling took place from December 
2014 to Marts 2016.  
For transportation to the laboratory, the samples were placed in a 
thick walled polystyrene box along with cooling elements. Within 6 
and 24 hours of collection, the samples were placed in 4°C storage 
and were processed in the laboratory, respectively.  
 
Data sources 
Data on AMU was obtained from the Danish Veterinary Medicine 
Statistic Program database (VetStat), which contains records on 
purchased medicines prescribed by veterinarians for animals. Each 
record has information on the product name, substance, dispensing-
type, amount, target species, age-group, diagnosis group and farm 
code (ID) (43). Data from VetStat were extracted two years before 
and three months after the sampling date of each farm to establish 
sufficient buffer time before and after the study periods to account 
for negative entries (44). The data were then cleaned according to 
guidelines by correcting mismatches of animal species and/or age-
group by cross-validating the data with CHR data (44).  
In order to produce comparable data across records, substances were 
converted into a unit measuring how many kilograms of pig could be 
treated per day, known as – Animal Defined Daily Doses per 
kilogram (ADD (mg/kg)) (45). 
Data on farms were obtained from the CHR, which stores information 
linked to a farm code (ID) referring to a specific geographical 
location, and data on movements of pigs were obtained from the 
PMD, which records the number of pigs, date, ID of origin farm and 
ID of destination farm for each movement (43, 46). By combining 
data from the CHR and PMD, the movements of pigs between farms 
and the annual number of pigs moved out of a farm either to another 
farm or to a slaughterhouse could be obtained (43, 46). As adjustment 
factor for farm size, a proxy measure was calculated. First, the annual 
production of sold and/or slaughtered pigs in a farm were multiplied 
by the national productivity averages for piglets, weaners and 
finishers. Thus, the number of days to produce a piglet, weaner and 
finisher, 30, 55, and 85 days, respectively, which then were divided 
by 365 days in order to calculate the number of piglets, weaners 
and/or finisher on any given day in a farm (41).   
 
Estimation of daily AMU 
The AMU was calculated for all AM product records (l), during a 
period (k), in an age-group (j) (piglets /weaners/finishers) in a farm 
(i) as ADDkgi j k l ,, measured as ADDkg/pig.day using the formula: 
  𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖  (𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴/𝑝𝑝𝑝𝑝𝐴𝐴.𝑑𝑑𝑑𝑑𝑑𝑑)  =  𝑝𝑝𝑝𝑝𝑝𝑝𝑑𝑑𝑝𝑝𝑝𝑝𝑝𝑝𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖  (𝑚𝑚𝐴𝐴) 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑖𝑖 ∗  𝐴𝐴𝐴𝐴𝐴𝐴𝑖𝑖 (𝑚𝑚𝐴𝐴 𝐴𝐴𝐴𝐴)⁄ ∗ 𝑝𝑝𝑝𝑝𝐴𝐴𝑑𝑑𝑖𝑖𝑖𝑖𝑖𝑖 
 
where: product = the number of milligram of an AM product in a 
specific farm/age-group/period, days = the interval in days between 
the day of the initial VetStat record and the day of the subsequent 
record, ADD = standard doses, and pigs = the number of 
piglets/weaners/finishers on any given day in a farm (16, 17). 
To calculate ADDkgi j k l , based on VetStat records, the days  was 
estimated for peroral as; days between records at farm, age-group 
and dispensing-type level, and for parenteral as; days between 
records at farm, age-group, dispensing-type and AM-class level (17).  
In addition, the calculation of days was based on three assumptions. 
First, if the number of days was less than eight, the following 
subsequent record date was used instead. Second, if no subsequent 
date was found, the mean of the former intervals in days was applied. 
If no prior number of days was available, 90 and 365 was utilised for 
peroral and parenteral dispensing-type, respectively. Third, all 
numbers of days exceeding 90 days for peroral dispensing and 365 
days for parenteral dispensing-type were replaced with 90 and 365 
days, respectively (17). 
 
Estimation of lifetime AMU  
The lifetime AMU is an average estimate that related to usage during 
the entire rearing period independent of rearing site (16). The 83 
finisher batches pathways were established by following them 
through rearing sites from the sampling farm back to farm of birth. 
Danish national averages for pig production productivity for 2015 
were applied for the rearing periods per unit (in days) (14), resulting 
in 30, 55 and 85 days in the farrowing (piglet), weaning (weaner) and 
finisher units (finisher), respectively (Fig. S1).  
Then the AMU for the 83 finisher batches, was calculated as the sum 
of the date- and product-specific AMU (ADDkgi j k l) for each AM-
class at dispensing-type level over the rearing periods; piglet, weaner 
and finisher. Next, the obtained amount was adjusted to suit the 
proportion of animals being moved from a farm. Finally, the absolute 
lifetime AMU for each AM-class at dispensing-type level were 
calculated for each finisher batch by summarising the AMU in the 
three units, given by their rearing pathways (Fig. S1). The lifetime 
AMU quantifies the total number of kg-doses per pig during the 
rearing period of 170 days. Even though AMU for sows was included 
in the usage for piglets, previous studies have shown that this affects 
the occurrence of AMR in the gut microbiome of piglets, thus, it was 
assumed that the usage of sows was equivalent to the usage of piglets 
(47).  
 
Estimation of AMR  
The methods used to extract DNA and obtain AMR abundance in the 
microbiome of finisher batches have been described in previous 
studies (13, 48). In brief, genes encoding resistance to 
aminoglycosides, beta-lactams, lincosamides, macrolides, 
macrolides-lincosamide-streptogramin B (MLSb), sulfonamides and 
tetracyclines, were quantified using shotgun metagenomic 
sequencing, and measured as Fragments per Kilobase reference per 
Million fragments (FPKM ) (13).   
 
DNA extraction  
For DNA extraction, a modiﬁed QIAamp Fast DNA Stool Mini Kit 
protocol was employed Qiagen, Valencia, CA, USA). Cryotubes with 
pooled faeces were gently thawed on ice. Prior to the protocol, 0.2 g 
of sample was mixed with 1 mL of InhibitEX buffer in a Lysing 
Matrix A tube (MP Biomedicals). Samples were treated with a 
TissueLyser (3×30 s, 30 Hz) and were chilled on ice between 
 
 
repetitions. Following bead beating, samples were heated to 95°C for 
7 min and centrifuged to eliminate larger stool particles. Then. DNA 
was eluted in 100 mL of elution buffer (13, 48).  
 
DNA sequencing  
PCR-free DNA libraries were generated and sequenced on the 
HiSeq2500 (Illumina) to generate roughly 7 gigabases of paired-end 
reads per sample, enough to get 20×coverage of bacteria with 1% 
abundance (13, 48). 
 
Read mapping (resistance) 
Resistance was quantiﬁed using the MGmapper tool against the 
ResFinder database, April 2017 (49). The database contains several 
highly homologous genes, thus, when reads map to identical parts of 
homologous gene variants unspeciﬁc mapping occurs. Read counts 
from variants of the same gene were aggregated to gene levels 
according to common gene names, resulting in the ﬁnal abundance 
matrix of 135 genes for the 83 finisher batches.  
 
Metagenomic data analysis 
For each AM-class, the raw read counts were normalized to length 
of each gene and sequencing depth of each sample, thus, measured 
as Fragments per Kilobase reference per Million fragments (FPKM) 
using the formula: 
 𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 = �𝑛𝑛 (𝑁𝑁 ∗ �𝑙𝑙 − (𝑝𝑝 − 2 ∗ 𝑚𝑚)�� �2 ∗ 106𝑅𝑅 ∗ 1000𝑏𝑏𝑝𝑝  
, where n = number of mapped reads, N = total number of reads, l = 
gene length, i = insert size, m = minimum mapping length, R = Reads 
and bp = base pair.  
The normalization takes into account that the pooling and sequencing 
of several indexed samples produces varying DNA library sizes, 
resulting in comparable FPKM values that are independence of 
sequencing depth.  
 
Data analyses 
The data analyses started by focusing on the quantitative usage of an 
AM-class and abundance of the respective AM-class resistance. 
Subsequently, uni-variable regression models were used to calculate 
the effect of lifetime AMU on the AMR abundance for the AM-
classes; aminoglycosides, extended-spectrum penicillins vs. beta-
lactams, lincosamides, macrolides, macrolides (MLSb), 
sulfonamides, and tetracyclines. When modelling, spectinomycin, 
and trimethoprim were not included in aminoglycosides and 
sulfonamides, respectively, instead, they constituted separate AM-
classes in the multi-variable models (Models 4-5) (Fig. 3). Focusing 
on the biologically most plausible AMU-AMR relationships in the 
initial analyses, will prevent overemphasizing results from more 
complex regression analyses that estimate the effect of several AM-
classes simultaneously. However, by including usage of several AM-
classes, the potential effects related to co-resistance and cross-
resistance were estimated. The diagnostic plots were applied for 
visual inspection of all of the estimated models, in order to assess if 
the assumptions of linear regression were fulfilled. The visual 
inspection included; whether the residuals were normally distributed 
and showed homoscedasticity. The assessment of potential 
influential observations was done using Cook’s distance (>1). 
Furthermore, all models were assessed for the influence of potential 
outlying observations on the estimated effects using bi-square robust 
regression (50). 
 
Regression analyses 
The analytical work was performed in several steps (Fig. 3): 
1. Uni-variable model - Model 1 
First, lifetime usage of aminoglycosides, extended-spectrum and 
narrow-spectrum penicillins, lincosamides, macrolides, 
sulfonamides and tetracyclines were plotted against aminoglycoside, 
beta-lactam, lincosamide, macrolide and MLSb, sulfonamides and 
tetracycline resistance abundance, respectively, in scatterplots. 
Hereafter, a LOESS local regression model using span width 0.75 
was added to each scatterplot to evaluate the relationship between 
lifetime AMU and AMR abundance (51). Based on visual inspections 
of the LOESS regression lines, it was decided to model the effect of 
AMU on AMR as linear. Afterwards, the estimated linear 
regression models with 95% CI of the respective AM-class were 
overlaid the observations in the scatterplots. The scatterplots were 
finalized by implementing bi-square robust regression.  
   2. Model 1 included updated design variables - Model 2 
To adjust the estimates for potential confounding, the updated design 
variables; production-type, number of slaughtered pigs and suppliers 
of pigs per year were added to the uni-variable models (Model 1). 
First, production-type was included to adjust for confounding, due to 
the uneven number between conventional and organic farms in the 
study sample. Subsequently, as a result of the organic farms 
significant effect in all models, the remaining regression analyses 
were performed for the conventional farms only. The variables, 
number of slaughtered pigs and number of suppliers of pigs per year, 
were first included one at a time, and afterwards, simultaneously to 
adjust for confounding.  
   3. Multi-variable model at dispensing-type level - Model 3 
In model 3, the effect of lifetime AMU at dispensing-type level of 
aminoglycosides, extended-spectrum penicillins, lincosamides, 
macrolides, sulfonamides and tetracycline on the AMR abundance of 
aminoglycosides, lincosamides, macrolides/MLSb, sulfonamides 
and tetracyclines were estimated, thereby estimating the effect of 
peroral and parenteral lifetime AMU on the respective AM-class 
resistance. The β-coefficients of parenteral and peroral dispensing-
type of the AM-class specific variable(s) were then compared to the 
β-coefficients of the initial uni-variable models (Model 1) to assess 
the difference between them. 
  4. Multi-variable model included all AM-classes at dispensing-type 
level and updated design variables - Model 4 
Then, multi-variable regression models included the potential direct 
and confounding effects of use of AM-classes other than the AM-
class specific as well as updated design variables were performed. 
These models included the effect of parenteral and peroral lifetime 
AMU of aminoglycosides, extended-spectrum and narrow-spectrum 
penicillins, lincosamides, macrolides, pleuromutilins, polymyxins, 
spectinomycin, sulfonamides, tetracyclines and trimethoprim on 
abundance of resistance of aminoglycosides, beta-lactams, 
lincosamides, macrolides, MLSb, sulfonamides and tetracyclines. 
The models were obtained using automated stepwise regression, with 
the AIC value as the criteria for variable selection (50, 51). 
Insignificant variables in the models were removed using manual 
stepwise exclusion. The comparison between models were performed 
using the ANOVA; Chi-square test. When these were not 
significantly different (p-value > 0.05), the simpler model was 
preferred.  
The explanatory variables kept in the models were checked for 
potential correlation. Afterward, the β-coefficients of the AM-class 
variable(s) specific for the AM-class resistance were compared to the 
β-coefficients of the multi-variable model-variable models (Model 3) 
to assess the difference between them. The final models were 
assessed for the influence of potential outlying observations on the 
estimated effects with bi-square robust regression. 
5. Uni-variable model at resistance gene level – Model 5 
At the gene level, uni-variable regression models of the effect of each 
lifetime AMU of the AM-classes; aminoglycosides, extended-
spectrum and narrow-spectrum penicillins, lincosamides, 
macrolides, pleuromutilins, polymyxins, spectinomycin, 
sulfonamides, tetracyclines and trimethoprim at parenteral and 
peroral level, on abundance of each resistance gene of 
aminoglycosides, beta-lactams, lincosamides, macrolides, MLSb, 
sulfonamides and tetracyclines were estimated. Genes that were 
found in less than 10 samples and regression results with p-values 
above 0.01 were not included in the assessment. 
 
 
6. Correlation matrix at resistance gene level - Matrix 6 
Based on the genes of the AM-classes; aminoglycosides, beta-
lactams, lincosamides, macrolides, MLSb, sulfonamides and 
tetracyclines, a correlation matrix using the spearman method was 
estimated (52). Genes that were found in less than 10 samples and 
correlation coefficient results with p-values less than 0.01 were 
excluded from assessment.  
 
 
Fig. 3. Overview of the regression analyses (Model 1-5) and 
correlation analysis (Model 6) performed. 
Predictive model 
The estimated effects of AMU on AMR in the presented 
observational study, the easy accessibility to data on AMU at pig 
farms (VetStat) and movements of the vast majority of pigs between 
farms (PMD) in Denmark, provide the opportunity to predict the 
overall AMR abundance in the majority of Danish finishers close to 
slaughter at national level (22, 23). Consequently, this framework 
also makes it possible to predict the relative effect of different AMU 
in all or a subset of pig farms on the overall AMR abundance in 
Danish finishers close to slaughter. In these predictions, it is assumed 
that the estimated effects of lifetime AMU on AMR abundance can 
be generalized across conventional pigs produced and slaughtered in 
Denmark. 
As an input to the simulation, the lifetime AMU in finisher batches 
delivered from finisher farms to slaughterhouses in Denmark was 
estimated based on data of finisher batches delivered for slaughter 
from April 2014 to June 2014. In this period, 3,079 finisher batches 
were delivered for slaughter. The lifetime AMU in finishers in each 
batch was estimated using a previously described algorithm (22).  
Initially in the simulation, the mean AMR abundance in finishers of 
each of the 3,079 batches was predicted using the estimated 
regression models (Model 4) from the observational study. Secondly, 
to obtain the abundance at national level, the number of finishers 
delivered for slaughter during the last 6 months from the 
corresponding farm was multiplied by the estimated mean of AMR 
abundance in a batch. As a result, the AMR abundance related to the 
different AM-classes was summarized across all batches and 
constitute the baseline measure of AMR abundance.  
Simultaneously, the same calculation was performed using data of 
AMU mimicking several different AMUs in either all of the 3,079 
batches or in a subset of those as input. The relative effect on the 
AMR abundance of the different AMUs scenarios were obtained by 
comparing the abundance of AMR to the baseline abundance. 
To include the uncertainty in the estimated regression parameters, the 
above calculation of AMR abundance and the relative change was 
carried out 100,000 times (iterations), and in each iteration, random 
values of the effect parameters were selected from Gaussian 
probability distributions. These distributions were defined using the 
point estimate (β-coefficient) of the effect as the mean and the 
standard error of the point estimate as standard deviation. Thereby, 
creating an uncertainty distribution around the relative effect of 
different lifetime AMU, which expressed the uncertainties in the 
estimated effect parameters. To avoid simulation noise in the 
confidence intervals, the same values for the effect parameters were 
used in the baseline and the different scenarios within each iteration. 
The validity of generalizing the estimated models to the overall 
production in Denmark was assessed by comparing the “location” of 
the lifetime AMU in the finisher batches included in the 
observational study across the deciles of the lifetime AMU in all 
finisher batches used in the prediction. 
 
The prediction model presents results from three different scenarios 
of lifetime AMU in the Danish pig production. In the first scenario, 
all parenteral and peroral tetracycline usage was ceased without 
replacement. In the second scenario, the reduction of the top-10% 
farms of peroral usage of tetracyclines per produced pig to the level 
just below these, combined with an equivalent replacement in doses 
of lifetime peroral macrolide usage. In the third scenario, all 
parenteral and peroral usage of extended-spectrum penicillins was 
ceased, combined with an equivalent replacement in doses of lifetime 
parenteral lincosamide usage. 
 
WPS Workbench, Version: 3.1.1.0.0, Microsoft Excel 2010, and R, 
version 3.3.3 were applied in all data processing and data analyses.  
The predictive modelling was performed using @RISK – risk 
analysis Add-in for Microsoft Excel, version 7.5.1. 
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 Supplementary material 
 
 
 
 
 
Fig. 5.2.1. The rearing pathways of the 83 finisher batches from birth site to finisher site compared with the 
day of sampling. From left, the first three vertical coloured bars represent the assumed days of antimicrobial 
usage (AMU) in the; sow-piglet (farrowing) unit, weaner unit and finisher unit. Each rectangle within the 
vertical bars represents a farm at a specific geographical location. Therefore, the rectangular size of a bar and 
a colour shift in a bar denotes that a farm has a different geographical location compared with the farm where 
sampling took place. The 10 different horizontally coherent bars depict the different rearing pathways of the 
83 finisher batches. The fourth vertical bar shows, the number of sampled finisher batches per horizontal 
coherent bar. 
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Fig. 5.2.2. The parenteral and peroral lifetime AMU, measured as ADDkg/pig of the AM-classes; aminoglycosides including spectinomycin, lincosamides, 
extended-spectrum penicillins, pleuromutilins, polymyxins, macrolides, narrow-spectrum penicillins, sulfonamides including trimethoprim and 
tetracyclines of the 83 finisher batches, ranked according to the total lifetime AMU in the batches. 
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Table 5.2.3. The coefficients with 95% confidence interval (CI), standard error (SE) and p-values of the multi-
variable linear regression models (Model 4) of parenteral and peroral lifetime AMU of all AM-classes on each 
AM-class and updated design variables on resistance abundance of aminoglycosides, beta-lactams, 
lincosamides, macrolides, MLSb, sulfonamides and tetracyclines, including the coefficients of bi-square robust 
regression analyses (rlm). Furthermore, for all models, the statistical estimate of model fit; adjusted R-squared 
(Adj R²), was applied. 
 
Resistance coef-ficients 
coefficients 
SE p-value   Adj. R² 
rlm 
(95% CI) coefficients 
Aminoglycosides                   
          
Model 4        0.25210  
  (intercept) 6.33825 (4.79942 - 7.87709) 0.77194 0.00000 ***  6.19630 
  Aminoglycosides (parenteral) 0.34091 (0.14388 - 0.53794) 0.09884 0.00094 ***  0.36440 
  Macrolides (peroral) 0.00943 (0.00096 - 0.01790) 0.00425 0.02969 *  0.00930 
  Pleuromutilins (peroral) 0.01715 (0.00574 - 0.02856) 0.00572 0.00375 **  0.01180 
  Tetracyclines (parenteral) 0.03758 (0.00263 - 0.07253) 0.01753 0.03544 *  0.03910 
  Tetracyclines (peroral) 0.01177 (-0.00003 - 0.02357) 0,01177 0.05055 .  0.01290 
                    
Beta-lactams                   
          
Model 4        0.15150  
  (intercept) 29.67841 (26.60727 - 32.74901) 1.54152 0.00000 ***  29.01510 
  Extended-spectrum penicillins (peroral) 0.15211 (0.05605 - 0.24818) 0.04822 0.00231 **  0.15100 
  Macrolides (peroral) 0.03464 (0.00823 - 0.06106) 0.01326 0.01086 *  0.03720 
                    
Lincosamides                   
          
Model 4         0.24280  
  (intercept) 26.53758 (23.17420 - 29.90276) 1.68889 0.00000 ***  26.36700 
  Lincosamides (parenteral) 0.59117 (0.20080 - 0.98155) 0.19592 0.00349 **  0.62970 
  Lincosamides (peroral) 0.32771 (0.16425 - 0.49117) 0.08203 0.00015 ***  0.33000 
 Tetracyclines (parenteral) 0.11352 (0.00312 - 0.22391) 0.0554 0.04402 *  0.07280 
                    
Macrolides                   
           
Model 4         0.44180  
  (intercept) 53.64111 (45.84518 - 61.43703) 3.91426 0.00000 ***  53.20090 
  Macrolides (peroral) 0.28225 (0.21083 - 0.353579) 0.03586 0.00000 ***  0.28620 
                    
MLSb                   
           
Model 4         0.52380  
  (intercept) 15.63985 (12.52425 - 18.75546) 1.56398 0.00000 ***  13.65330 
  Aminoglycosides (parenteral) 0.81576 (0.16757 - 1.46394) 0.32538 0.01430 *  0.83680 
  Macrolides (peroral) 0.10649 (0.07923 - 0.13375) 0.01368 0.00005 ***  0.11350 
                    
Sulfonamides                   
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Resistance coef-ficients 
coefficients 
SE p-value   Adj. R² 
rlm 
(95% CI) coefficients 
Model 4         0.08876  
  (intercept) 0.09696 (0.05936 - 0.13456) 0.01888 0.00000 ***  0.06810 
  Polymyxins (peroral) 0.00343 (0.00109 - 0.00577) 0.00118 0.00466 **  0.00400 
           
Tetracyclines                   
           
Model 4        0.26780  
  (intercept) 266.70323 (247.08080 - 286.32567) 9.84793 0.00000 ***  266.63440 
  Macrolides (peroral) 0.13280 (0.01331 - 0.25229) 0.05997 0.02990 *  0.11960 
  Tetracyclines (parenteral) 0.67628 (0.15015 - 1.20241) 0.26405 0.01250 *  0.67080 
  Tetracyclines (peroral) 0.44507 (0.26758 - 0.62255) 0.08907 0.00000 ***  0.45440 
          
* Level of significance (0: ***, 0.001: **, 0.01: *, 0.05: .) 
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Fig. 5.2.4. The β-coefficients from the uni-variable regression analyses of parenteral and peroral lifetime AMU 
of aminoglycosides, extended-spectrum penicillins, lincosamides, macrolides, narrow-spectrum penicillins, 
pleuromutilins, polymyxins, spectinomycin, sulfonamides, tetracyclines and trimethoprim on the abundance 
of all resistance genes within the AM-classes; aminoglycosides, beta-lactams, lincosamides, macrolides, 
MLSb, sulfonamides and tetracyclines. Only results from linear regression analyses with p-values of less than 
0.01 are plotted. The size of a point illustrates the size of the β-coefficient. The colour of a point, illustrates the 
variation of the resistance genes that the antimicrobial usage was able to explain (R2). 
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Fig. 5.2.5. Correlation matrix of the resistance genes within the AM-classes; aminoglycosides, beta-lactams, 
lincosamides, macrolides, MLSb, sulfonamides and tetracyclines, with the significance level set to 0.01.  
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 Discussion 
 
The main focal point of the third manuscript was the model predicting the effect of altered lifetime 
AMU in finisher batches on the abundance of AMR genes (AMR abundance) in their gut microbiome 
close to slaughter at national level. The effect parameters used in the model were based on effect 
estimates from linear regression models of individual AM-classes determining the quantitative effect 
of lifetime AMU in finisher batches on AMR abundance in their gut microbiome close to slaughter, 
i.e. the main goal of this thesis.   
 
The study farms were selected using stratified sampling based on production-type (conventional 
or organic), the annual number of pigs delivered for slaughter and the annual number of suppliers of 
pigs. The restrictive selection aimed at obtaining a representative study sample compared with farms 
producing the majority of pigs slaughtered annually in Denmark, with the predominant supplier paths, 
which makes it possible to draw inferences from the study sample to the source population. The over 
representation of relatively large farms was established to study the AMU-AMR associations in farms 
with a size and production system in alignment with the structural development in pig farms expected 
by the pig industry in the future. 
 
Several farmers (23%) were uninterested in participating in the study; the reasons for their choice 
lack of time or financial compensation, have previous had bad experience when participating etc. 
Therefore, the impact of non-participants compared with our results is unknown. The association 
between AMU and AMR could potentially be biased due to non-participants. Of those asked to 
participate, 38% accepted while 23% had altered/ceased their production, and 16% could not be 
reached.  
 
Structured interviews with detailed farm management questions were carried out in connection 
with the farm visits. The questions covered four main subjects of interest, basic information; 
production-system and number of pigs per age-group, production parameters; supplier(s) CHR 
number and number of suppliers per batch, farm management; mixing of pigs from separate batches, 
all-in/all-out managing, cleaning, disinfection, number of days between batches and feed purchase, 
and AMU; farm records and vet instruction to the extent possible. The problem was that these 
potential risk factors all related to events in the finisher unit, and initial assessments revealed that 
none of them interacted with the AMU in regression modelling. Consequently, the variables were 
omitted from all analyses. Hereafter, the effect of lifetime AMU on AMR abundance was only 
assessed compared with the design variables as confounders, though updated to represent the batch 
the most. In the assessment of potential risk factors influencing the level of AMR of a finisher batch, 
a holistic approach rather that the traditional farm level might be a better choice. After omitting all 
interview data from analyses, the farm-records and vet instruction regarding AMU were used to 
validate the lifetime AMU.  
 
The finisher batches varied in rearing pathways, however, the pathways of the majority of batches 
were simple, i.e. pigs in a unit originated from the same farm or from one farm only. The rearing 
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pathway of two finisher batches stood out, due to the complexity of their pathway that included five 
and seven farms, respectively (Fig. 5.2.1). Furthermore, in five cases, two finisher batches came from 
farms owned by one farmer. In addition, it was decided to consider a CHR-farm as an epidemiological 
unit without considering ownership of supplier farms. Consequently, in four cases, two finisher 
batches originated from the same supplier farm. Since the farm of origin and farm usage history have 
been demonstrated to have an effect of AMR abundance (Dawson et al., 1984; Dorado-García et al., 
2016), the batches may share similarities.  
 
Lifetime AMU was calculated as the total amount of individual AM-classes throughout the rearing 
period at dispensing-type level. By doing so, it was not possible to distinguish between differences in 
AMU within the three rearing periods. That fact that the lifetime AMU does not distinguish between 
usage within the three rearing periods, known to affect the occurrence of AMR in finishers close to 
slaughter differently (Callens et al., 2015; Birkegård et al., 2018), may account for some of the non-
explained variation in AMR abundance between batches.  
 
The finisher batches were ranked according to their total AMU to display, the differences between 
the batches usage at age-group level (Fig. 5.2.2.). The first five batches came from farms with organic 
production that had a small amount of parenteral AMU. Parenteral AMs were used mostly for sows 
and piglets and to a lesser extent to weaners and finishers, while the peroral AMs were used mainly 
for weaners and finishers and the smallest amount was used for sows and piglets. Several of the 
finisher batches were using unexpected large amounts of peroral AMs while in the finisher unit, which 
were related to farms with finisher systems only. This finding has also been demonstrated in other 
studies (Hybschmann et al., 2011; van der Fels-Klerx et al., 2011). However, as these farms produced 
from 3,500 to 28,900 finishers annually, the high usage was not associated with farm size. In contrast, 
several finisher batches had no usage of peroral AMs with no common features to explain the lack of 
peroral usage. In general, the usage of peroral AMs was widespread and the peroral macrolide 
pleuromutilins and tetracyclines were the most used AMs. Although the colistin usage seemed minor, 
usage occurred in all three rearing periods, which is worrying given the importance of this substance 
in human medicine (Fig. 5.2.2.).    
 
The estimated effect of AMU on AMR barely changed when the updated design variables were 
included, indicating that the effect of AMU on AMR at AM-class level is not strongly influenced by 
farm size and supplier number. However, the design variables are only based on the finisher unit not 
the entire rearing pathway. The low level of AMR abundance of most AM-classes in the organic 
production compared with conventional production has been demonstrated (Österberg et al., 2016), 
and AMR has equally been demonstrated to persist in farms with no AMU (Zhang et al., 2013). The 
AMR in the organic farms may therefore constitute baseline levels, in that case difficulties could arise 
if aiming to bring the AMR abundance below the baseline based solely on reducing AMU. The higher 
level of beta-lactam resistance in the organic farms coincided with parenteral narrow-spectrum 
penicillin usage as their main drug choice, while the higher level of sulfonamide resistance could not 
be explained.  
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The scatterplots of the uni-variable regression models indicated simple linear relationships 
between lifetime AMU in finisher batches and AMR abundance in their gut microbiome close to 
slaughter for all AM-classes. Hence, in the multi-variable regression models, the effects of lifetime 
AMU on AMR abundance were estimated as linear, which was supported by visual inspection of the 
model’s diagnostic plots. As AMU and AMR is low in Denmark, extrapolation of the observed linear 
effect of lifetime AMU to AMR abundance to higher levels of AMU should be carried out with 
caution. 
 
Generally, the peroral AMs appeared to affect the AMR abundance far more broadly than the 
parenteral AMs, which in turn had a higher effect on resistance abundancy. The broader effect of 
peroral AMs may be due to their widespread but intermittent usage during the weaner and finisher 
rearing periods. Several studies have assessed the effect of administration routes, and demonstrated 
that peroral AMs had the most significant effect on AMR (Wiuff et al., 2003; Zhang et al., 2013), 
though one study found no difference (Græsbøll et al., 2017). The higher effect of parenteral AMs 
may be the result of environmental contamination of AMs and their metabolites from individually 
treated pigs, leading to the continuous presence of sub-therapeutic doses (Dawson et al., 1984; 
Kietzmann et al., 1995; Looft et al., 2012; Singer et al., 2016). Alternatively, the difference between 
dispensing-type could occur, because they are affecting different resistance genes. In addition, the  
absorption, distribution and elimination of AM substances may also contribute to the different effect 
observed between parenteral and peroral AMs on AMR abundance (Wiuff et al., 2003; Zhang et al., 
2013). Overall, the results obtained for parenteral AMs were unexpected.  
 
The lacking effect of parenteral extended-spectrum penicillins, macrolides and sulfonamides 
should be interpreted with caution, as they were used mainly during the piglet-rearing period. The 
lifetime AMU does not distinguish between usages at different rearing periods. Consequently, usage 
of these AMs in the finisher unit might have affected resistance abundance. Therefore, this study 
could not demonstrate that usage of parenteral extended-spectrum penicillins, macrolides and 
sulfonamides in the piglet-rearing period affects the resistance abundance in their gut microbiome at 
the time of slaughter. 
 
The wide-ranging co-selection of peroral macrolides in the multi-variable regression models was 
a finding with parallels to other studies. Rosengren et al. (2007) found that the occurrence of 
sulfamethoxazole and chloramphenicol resistance was six times higher in farms with high macrolide 
usage compared with farms with no usage of macrolides. Looft et al. (2012) also demonstrated the 
potential for co-selection from a single AM-class usage. Interestingly, it was the most frequently used 
AMs, peroral macrolides and parenteral and peroral tetracyclines that resulted in the observed 
widespread co-selection. The increased occurrence of multi-drug AMR and resistance genes affecting 
several AMs is worrying as it substantially enhances the spread of AMR (Levy and Marshall, 2004; 
Andersson and Hughes, 2011; Dorado-García et al., 2016). 
  
The underlying effect of parenteral and peroral AMs on individual resistance genes, revealed that 
peroral macrolide usage affected other AM-classes, though this related mainly to a small number of 
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resistance genes. Similar findings were shown for the parenteral aminoglycoside usage, which 
affected a small number of resistance genes in several other AM-classes. The correlation matrix 
between the abundance of AMR genes, revealed that the deviating behaviour of tet(X) was due to the 
correlation with several macrolide and MLSb genes, and that the lack of effect of the sulfonamide 
usage on the corresponding genes was probably due to the correlation between sul1 and sul2. 
 
This study included a vast number of correlation and regression analyses at gene level. As a 
consequence, a high probability of false discovery was expected, which was circumvented by 
reducing the significance level from 0.05 to 0.01. Despite taking this precaution, the results from 
these analyses should be viewed as indicative only and as a supporting tool for the assessing and 
understanding of the quantitative effect of lifetime AMU on AMR abundance. 
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6. Conclusions and perspectives 
This thesis demonstrates that register data can be applied in calculating lifetime AMU in finisher 
batches close to slaughter independent of rearing site and production system. The developed method 
revealed that the entire rearing period must be taken into account when studying the effect of lifetime 
AMU in finishers on AMR abundance in their gut microbiome close to slaughter. Additionally, the 
thesis provides insight into the limitations and disadvantages of the developed method. Finally, the 
thesis quantifies the effect of lifetime AMU in finisher batches on AMR abundance in their gut 
microbiome close to slaughter. 
 
The most time-consuming work in this study concerned quality checking of all the components 
forming the lifetime AMU as well as the ResFinder’s gene allocation to AM-class level.  
 
The first study offers a new method for calculating AMU in finishers based on register data, which 
estimate the lifetime exposure of finishers from birth piglets to the time of slaughter. The 
measurement in its current form suffers from the inability to separate the AMU in sows from the 
AMU in piglets. A separation of the two would have provided the means for biomass adjustments 
that included both numbers of pigs and their mean weight for each rearing period. By omitting the 
mean weight of pigs in the lifetime AMU calculations, the usage in finishers may be over-emphasised 
compared with the number of pigs actually treated. Notwithstanding this issue, the method offers a 
framework for future development of more sophisticated methods for measuring the lifetime AMU 
of young production animals across countries.  
 
With advances in inexpensive metagenomics methods, it is expected that these will gradually 
supersede the traditional cultivation methods. The output of metagenomics methods needs to be 
translated into meaningful outcomes, e.g. phenotypical resistance and resistance mechanisms, in order 
to genuinely assess the importance of the outcomes. In this study, the lifetime AMU had a significant 
effect on the abundance of AMR genes. On the other hand, the resistance genes may not constitute a 
risk to humans, since the phenotypical resistance obtained by cultivation of E. coli compared with 
any of the approaches of calculating AMU showed no association. A huge task lies ahead, to develop 
methods that can provide metagenomic data equalling count data from cultivation. 
 
The second study validated the lifetime AMU. In general, the lifetime AMU was improved by 
altering the method of data transformation, i.e. both accuracy and precision increased, which was 
additionally confirmed by re-analyses of lifetime AMU and AMR abundance of the ten finisher 
batches from the previous study. Based on the results, the study demonstrated that by means of data 
transformation the CHR, PMD and VetStat databases can be used to calculate lifetime AMU that 
mimics the “true” usage accurately and with modest precision. In addition, the reliability coefficients 
revealed that the calculations of the daily amounts of AMs used per pig underestimate the usage 
independent of the smoothing method.  
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In Denmark, VetStat, PMD and CHR give access to data at farm unit level, thereby providing 
unique opportunities to study AMU across farms and units, and its effect on AMR. In addition, the 
data is easily obtained for the entire population of pigs. However, several adverse issues were 
encountered that potentially explain the modest precision of the most valid transformation method. 
Minor efforts could be usefully directed towards ensuring correct data entries, which would 
immensely improve the lifetime AMU. 
 
These results highlight the general importance of valid data in epidemiological studies in order to 
obtain unbiased quantitative estimates of effects and reduce the risk of erroneous conclusions, i.e. 
access to accurate and precise data when calculating the lifetime AMU is key to obtain reliable 
regression coefficients of the effect of AMU on AMR. Even though the validation study sample was 
small, it provides sufficient knowledge to improve the lifetime AMU. Equal importantly, the study 
gave insight into vet instructions and usage patterns in farms to be considered when associations 
between AMU and AMR are assessed. Nonetheless, it would be relevant to perform a comprehensive 
study to gain knowledge of the prevalence of the encountered issues, as this will provide trustworthy 
measurement errors of the effect estimates, thus, their reliability. 
 
The third study assessed the effect of lifetime AMU on AMR abundance. Overall, the study 
generated knowledge of the quantitative effect of parenteral and peroral lifetime AMU on AMR 
abundance, at AM-class level, in the gut microbiome of finisher batches close to slaughter. Although 
significant effects of lifetime AMU were found for AMR abundance of every AM-class resistance 
investigated, the AMUs could explain only between 9% - 52% of the variation in AMR. The inability 
to assess risk factors was a huge step backwards. Therefore, a holistic approach should be employed 
when evaluating risk factors related to finisher batches, e.g., inherited AMR level as a result of 
previous AMU at rearing sites and the effect of mixing pigs with different AMR levels.  
 
Even though models do not confirm causal relationships, rather, it assumes causal links and then 
test how strong they would be if the model were a correct representation of reality (Martin, 2014), 
our results combined with knowledge from similar studies suggest causal associations. Subsequently, 
our results provide additional knowledge in the understanding of the complexity of AMR emergence 
and spread across the pig population. 
 
The effect estimates from the quantification study combined with detailed data on lifetime AMU 
of the majority of finishers in Denmark have been applied as inputs to the development of a national 
scale predictive model, which enables testing of different AMU scenarios prior to potentially 
selecting the most efficient intervention. The predictive model will also facilitate predictions of the 
amount of AMU reduction required to reach a desired reduction in AMR. In itself, this provides a 
significant tool for the Danish authorities and other stakeholders, but it also provides an example of 
what is feasible and what data will be needed in order to provide guidance for major political and 
targeted interventions regarding production animals globally. Thus, the thesis has provided a 
framework for further development that might eventually assist in reducing AMR and safeguarding 
AMs for the future. 
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 Appendix A. Additional results to Manuscript I 
 
Fig. A1. Univariable linear regression plots (solid line) with 95% confidence interval (grey outline) of WCS – 
RPKM of the AMR genes of: aminoglycosides, lincosamides, macrolides, beta-lactams, sulfonamides and 
tetracyclines as a function of treatment days during rearing (160 days) for the AM classes: aminoglycosides, 
lincosamides, macrolides, extended-spectrum penicillins, sulfonamides and tetracyclines, respectively. The 
red points denote the initially high users and the blue points depict the initially low users. The function and the 
R-squared (R2) value are shown in the top left corner of each model.  
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 Appendix B. Additional results to Manuscript II 
Table B1. The counted observations, the completeness (Compl.), the correctness (Correct.), the correlation 
coefficient (r), the average adjusted r, the Fisher’s z estimate, and the average adjusted correlation coefficient 
through Fisher’s z transformation (rz) at farm, age-group (piglets – sows, weaners and finishers), dispensing-
type (parenteral and peroral), and AM-class (aminoglycosides, aminoglycosides combined with narrow-
spectrum (nrw.) penicillins, colistin, lincosamides combined with spectinomycin, macrolides, phenicols, 
narrow-spectrum (nrw.) penicillins, extended-spectrum (ext.) penicillins, sulfonamides combined with 
trimethoprim (TMP), tetracyclines and tiamulin) level between Dosesfarm  and Dosesmethod.1, Dosesmethod.2. 
Dosesmethod.3, Dosesmethod.4 and Dosesmethod.5, respectively. In addition, the reliability coefficient (𝝆𝝆xx) without and 
with average adjustment at farm, age-group, dispensing type, and antimicrobial class level for the Dosesmethod.1, 
Dosesmethod.2. Dosesmethod.3, Dosesmethod.4 and Dosesmethod.5. 
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Method 1 
       
         
 Counts Comple. Correct. r Fisher's z rz 𝝆𝝆xx 
        
Study population 787 0.597 0.914 0.701 0.868 0.701 0.604 
Farm 1 10 0.667 0.857 0.167 0.168  0.063 
Farm 2 56 0.623 0.917 0.706 0.878  0.534 
Farm 3 20 0.600 1.000 -0.024 -0.025  0.475 
Farm 4 109 0.842 0.914 0.898 1.460  0.826 
Farm 5 33 0.273 1.000 0.618 0.721  0.456 
Farm 6 98 0.404 0.905 0.240 0.245  0.208 
Farm 7 24 0.870 0.952 0.390 0.412  0.406 
Farm 8 62 0.797 0.940 0.651 0.778  0.549 
Farm 9 22 0.588 0.667 -0.188 -0.191  0.403 
Farm 10 107 0.867 0.978 0.936 1.706  0.885 
Farm 11 36 0.286 0.909 0.868 1.324  0.753 
Farm 12 18 0.118 0.667 0.450 0.485  0.403 
Farm 13 46 0.486 0.667 0.562 0.635  0.473 
Farm 14 72 0.507 0.973 0.870 1.335  0.687 
Farm 15 55 0.296 0.941 0.259 0.265  0.376 
Farm 16 19 0.706 0.857 0.541 0.605  0.452 
Adj.by farm  0.558 0.884 0.496 0.675 0.588 0.497 
Sows - Piglets 271 0.743 0.951 0.830 1.187  0.723 
Weaners 261 0.551 0.882 0.496 0.544  0.528 
Finishers 255 0.485 0.893 0.541 0.606  0.476 
Adj. by age-group  0.593 0.909 0.622 0.779 0.652 0.576 
Parenteral 585 0.594 0.946 0.868 1.324  0.774 
Peroral 202 0.609 0.826 0.378 0.398  0.419 
Adj. by dispensing-type  0.601 0.886 0.623 0.861 0.697 0.597 
Aminoglycosides 25 0.684 0.684 0.673 0.816  0.525 
Aminoglycosides-Penicillins (nrw.) 45 0.568 0.962 0.819 1.155  0.692 
Colistin 12 0.800 0.800 0.845 1.239  0.652 
Lincosamides 41 0.400 0.941 0.316 0.327  0.337 
Lincosamides - Spectinomycin 44 0.619 0.929 0.753 0.980  0.622 
Macrolides 102 0.670 0.847 0.541 0.606  0.500 
Phenicols 3 0.667 1.000 0.733 0.935  0.386 
Penicillins (nrw.) 118 0.513 0.984 0.958 1.921  0.922 
Penicillins (ext.) 72 0.786 0.965 0.607 0.705  0.514 
Sulfonamides - TMP 82 0.727 0.918 0.851 1.259  0.749 
Tetracyclines 203 0.539 0.912 0.531 0.592  0.410 
Tiamulin 40 0.487 0.950 0.545 0.611  0.581 
Adj. by AM-class  0.622 0.908 0.681 0.929 0.730 0.574 
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Method 2 
       
         
 Counts Comple. Correct. r Fisher's z rz 𝝆𝝆xx 
Study population 814 0.715 0.885 0.747 0.965 0.747 0.654 
Farm 1 12 1.000 0.750 0.428 0.457  0.117 
Farm 2 61 0.792 0.840 0.727 0.923  0.564 
Farm 3 20 0.600 1.000 -0.038 -0.038  0.472 
Farm 4 112 0.941 0.896 0.906 1.505  0.844 
Farm 5 33 0.394 1.000 0.691 0.851  0.569 
Farm 6 101 0.638 0.896 0.286 0.294  0.242 
Farm 7 24 0.957 0.957 0.413 0.439  0.425 
Farm 8 64 0.847 0.909 0.699 0.865  0.577 
Farm 9 22 0.765 0.722 0.387 0.408  0.532 
Farm 10 107 0.895 0.979 0.931 1.662  0.875 
Farm 11 37 0.429 0.882 0.831 1.192  0.703 
Farm 12 22 0.235 0.444 0.278 0.286  0.431 
Farm 13 49 0.514 0.613 0.576 0.656  0.500 
Farm 14 74 0.634 0.938 0.912 1.537  0.748 
Farm 15 56 0.463 0.926 0.753 0.980  0.685 
Farm 16 20 0.882 0.833 0.781 1.048  0.671 
Adj.by farm  0.687 0.849 0.598 0.817 0.673 0.560 
Sows - Piglets 279 0.851 0.925 0.842 1.227  0.739 
Weaners 267 0.638 0.866 0.541 0.605  0.560 
Finishers 268 0.647 0.852 0.635 0.749  0.559 
Adj. by age-group  0.712 0.881 0.672 0.860 0.696 0.619 
Parenteral 600 0.693 0.920 0.876 1.357  0.784 
Peroral 214 0.788 0.801 0.478 0.520  0.494 
Adj. by dispensing-type  0.740 0.861 0.677 0.938 0.734 0.639 
Aminoglycosides 27 0.947 0.692 0.867 1.321  0.797 
Aminoglycosides-Penicillins (nrw.) 47 0.659 0.906 0.830 1.187  0.709 
Colistin 12 0.900 0.818 0.774 1.030  0.592 
Lincosamides 44 0.475 0.826 0.358 0.375  0.367 
Lincosamides-Spectinomycin 45 0.786 0.917 0.817 1.148  0.729 
Macrolides 103 0.769 0.854 0.685 0.839  0.605 
Phenicols 3 0.667 1.000 0.733 0.935  0.386 
Penicillins (nrw.) 123 0.641 0.926 0.957 1.914  0.921 
Penicillins (ext.) 73 0.843 0.952 0.634 0.748  0.537 
Sulfa - TMP 83 0.805 0.912 0.859 1.290  0.761 
Tetracyclines 211 0.705 0.883 0.536 0.598  0.449 
Tiamulin 43 0.538 0.840 0.543 0.609  0.583 
Adj. by AM-class  0.728 0.877 0.716 1.000 0.761 0.620 
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Method 3 
       
         
 Counts Comple. Correct. r Fisher's z rz 𝝆𝝆xx 
Study population 827 0.754 0.873 0.761 0.999 0.761 0.673 
Farm 1 13 1.000 0.692 0.507 0.558  0.220 
Farm 2 61 0.811 0.843 0.727 0.923  0.564 
Farm 3 21 0.700 0.933 -0.045 -0.045  0.472 
Farm 4 114 0.950 0.881 0.868 1.324  0.795 
Farm 5 34 0.515 0.944 0.821 1.158  0.711 
Farm 6 102 0.681 0.889 0.287 0.295  0.277 
Farm 7 24 1.000 0.958 0.475 0.516  0.459 
Farm 8 64 0.847 0.909 0.699 0.865  0.577 
Farm 9 23 0.824 0.700 0.625 0.733  0.620 
Farm 10 107 0.895 0.979 0.931 1.664  0.876 
Farm 11 38 0.657 0.885 0.828 1.183  0.738 
Farm 12 26 0.353 0.400 0.348 0.364  0.465 
Farm 13 50 0.649 0.649 0.598 0.690  0.526 
Farm 14 74 0.634 0.938 0.923 1.607  0.833 
Farm 15 56 0.463 0.926 0.753 0.980  0.685 
Farm 16 20 0.882 0.833 0.808 1.122  0.711 
Adj.by farm  0.741 0.835 0.635 0.871 0.702 0.596 
Sows - Piglets 279 0.854 0.925 0.842 1.227  0.739 
Weaners 271 0.671 0.853 0.552 0.622  0.570 
Finishers 277 0.730 0.830 0.668 0.807  0.602 
Adj. by age-group  0.752 0.870 0.687 0.885 0.709 0.637 
Parenteral 608 0.730 0.908 0.877 1.363  0.787 
Peroral 219 0.832 0.788 0.509 0.561  0.527 
Adj. by dispensing-type  0.781 0.848 0.693 0.962 0.745 0.657 
Aminoglycosides 27 1.000 0.704 0.919 1.585  0.866 
Aminoglycosides-Penicillins (nrw.) 49 0.705 0.861 0.833 1.198  0.715 
Colistin 14 0.900 0.692 0.805 1.114  0.707 
Lincosamides 47 0.650 0.788 0.377 0.397  0.379 
Lincosamides-Spectinomycin 45 0.786 0.917 0.803 1.108  0.718 
Macrolides 103 0.824 0.862 0.725 0.918  0.641 
Phenicols 3 0.667 1.000 0.733 0.935  0.386 
Penicillins (nrw.) 125 0.675 0.908 0.958 1.919  0.922 
Penicillins (ext.) 73 0.843 0.952 0.633 0.746  0.536 
Sulfonamides - TMP 83 0.818 0.913 0.862 1.303  0.765 
Tetracyclines 215 0.751 0.868 0.571 0.649  0.505 
Tiamulin 43 0.538 0.840 0.452 0.487  0.548 
Adj. by AM-class  0.763 0.859 0.723 1.030 0.774 0.641 
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Method 4 
       
         
 Counts Comple. Correct. r Fisher's z rz 𝝆𝝆xx 
Study population 854 0.834 0.851 0.765 1.009 0.765 0.680 
Farm 1 12 1.000 0.750 0.477 0.519  0.116 
Farm 2 61 0.981 0.867 0.738 0.946  0.581 
Farm 3 21 0.850 0.944 0.061 0.061  0.489 
Farm 4 126 0.980 0.798 0.857 1.283  0.787 
Farm 5 33 0.606 1.000 0.818 1.150  0.709 
Farm 6 103 0.723 0.883 0.327 0.339  0.293 
Farm 7 24 0.957 0.957 0.413 0.439  0.425 
Farm 8 67 1.000 0.881 0.667 0.806  0.561 
Farm 9 27 0.941 0.615 0.641 0.760  0.627 
Farm 10 107 0.962 0.981 0.928 1.640  0.870 
Farm 11 39 0.571 0.833 0.830 1.187  0.739 
Farm 12 20 0.176 0.500 0.321 0.332  0.454 
Farm 13 58 0.649 0.533 0.694 0.855  0.620 
Farm 14 74 0.915 0.956 0.933 1.681  0.856 
Farm 15 58 0.556 0.882 0.769 1.017  0.701 
Farm 16 24 0.941 0.696 0.826 1.175  0.731 
Adj.by farm  0.801 0.817 0.644 0.887 0.710 0.597 
Sows - Piglets 284 0.969 0.917 0.853 1.268  0.757 
Weaners 291 0.782 0.798 0.541 0.606  0.575 
Finishers 279 0.739 0.824 0.666 0.803  0.598 
Adj. by age-group  0.830 0.846 0.687 0.892 0.713 0.644 
Parenteral 619 0.818 0.897 0.885 1.397  0.800 
Peroral 235 0.883 0.738 0.519 0.575  0.536 
Adj. by dispensing-type  0.850 0.818 0.702 0.986 0.756 0.668 
Aminoglycosides 25 1.000 0.760 0.918 1.574  0.864 
Aminoglycosides-Penicillins (nrw.) 51 0.932 0.854 0.919 1.584  0.858 
Colistin 16 0.900 0.600 0.832 1.194  0.733 
Lincosamides 46 0.600 0.800 0.776 1.035  0.710 
Lincosamides-Spectinomycin 43 0.976 0.976 0.917 1.570  0.863 
Macrolides 108 0.835 0.817 0.689 0.845  0.612 
Phenicols 3 0.333 1.000 0.155 0.156  0.180 
Penicillins (nrw.) 130 0.778 0.875 0.970 2.092  0.943 
Penicillins (ext.) 75 0.914 0.928 0.640 0.759  0.549 
Sulfonamides - TMP 83 0.909 0.921 0.876 1.360  0.789 
Tetracyclines 217 0.788 0.864 0.570 0.648  0.501 
Tiamulin 57 0.846 0.647 0.532 0.593  0.581 
Adj. by AM-class  0.818 0.837 0.733 1.118 0.807 0.682 
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Method 5 
       
         
 Counts Comple. Correct. r Fisher's z rz 𝝆𝝆xx 
Study population 855 0.859 0.853 0.765 1.009 0.765 0.682 
Farm 1 11 0.889 0.800 0.696 0.860  0.200 
Farm 2 61 0.981 0.867 0.738 0.946  0.581 
Farm 3 21 0.900 0.947 0.029 0.029  0.486 
Farm 4 126 1.000 0.802 0.851 1.261  0.781 
Farm 5 34 0.667 0.957 0.820 1.156  0.712 
Farm 6 103 0.777 0.890 0.321 0.333  0.302 
Farm 7 24 1.000 0.958 0.475 0.516  0.459 
Farm 8 67 1.000 0.881 0.667 0.806  0.561 
Farm 9 25 1.000 0.680 0.610 0.709  0.604 
Farm 10 107 0.971 0.981 0.927 1.640  0.870 
Farm 11 39 0.571 0.833 0.830 1.187  0.739 
Farm 12 21 0.235 0.500 0.326 0.339  0.456 
Farm 13 60 0.811 0.566 0.738 0.946  0.661 
Farm 14 74 0.915 0.956 0.933 1.681  0.856 
Farm 15 58 0.556 0.882 0.769 1.017  0.701 
Farm 16 24 0.941 0.696 0.826 1.175  0.731 
Adj.by farm  0.826 0.825 0.660 0.913 0.722 0.606 
Sows - Piglets 284 0.969 0.917 0.853 1.268  0.757 
Weaners 293 0.823 0.800 0.544 0.609  0.578 
Finishers 278 0.776 0.835 0.662 0.797  0.600 
Adj. by age-group  0.856 0.850 0.686 0.891 0.712 0.645 
Parenteral 620 0.846 0.899 0.886 1.404  0.802 
Peroral 235 0.899 0.742 0.514 0.568  0.536 
Adj. by dispensing-type  0.873 0.820 0.700 0.986 0.756 0.669 
Aminoglycosides 25 1.000 0.760 0.918 1.574  0.864 
Aminoglycosides-Penicillins (nrw.) 51 0.932 0.854 0.919 1.584  0.858 
Colistin 16 0.900 0.600 0.832 1.194  0.733 
Lincosamides 46 0.600 0.800 0.776 1.035  0.710 
Lincosamides-Spectinomycin 43 0.976 0.976 0.917 1.570  0.863 
Macrolides 109 0.890 0.818 0.676 0.821  0.605 
Phenicols 3 0.333 1.000 0.155 0.156  0.180 
Penicillins (nrw.) 130 0.778 0.875 0.970 2.092  0.943 
Penicillins (ext.) 75 0.914 0.928 0.640 0.759  0.549 
Sulfonamides - TMP 83 0.935 0.923 0.885 1.396  0.801 
Tetracyclines 220 0.850 0.859 0.579 0.661  0.512 
Tiamulin 54 0.846 0.688 0.526 0.585  0.579 
Adj. by AM-class  0.830 0.840 0.733 1.119 0.807 0.683 
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Table B2. Treatment age-group instructed by the vets compared to the recorded age-group in VetStat of the 
AM-classes; aminoglycosides, aminoglycosides combined with narrow-spectrum (nrw.) penicillins, colistin, 
lincosamides, lincosamides combined with spectinomycin, macrolides, extended-spectrum (ext.) penicillins, 
narrow-spectrum (nrw.) penicillins, sulfonamides combined with trimethoprim (TMP), tetracyclines and 
tiamulin, used in the study.   
 
AM-class Dispensering Vet- instruction 
VetStat- 
record Count 
Aminoglycosides Peroral Piglet Sow 17 
Aminoglycosides - Penicillins (nwr.) Parenteral Piglet Sow 22 
Aminoglycosides - Penicillins (nwr.) Parenteral Weaner Sow 1 
Aminoglycosides - Penicillins (nwr.) Parenteral Weaner Weaner 1 
Colistin Peroral Piglet Sow 1 
Colistin Peroral Weaner Weaner 5 
Lincosamides Parenteral Sow Sow 7 
Lincosamides Parenteral Finisher Finisher 6 
Lincosamides - spectinomycin Parenteral Piglet Sow 8 
Lincosamides - spectinomycin Peroral Weaner Weaner 8 
Macrolides Parenteral Sow Sow 8 
Macrolides Parenteral Weaner Weaner 7 
Macrolides Parenteral Finisher Finisher 9 
Macrolides Parenteral_LA Piglet Sow 20 
Macrolides Parenteral_LA Weaner Weaner 2 
Macrolides Peroral Weaner Weaner 7 
Macrolides Peroral Finisher Finisher 6 
Penicillins (nwr.) Parenteral Sow Sow 15 
Penicillins (nwr.) Parenteral Weaner Weaner 9 
Penicillins (nwr.) Parenteral Finisher Finisher 28 
Penicillins (ext.) Parenteral Finisher Finisher 1 
Penicillins (ext.) Parenteral_LA Piglet Sow 28 
Penicillins (ext.) Parenteral_LA Sow Sow 11 
Penicillins (ext.) Peroral Weaner Weaner 7 
Sulfonamides -TMP Parenteral Piglet Sow 12 
Sulfonamides -TMP Parenteral Piglet Weaner 6 
Sulfonamides -TMP Parenteral Sow Sow 28 
Sulfonamides -TMP Parenteral Weaner Weaner 7 
Sulfonamides -TMP Parenteral Finisher Finisher 2 
Sulfonamides -TMP Peroral Sow Sow 1 
Sulfonamides -TMP Peroral Weaner Weaner 5 
Tetracyclines Parenteral Sow Sow 14 
Tetracyclines Parenteral Weaner Sow 1 
Tetracyclines Parenteral Weaner Weaner 13 
Tetracyclines Parenteral Finisher Finisher 21 
Tetracyclines Parenteral_LA Weaner Weaner 8 
Tetracyclines Parenteral_LA Finisher Weaner 1 
Tetracyclines Parenteral_LA Finisher Finisher 4 
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Tetracyclines Peroral Weaner Weaner 19 
Tetracyclines Peroral Finisher Finisher 12 
Tiamulin Parenteral Sow Sow 9 
Tiamulin Parenteral Finisher Finisher 1 
Tiamulin Peroral Weaner Weaner 3 
Tiamulin Peroral Weaner Finisher 7 
Total 
   
408 
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Fig. B3. Relative error between the treatment dose instructed by the vets and the standard ADD of parenteral, 
parenteral long-acting (LA) and peroral antimicrobials. Four observation (parenteral_LA (#3) and parenteral 
(#1)) were removed because the relative difference was more than 9 times higher compared to the standard 
ADD, thus assumed to be writing error. 
 
 
 
Fig. B4. Relative error between the treatment duration instructed by the vets and the standard treatment 
duration from the medicine catalogue of the Danish Veterinary Medical Industry of parenteral, parenteral long-
acting (LA) and peroral.  
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Table B5. Overview of the antimicrobial classes, dispensing types and diseases registered in the vet instructions 
Antimicrobial class Dispensing Disease 
Aminoglycosides Peroral Coli-diarrhea, Diarrhea 
Aminoglycosides-Penicillins (nrw.) Parenteral Arthritis 
Colistin Peroral Coli-diarrhea, Diarrhea 
Lincosamides Parenteral Arthritis, Mycoplasma 
Lincosamides-Spectinomycin Parenteral Diarrhea 
 
Peroral Diarrhea, Lawsonia, Post-weaning enteritis 
Macrolides Parenteral Diarrhea, Lawsonia, Mastitis, Pasteurella, 
Pneumonia  
Parenteral_LA Mycoplasma, Pasteurella, Pneumonia 
 
Peroral Diarrhea, Glassers disease, Lawsonia 
Penicillins (nrw.) Parenteral Arthritis, Meningitis,  
MMA (mastitis/metritis/agalactia), Pneumonia, 
Ulcer 
Penicillins (ext.) Parenteral Ear inflammation 
 
Parenteral_LA Arthritis, MMA (mastitis/metritis/agalactia), 
Omphalitis  
Peroral Arthritis, Coli-diarrhea, Meningitis, Pasteurella 
Sulfonamides-Trimethoprim Parenteral Coli-diarrhea, Diarrhea, Meningitis,  
MMA (mastitis/metritis/agalactia),  
Post-weaning enteritis  
Peroral Arthritis, Pneumonia, Metritis 
Tetracyclines Parenteral Abscess, Arthritis, Diarrhea, Hoof abscess, 
Lawsonia, Regional enteritis,  Ulcer  
Parenteral_LA Arthritis, Lawsonia, Pneumonia 
 
Peroral Lawsonia, Pneumonia , Regional enteritis 
Pleuromutilins Parenteral Arthritis, Mycoplasma 
 
Peroral Diarrhea, Lawsonia, Mycoplasma,  
Regional enteritis, Pneumonia 
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Fig. B6. Differences in number of pigs by comparing the number of sows, weaners and finishers registered in 
the CHR with the number of piglet, weaners and finisher registered in the PMD (production). 
